[
  {
    "objectID": "writing.html",
    "href": "writing.html",
    "title": "Writing & Media",
    "section": "",
    "text": "Random intercepts do not fix confounding\n\n\nA common misconception in epidemiology is that random intercepts can fix confounding. This post demonstrates through simulation that this is not the case, and provides…\n\n\n\nJul 14, 2025\n\n\n\n\n\n\n\n\n\n\nEksplosiv økning: Barn sliter med hukommelsen\n\n\nIn the media • NRK\n\n\nNordmenn går stadig oftere til legen fordi de sliter med hukommelsen. Blant barn i alderen 5–14 år har det vært nær en tredobling i antall legebesøk de siste årene.\n\n\n\nJun 13, 2025\n\n\n\n\n\n\n\n\n\n\nLøfterik behandling av long covid uten bevis\n\n\nOp-ed • Forskersonen\n\n\nVi må prioritere forebygging av long covid, akkurat som vi gjør med alle andre sykdommer, samtidig som vi utvikler bedre behandling.\n\n\n\nMay 10, 2025\n\n\n\n\n\n\n\n\n\n\nPromising long COVID treatment without evidence\n\n\nOp-ed • Forskersonen\n\n\nWe must prioritize prevention of long COVID, just as we do with all other diseases, while developing better treatment.\n\n\n\nMay 10, 2025\n\n\n\n\n\n\n\n\n\n\nVi må beskytte lærerne mot long covid\n\n\nOp-ed • Utdanningsnytt\n\n\nHeldigvis kan luftbårne virus forebygges ved å rense inneluften.\n\n\n\nApr 22, 2025\n\n\n\n\n\n\n\n\n\n\nWe must protect teachers from long COVID\n\n\nOp-ed • Utdanningsnytt\n\n\nFortunately, airborne viruses can be prevented by purifying indoor air.\n\n\n\nApr 22, 2025\n\n\n\n\n\n\n\n\n\n\nAll-cause mortality in Norway\n\n\nExamining all-cause mortality in Norway using publically available mortality data from SSB.\n\n\n\nMar 25, 2025\n\n\n\n\n\n\n\n\n\n\nDe fleste tenker ikke på covid lenger - men for Gro-Rita har viruset endret alt\n\n\nIn the media • Bladet Vesterålen\n\n\nPandemien roet seg. Bort med munnbind, én meter-avstand og covid-tester. Men for noen tok det aldri slutt. Noen ble ikke friske.\n\n\n\nMar 23, 2025\n\n\n\n\n\n\n\n\n\n\nStadig flere barn til legen med utmattelse etter pandemien\n\n\nIn the media • Utdanningsnytt\n\n\nVi ser at barn i aldersgruppen 5 til 14 år stadig oftere kontakter fastlegen på grunn av utmattelse. Etter 2022 har tallet steget med 31 prosent, sier forsker Richard Aubrey…\n\n\n\nMar 12, 2025\n\n\n\n\n\n\n\n\n\n\nDramatiske korona-funn: – Store mørketall\n\n\nIn the media • Nettavisen\n\n\nIfølge den nye studien er forekomsten av ME og utmattelsessyndrom 15 ganger høyere enn før pandemien.\n\n\n\nJan 21, 2025\n\n\n\n\n\n\n\n\n\n\nDebatten om sykefravær er ført på feil premisser\n\n\nOp-ed • Fri Fagbevegelse\n\n\nCovid er farligere enn du tror. Hver reinfeksjon er som å spille russisk rulett med kronisk sykdom. Sykefravær er bare toppen av isfjellet.\n\n\n\nJan 18, 2025\n\n\n\n\n\n\n\n\n\n\nThe sick leave debate is based on wrong premises\n\n\nOp-ed • Fri Fagbevegelse\n\n\nCOVID is more dangerous than you think. Each reinfection is like playing Russian roulette with chronic disease. Sick leave is just the tip of the iceberg.\n\n\n\nJan 18, 2025\n\n\n\n\n\n\n\n\n\n\nCovid er farligere enn du tror\n\n\nOp-ed • NRK\n\n\nDet er stor grunn til å være bekymret for senskadene av covid.\n\n\n\nNov 11, 2024\n\n\n\n\n\n\n\n\n\n\nCOVID is more dangerous than you think\n\n\nOp-ed • NRK\n\n\nThere is good reason to be concerned about the long-term consequences of COVID.\n\n\n\nNov 11, 2024\n\n\n\n\n\n\n\n\n\n\nSenfølger av covid-19 er vanlige og ofte vedvarende\n\n\nOp-ed • Aftenposten\n\n\nDet er ikke overraskende at økningen i sykefravær drives av diagnoser som alle er forbundet med senfølger etter koronasmitte.\n\n\n\nOct 2, 2024\n\n\n\n\n\n\n\n\n\n\nLong Covid is common and often permanent\n\n\nOp-ed • Aftenposten\n\n\nIt is not surprising that the increase in sick leave is driven by diagnoses that are all associated with long covid.\n\n\n\nOct 2, 2024\n\n\n\n\n\n\n\n\n\n\nForebygg covid-19, forebygg sykefravær\n\n\nOp-ed • Dag og Tid\n\n\nDet er gode bevis for at en stor del av økningen i sykefraværet skyldes senfølger av covid-19.\n\n\n\nSep 27, 2024\n\n\n\n\n\n\n\n\n\n\nPrevent COVID-19, prevent sick leave\n\n\nOp-ed • Dag og Tid\n\n\nThere is good evidence that a large proportion of the increase in sick leave is due to long covid.\n\n\n\nSep 27, 2024\n\n\n\n\n\n\n\n\n\n\nAngrepet mot folkehelsa fortsetter\n\n\nOp-ed • Fædrelandsvennen\n\n\nPreben Aavitsland begynte sine angrep på bruk av munnbind den 30. januar 2020, hvor han kalte bruken «en kulturell greie.»\n\n\n\nAug 13, 2024\n\n\n\n\n\n\n\n\n\n\nThe attack on public health continues\n\n\nOp-ed • Fædrelandsvennen\n\n\nPreben Aavitsland began his attacks on the use of face masks on January 30, 2020, where he called the use “a cultural thing.”\n\n\n\nAug 13, 2024\n\n\n\n\n\n\n\n\n\n\nFlere unge døde av sykdom: Forskere slår alarm\n\n\nIn the media • NRK\n\n\nSykdom tok uvanlig mange unge menneskeliv i fjor. Forskere frykter at senfølger av covid-19 er årsaken.\n\n\n\nJun 28, 2024\n\n\n\n\n\n\n\n\n\n\nTendensiøs statistikk om senfølger\n\n\nOp-ed • Dag og tid\n\n\nMyndighetene må anerkjenne at senfølger eksisterer og utgjør et samfunnsproblem.\n\n\n\nMay 3, 2024\n\n\n\n\n\n\n\n\n\n\nBiased statistics about long-term consequences of COVID-19\n\n\nOp-ed • Dag og Tid\n\n\nAuthorities must acknowledge that long-term consequences of COVID-19 exist and constitute a societal problem.\n\n\n\nMay 3, 2024\n\n\n\n\n\n\n\n\n\n\nReagerer på høye dødstall blant unge\n\n\nIn the media • NRK\n\n\nFor første gang på minst 20 år er det registrert overdødelighet blant unge i Norge. Det viser beregninger forskere har utført. – Jeg har aldri sett noe lignende, sier…\n\n\n\nMar 3, 2024\n\n\n\n\n\n\n\n\n\n\nSlår alarm: Rekordmange til lege med utmattelse\n\n\nIn the media • NRK\n\n\nTallet på pasienter som oppsøker lege med utmattelse, har eksplodert under pandemien. Nå slår en FHI-forsker alarm.\n\n\n\nJan 4, 2024\n\n\n\n\n\n\n\n\n\n\nSounding alarm: Record numbers to doctor with exhaustion\n\n\nIn the media • NRK\n\n\nThe number of patients seeking medical attention for exhaustion has exploded during the pandemic. Now an FHI researcher sounds the alarm.\n\n\n\nJan 4, 2024\n\n\n\n\n\n\n\n\n\n\nAll-cause mortality in Norway\n\n\nExamining all-cause mortality in Norway using publically available mortality data from SSB.\n\n\n\nAug 26, 2023\n\n\n\n\n\n\n\n\n\n\nMultivariate imputation by chained equations (MICE) with interaction terms\n\n\nExamining how MICE works with interaction terms.\n\n\n\nApr 20, 2023\n\n\n\n\n\n\n\n\n\n\nSparse inference\n\n\nExamining sparse inference using both frequentist and bayesian methodology.\n\n\n\nApr 14, 2023\n\n\n\n\n\n\n\n\n\n\nSampling bias\n\n\nExamining sampling bias in simulated data.\n\n\n\nFeb 23, 2023\n\n\n\n\n\n\n\n\n\n\nAll-Cause Mortality in Norway\n\n\nExamining all-cause mortality in Norway using publically available mortality data from SSB.\n\n\n\nDec 13, 2022\n\n\n\n\n\n\n\n\n\n\nCustom Airflow Docker operator (poor-man’s Kubernetes)\n\n\nAirflow is a platform to programmatically author, schedule, and monitor workflows data. Operators are the main building blocks that encapsulate logic to do a unit of work.…\n\n\n\nJul 18, 2022\n\n\n\n\n\n\n\n\n\n\nSykdomspulsen receives prize for best poster\n\n\nSykdomspulsen received the prize for best poster at Helse- og Kvalitetsregisterkonferansen 2021.\n\n\n\nNov 18, 2021\n\n\n\n\n\n\nNo matching items\n\nRSS Feed"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Richard Aubrey White, Ph.D.",
    "section": "",
    "text": "Richard is an applied statistician specializing in infectious diseases, based in Oslo, Norway.\nHe leads the Norwegian Syndromic Surveillance System (NorSySS) at the Norwegian Institute of Public Health, developing real-time systems to monitor population health and detect outbreaks. NorSySS conducts over one million automated analyses daily, tracking more than 100 disease syndromes across Norway’s five million residents.\nHis work focuses on syndromic surveillance, signal detection algorithms, and the design of real-time reporting systems for public health operations. Combining statistical modeling with operational epidemiology, he builds infrastructure that supports health authorities nationwide.\nFrom 2015 to 2022, he served as statistical lead for the Norwegian Mortality Monitoring System (NorMOMO), conducting weekly analyses of all-cause mortality data for Norway and contributing to the European monitoring system for total mortality (EuroMOMO).\nHis international field experience includes performing needs assessments in Sri Lanka and developing/managing surveillance systems for Ebola in Sierra Leone, acute watery diarrhea/cholera in Mozambique, and maternal health in Palestine.\nContact: hello@rwhite.no"
  },
  {
    "objectID": "index.html#education",
    "href": "index.html#education",
    "title": "Richard Aubrey White, Ph.D.",
    "section": "Education",
    "text": "Education\nHarvard University, USA\n\n2011–2012 / Ph.D. in Biostatistics\n\n2009–2011 / M.A. in Biostatistics (Frank Knox fellowship)\n\nUniversity of Wollongong, Australia\n\n2005–2009 / B. Advanced Mathematics in Applied Statistics (First Class Honours)\n\nUniversity of Bergen, Norway\n\n2022–2023 / One year program (årsstudium) in Nordic languages and literature"
  },
  {
    "objectID": "index.html#key-publications",
    "href": "index.html#key-publications",
    "title": "Richard Aubrey White, Ph.D.",
    "section": "Key Publications",
    "text": "Key Publications\n\nWhite, R. A. et al. (2024). “Aberrations in medically certified sick leave and primary healthcare consultations in Norway in 2023 compared to pre-COVID-19-pandemic trends”. In: Archives of Public Health 82.1, p. 187. ISSN: 2049-3258. DOI: 10.1186/s13690-024-01411-4. URL: https://www.rwhite.no/articles/2024-white.pdf.\n\n\nWickremesekera, S. et al. (2022). “Sri Lanka Complex Emergency - Needs Assessment Report, October 2022”. In: International Federation of Red Cross and Red Crescent Societies. URL: https://www.rwhite.no/articles/2022-wickremesekera.pdf."
  },
  {
    "objectID": "index.html#key-projects",
    "href": "index.html#key-projects",
    "title": "Richard Aubrey White, Ph.D.",
    "section": "Key Projects",
    "text": "Key Projects\n\nNorwegian Syndromic Surveillance System (NorSySS)\nResearcher/Project Manager, 2023–now\nLeading Norway’s national syndromic surveillance system that monitors 100+ disease syndromes through automated analysis of GP consultations. The system processes over 1 million analyses daily, providing real-time disease monitoring across all Norwegian municipalities and alerting health authorities to potential outbreaks.\n\n\nSykdomspulsen: Real-Time Disease Surveillance\nResearcher/Technical Lead, 2019–2023\nBuilt and led an 8-person team developing Norway’s award winning comprehensive disease surveillance platform. Created automated statistical analyses for mortality monitoring (as part of EuroMOMO), COVID-19 surveillance, and 80+ infectious disease syndromes, generating 1000+ daily reports for health authorities.\n\n\nCore Surveillance 9 (cs9) Framework\nResearcher/Lead Developer, 2014–now\nDeveloping cs9, an open-source R framework that serves as the foundational infrastructure for large-scale disease surveillance systems. This comprehensive platform enables rapid deployment of automated surveillance capabilities and serves as the technical backbone powering both NorSySS and award winning Sykdomspulsen as independent surveillance implementations."
  },
  {
    "objectID": "index.html#technical-skills",
    "href": "index.html#technical-skills",
    "title": "Richard Aubrey White, Ph.D.",
    "section": "Technical Skills",
    "text": "Technical Skills\nProgramming & Analysis\nR (20+ years) • STATA (15+ years) • Python (1 year)\nInfrastructure & DevOps\nDocker (10+ years) • CI/CD (10+ years) • Kubernetes (1 year)\nLanguages\nEnglish (Fluent) • Norwegian (B2)"
  },
  {
    "objectID": "index.html#scientific-production",
    "href": "index.html#scientific-production",
    "title": "Richard Aubrey White, Ph.D.",
    "section": "Scientific Production",
    "text": "Scientific Production\nScientific articles\n92 publications • 64 680 citations • 45 h-index\nR packages on CRAN\n                \nR packages on GitHub\ncsdb • csstyle • cs9 • MOMO • nowcast"
  },
  {
    "objectID": "index.html#norwegian-institute-of-public-health-niphfhi",
    "href": "index.html#norwegian-institute-of-public-health-niphfhi",
    "title": "Richard Aubrey White, Ph.D.",
    "section": "Norwegian Institute of Public Health (NIPH/FHI)",
    "text": "Norwegian Institute of Public Health (NIPH/FHI)\n\nResearcher/Project Manager — Norwegian Syndromic Surveillance System (NorSySS)\n02.2023–now / Oslo, Norway\n\nProject manager for NorSySS, a surveillance system of infectious diseases based on consultations with general practitioners and out-of-hours primary care facilities.\nComplex statistical analyses automatically run for all locations in Norway, producing reports and alerting various stakeholders.\nTechnology stack: R, Kubernetes, Docker/Podman, CI/CD (Jenkins/GoCD/ArgoCD), Apache Airflow, Core Surveillance 9 (cs9).\nScale: Surveils 100+ syndromes across all Norwegian municipalities.\nOrganized the 2023 Northern European Symposium on Automated Surveillance.\n\n\n\nResearcher/Technical Lead — Sykdomspulsen: Real-Time Surveillance\n07.2019–01.2023 / Oslo, Norway\n\nTech lead for award winning Sykdomspulsen (8-person team), a real-time analysis and disease surveillance system.\nComplex statistical analyses automatically run for all locations in Norway, producing reports and alerting various stakeholders.\nResponsible for training, mentoring, supervision, and quality assurance of statistical methods and code.\nTechnology stack: R, Kubernetes, Docker/Podman, CI/CD (Jenkins/GoCD/ArgoCD), Apache Airflow, Core Surveillance 9 (cs9).\nSurveillance areas:\n\nMortality monitoring: All cause/cause-specific/attributable mortality (part of EuroMOMO network), vaccine associated mortality.\nInfectious diseases: COVID-19, influenza, tuberculosis, IPD, meningococcal disease, pertussis.\nAdditional monitoring: Antibiotic use, gastritis, 80+ syndromes via NorSySS.\n\nScale: 1,000,000+ analyses per day, 1,000+ automatic reports (PDF/Excel/email/SMS) per day.\nInteractive website for municipal health authorities and APIs for internal/external use.\n\n\n\nResearcher — Infectious Disease Epidemiology\n06.2014–06.2019 / Oslo, Norway\n\nAdvised outbreak teams and researchers in statistical concepts, methods, and programming.\nStatistical supervision:\n\nFive EPIET fellows.\nNine Ph.D. students.\nFocus: Mentoring, quality assurance of statistical methods and peer-reviewed publications.\n\nKey research projects:\n\nStatistical protocol for 60,000-person longitudinal study on Norwegian water usage.\nModeled 2014 Ebola outbreak likelihood of cases reaching Norway and entry screening effectiveness.\nModeled HCV burden in Norwegian people who inject drugs.\n\nData monitoring committees:\n\nHead statistician for PEEP RCT (Haydom, Tanzania).\nHead statistician for Safer Births Moyo RCT (Muhimbili, Tanzania).\n\nSurveillance systems:\n\nGastritis/respiratory outbreaks (NorSySS).\nNotifiable disease outbreaks (MSIS).\nMortality monitoring (EuroMOMO).\nDeveloped interactive websites and signal processing infrastructure.\n\n\n\n\nPostdoctoral Researcher — Genes and Environment\n01.2012–05.2014 / Oslo, Norway\n\nDeveloped database management structures to allow for the construction of analysis datasets from multiple disparate sources (e.g. written questionnaires, lab toxicant concentrations, Illumina microbial data).\nInvestigated the relationship between seasonality, sunlight, and suicide.\nInvestigated the relationship between gun ownership and completed suicide in the US, highlighting the lack of method substitution where gun ownership is less prevalent."
  },
  {
    "objectID": "index.html#consortium-for-statistics-in-disease-surveillance-csids",
    "href": "index.html#consortium-for-statistics-in-disease-surveillance-csids",
    "title": "Richard Aubrey White, Ph.D.",
    "section": "Consortium for Statistics in Disease Surveillance (CSIDS)",
    "text": "Consortium for Statistics in Disease Surveillance (CSIDS)\n\nChairperson\n01.2023–now / Oslo, Norway\n\nOverseeing the collaboration between statisticians, epidemiologists, and researchers, working on the development of R packages used for disease surveillance."
  },
  {
    "objectID": "index.html#norwegian-red-cross-norcross",
    "href": "index.html#norwegian-red-cross-norcross",
    "title": "Richard Aubrey White, Ph.D.",
    "section": "Norwegian Red Cross (NorCross)",
    "text": "Norwegian Red Cross (NorCross)\n\nHead Statistician (IFRC)\n04.2024–05.2024 / Oslo, Norway\n\nHead statistician (remote) for a 1800-household multi-sector nationwide needs assessment, in response to the complex humanitarian emergency in Sri Lanka.\nDeveloped statistical protocol for all sectors, and analyzed most of the data\n\n\n\nHealth Officer (IFRC)\n08.2022–09.2022 / Colombo, Sri Lanka\n\nHead statistician for a 3100-household multi-sector nationwide needs assessment (annex), in response to the complex humanitarian emergency in Sri Lanka.\nDeveloped statistical protocol for all sectors, questions for the health sector, and analyzed most of the data.\n\n\n\nCommunity Based Surveillance Delegate (IFRC)\n04.2019–05.2019 / Beira, Mozambique\n\nResponded to the cholera outbreak in Beira caused by Cyclone Idai.\nManaged a real-time surveillance system for people with diarrhea visiting Red Cross oral rehydration points.\nLiaised with the MOH on issues of interest, such as serious cases of diarrhea and self-reported bloody diarrhea."
  },
  {
    "objectID": "index.html#norwegian-scientific-committee-for-food-and-environment-vkm",
    "href": "index.html#norwegian-scientific-committee-for-food-and-environment-vkm",
    "title": "Richard Aubrey White, Ph.D.",
    "section": "Norwegian Scientific Committee for Food and Environment (VKM)",
    "text": "Norwegian Scientific Committee for Food and Environment (VKM)\n\nExternal Expert — Next Generation Risk Assessment in Practice\n01.2023–12/2023 / Oslo, Norway\n\nDeveloped statistical protocol for the evaluation of INVITES-IN, a tool for assessing the internal validity of in vitro studies."
  },
  {
    "objectID": "index.html#palestinian-national-institute-of-public-health-pniph",
    "href": "index.html#palestinian-national-institute-of-public-health-pniph",
    "title": "Richard Aubrey White, Ph.D.",
    "section": "Palestinian National Institute of Public Health (PNIPH)",
    "text": "Palestinian National Institute of Public Health (PNIPH)\n\nStatistician\n09.2017–09.2019 / Ramallah, Palestine\n\nTrained local staff in data management and statistical programming for the national maternal and child health registry.\nUsed raw survey data to validate indicators from the newly formed national healthcare worker registry."
  },
  {
    "objectID": "index.html#world-health-organization-who",
    "href": "index.html#world-health-organization-who",
    "title": "Richard Aubrey White, Ph.D.",
    "section": "World Health Organization (WHO)",
    "text": "World Health Organization (WHO)\n\nGIS Expert/Data Manager — Global Outbreak Alert and Response Network (GOARN)\n01.2015—02.2015 / Kambia, Sierra Leone\n\nResponded to the 2013–2016 Western African Ebola virus epidemic.\nDeveloped and managed a real-time surveillance system for the Ebola outbreak in Kambia, linking the national emergency number, Ebola holding centers, Ebola community care centers, Ebola treatment centers, and burials.\nGeocoded and mapped relevant outbreak data (alerts, cases, border crossings).\nGenerated daily sitreps using GIS data and epidemiological information from the surveillance database.\nTrained and supervised international and national staff in the use of the Kambian Ebola surveillance system.\n\n\n\nBiostatistician — Mortality and Burden of Disease\n04.2011–11.2011 / Geneva, Switzerland\n\nCollected cause of death data from multiple national cause of death registries into a database and calculated avoidable mortality estimates for disease groups over time, comparing trends in high income versus developing countries.\nProduced disease prevalence estimates for the Global Burden of Disease project (GBD 2010), most notably for vision loss, micronutrient deficiency, and stunting for all UN member nations, in all sex/age combinations, from 1990 to 2010.\n\n\n\nBiostatistician — Stop TB Department\n06.2010–11.2010 / Boston, USA\n\nLiaised with NGOs from South Africa, Uzbekistan, Bangladesh, and Peru to gain access to MDR-TB datasets, then managed, cleaned, and analysed the datasets.\nProvided recommendations for the WHO Guidelines for the Programmatic Management of Drug Resistant Tuberculosis (3rd edition) via multi-cohort survival analyses to determine factors affecting detection of MDR-TB and survival in a programmatic context."
  },
  {
    "objectID": "publications.html",
    "href": "publications.html",
    "title": "White, Ph.D.",
    "section": "",
    "text": "92 scientific articles (64 680 citations, 45 h-index)."
  },
  {
    "objectID": "publications.html#key-publications",
    "href": "publications.html#key-publications",
    "title": "White, Ph.D.",
    "section": "Key Publications",
    "text": "Key Publications\n\nWhite, R. A. et al. (2024). “Aberrations in medically certified sick leave and primary healthcare consultations in Norway in 2023 compared to pre-COVID-19-pandemic trends”. In: Archives of Public Health 82.1, p. 187. ISSN: 2049-3258. DOI: 10.1186/s13690-024-01411-4. URL: https://www.rwhite.no/articles/2024-white.pdf.\n\n\nWickremesekera, S. et al. (2022). “Sri Lanka Complex Emergency - Needs Assessment Report, October 2022”. In: International Federation of Red Cross and Red Crescent Societies. URL: https://www.rwhite.no/articles/2022-wickremesekera.pdf."
  },
  {
    "objectID": "publications.html#section",
    "href": "publications.html#section",
    "title": "White, Ph.D.",
    "section": "2025",
    "text": "2025\n\n[92] Asif, S. et al.  (2025). “Factors influencing the choice of lumbar epidural analgesia and its association with postpartum depression risk”. In: European Journal of Anaesthesiology| EJA 42.7, pp. 626–636.\n\n\n[91] Olsson, K. et al.  (2025). “A registry study on nonsyndromic craniosynostosis: Long-term associations with academic achievement”. In: Journal of Plastic, Reconstructive & Aesthetic Surgery 100, pp. 104–111. URL: https://www.rwhite.no/articles/2025-olsson.pdf.\n\n\n[90] Rø, G. et al.  (2025). “Estimating the trend of COVID-19 in Norway by combining multiple surveillance indicators”. In: PloS one 20.1, p. e0317105. URL: https://www.rwhite.no/articles/2025-ro.pdf.\n\n\n[89] Özel, F. et al.  (2025). “Associations between autism, gender dysphoria and gender incongruence: insights from the Swedish Gender Dysphoria Study (SKDS)”. In: Psychiatry Research, p. 116591. URL: https://www.rwhite.no/articles/2025-ozel.pdf."
  },
  {
    "objectID": "publications.html#section-1",
    "href": "publications.html#section-1",
    "title": "White, Ph.D.",
    "section": "2024",
    "text": "2024\n\n[88] Buer, S. et al.  (2024). “Executive deficits after SARS-CoV-2 infection: A cross-sectional population study”. In: Brain, Behavior, & Immunity - Health 41, p. 100857. ISSN: 2666-3546. URL: https://www.rwhite.no/articles/2024-buer.pdf.\n\n\n[87] Gidén, K. et al.  (2024). “Remission or Persistence? A Prediction Tool to Identify Women at Risk for Long-Term Depressive Symptoms Postpartum”. In: Depression and Anxiety 2024.1, p. 7734542. URL: https://www.rwhite.no/articles/2024-giden.pdf.\n\n\n[86] Gleditsch, R. N. et al.  (2024). “Vaccine coverage among children born to immigrant parents in Norway, 2000–2020”. In: Vaccine 42.12, pp. 3049–3056. URL: https://www.rwhite.no/articles/2024-gleditsch.pdf.\n\n\n[85] Hyllestad, S. et al.  (2024). “Estimating the risk of gastrointestinal illness associated with drinking tap water in Norway: a prospective cohort study”. In: BMC Public Health 24.1, p. 2107. URL: https://www.rwhite.no/articles/2024-hyllestad.pdf.\n\n\n[84] Lyngstad, T. M. et al.  (2024). “Årsrapport 2023. Overvåkning av infeksjonssykdommer som smitter fra mat, vann og dyr, inkludert vektorbårne sykdommer”. In: Folkehelseinstituttet. URL: https://www.rwhite.no/articles/2024-lyngstad.pdf.\n\n\n[83] White, R. A. et al.  (2024). “Aberrations in medically certified sick leave and primary healthcare consultations in Norway in 2023 compared to pre-COVID-19-pandemic trends”. In: Archives of Public Health 82.1, p. 187. ISSN: 2049-3258. DOI: 10.1186/s13690-024-01411-4. URL: https://www.rwhite.no/articles/2024-white.pdf."
  },
  {
    "objectID": "publications.html#section-2",
    "href": "publications.html#section-2",
    "title": "White, Ph.D.",
    "section": "2023",
    "text": "2023\n\n[82] Axfors, C. et al.  (2023). “Prepregnancy participation and performance in world’s largest cross-country ski race as a proxy for physical exercise and fitness, and perinatal outcomes: prospective registry-based cohort study”. In: BJOG: An International Journal of Obstetrics & Gynaecology. URL: https://www.rwhite.no/articles/2023-axfors.pdf.\n\n\n[81] Engebretsen, S. et al.  (2023). “Regional probabilistic situational awareness and forecasting of COVID-19”. In: PLOS Computational Biology 19.1, pp. 1-26. URL: https://www.rwhite.no/articles/2023-engebretsen.pdf.\n\n\n[80] Mathisen, G. H. et al.  (2023). “Protocol: Testing the performance of INVITES-IN, a tool for assessing the internal validity of in vitro studies”. In: Evidence-Based Toxicology 1.1, p. 2293289. URL: https://www.rwhite.no/articles/2023-mathisen.pdf.\n\n\n[79] Ruiz, P. L. et al.  (2023). “Short-term safety of COVID-19 mRNA vaccines with respect to all-cause mortality in the older population in Norway”. In: Vaccine 41.2, pp. 323–332. URL: https://www.rwhite.no/articles/2023-ruiz.pdf."
  },
  {
    "objectID": "publications.html#section-3",
    "href": "publications.html#section-3",
    "title": "White, Ph.D.",
    "section": "2022",
    "text": "2022\n\n[78] Banti, A. B. et al.  (2022). “How many of persistent coughers have pulmonary tuberculosis? Population-based cohort study in Ethiopia”. In: BMJ open 12.5, p. e058466. URL: https://www.rwhite.no/articles/2022-banti.pdf.\n\n\n[77] Karamanis, G. et al.  (2022). “Gender dysphoria in twins: a register-based population study”. In: Scientific Reports 12.1, pp. 1–8. URL: https://www.rwhite.no/articles/2022-karamanis.pdf.\n\n\n[76] Skaland, R. G. et al.  (2022). “Impacts of climate change on drinking water quality in Norway”. In: Journal of Water and Health 20.3, pp. 539–550. URL: https://www.rwhite.no/articles/2022-skaland.pdf.\n\n\n[75] Swanson, D. et al.  (2022). “A One Health real-time surveillance system for nowcasting Campylobacter gastrointestinal illness outbreaks, Norway, week 30 2010 to week 11 2022”. In: Eurosurveillance 27.43, p. 2101121. URL: https://www.rwhite.no/articles/2022-swanson.pdf.\n\n\n[74] Wickremesekera, S. et al.  (2022). “Sri Lanka Complex Emergency - Needs Assessment Report, October 2022”. In: International Federation of Red Cross and Red Crescent Societies. URL: https://www.rwhite.no/articles/2022-wickremesekera.pdf."
  },
  {
    "objectID": "publications.html#section-4",
    "href": "publications.html#section-4",
    "title": "White, Ph.D.",
    "section": "2021",
    "text": "2021\n\n[73] Herrador, B. G. et al.  (2021). “Heavy weather events, water quality and gastroenteritis in Norway”. In: One Health 13, p. 100297. URL: https://www.rwhite.no/articles/2021-herrador.pdf.\n\n\n[72] Indremo, M. et al.  (2021). “Validity of the Gender Dysphoria diagnosis and incidence trends in Sweden: a nationwide register study”. In: Scientific reports 11.1, pp. 1–10. URL: https://www.rwhite.no/articles/2021-indremo.pdf.\n\n\n[71] Isbeih, M. et al.  (2021). “Gestational age recorded at delivery versus estimations using antenatal care data from the Electronic Maternal and Child Health Registry in the West Bank: a comparative analysis”. In: The Lancet 398, p. S31. URL: https://www.rwhite.no/articles/2021-isbeih.pdf.\n\n\n[70] Jenness, S. M. et al.  (2021). “Measles vaccine coverage among children born to Somali immigrants in Norway”. In: BMC Public Health 21.1, pp. 1–8. URL: https://www.rwhite.no/articles/2021-jenness.pdf.\n\n\n[69] Makris, G. D. et al.  (2021). “Sunshine, temperature and suicidal behaviour in patients treated with antidepressants: an explorative nested case–control study”. In: Scientific Reports 11.1, pp. 1–12. URL: https://www.rwhite.no/articles/2021-makris.pdf.\n\n\n[68] Nørgaard, S. K. et al.  (2021). “Real-time monitoring shows substantial excess all-cause mortality during second wave of COVID-19 in Europe, October to December 2020”. In: Eurosurveillance 26.2, p. 2002023. URL: https://www.rwhite.no/articles/2021-norgaard.pdf.\n\n\n[67] Winje, B. A. et al.  (2021). “The risk of invasive pneumococcal disease differs between risk groups in Norway following widespread use of the 13-valent pneumococcal vaccine in children”. In: Microorganisms 9.8, p. 1774. URL: https://www.rwhite.no/articles/2021-winje.pdf."
  },
  {
    "objectID": "publications.html#section-5",
    "href": "publications.html#section-5",
    "title": "White, Ph.D.",
    "section": "2020",
    "text": "2020\n\n[66] Bränn, E. et al.  (2020). “Inflammatory markers in women with postpartum depressive symptoms”. In: Journal of neuroscience research 98.7, pp. 1309–1321. URL: https://www.rwhite.no/articles/2020-brann.pdf.\n\n\n[65] Hauge, S. H. et al.  (2020). “Urbanization and preparedness for outbreaks with high-impact respiratory pathogens”. In: Norwegian Institute of Public Health. URL: https://www.rwhite.no/articles/2020-hauge.pdf.\n\n\n[64] Vestergaard, L. S. et al.  (2020). “Excess all-cause mortality during the COVID-19 pandemic in Europe–preliminary pooled estimates from the EuroMOMO network, March to April 2020”. In: Eurosurveillance 25.26, p. 2001214. URL: https://www.rwhite.no/articles/2020-vestergaard.pdf."
  },
  {
    "objectID": "publications.html#section-6",
    "href": "publications.html#section-6",
    "title": "White, Ph.D.",
    "section": "2019",
    "text": "2019\n\n[63] Benedetti, G. et al.  (2019). “Identifying exceptional malaria occurrences in the absence of historical data in South Sudan: a method validation”. In: Public Health Action 9.3, pp. 90–95. URL: https://www.rwhite.no/articles/2019-benedetti.pdf.\n\n\n[62] Edwards, C. H. et al.  (2019). “Evaluating costs and health consequences of sick leave strategies against pandemic and seasonal influenza in Norway using a dynamic model”. In: BMJ open 9.4, p. e027832. URL: https://www.rwhite.no/articles/2019-edwards.pdf.\n\n\n[61] Henriksson, H. E. et al.  (2019). “Spring peaks and autumn troughs identified in peripheral inflammatory markers during the peripartum period”. In: Scientific reports 9.1, pp. 1–13. URL: https://www.rwhite.no/articles/2019-henriksson.pdf.\n\n\n[60] MacDonald, E. et al.  (2019). “The role of domestic reservoirs in domestically acquired Salmonella infections in Norway: epidemiology of salmonellosis, 2000–2015, and results of a national prospective case–control study, 2010–2012”. In: Epidemiology & Infection 147. URL: https://www.rwhite.no/articles/2019-macdonald.pdf.\n\n\n[59] Nielsen, J. et al.  (2019). “European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered?” In: Clinical microbiology and infection 25.10, pp. 1266–1276. URL: https://www.rwhite.no/articles/2019-nielsen.pdf.\n\n\n[58] Salih Joelsson, L. et al.  (2019). “Investigating the effect of lifestyle risk factors upon number of aspirated and mature oocytes in in vitro fertilization cycles: Interaction with antral follicle count”. In: PloS one 14.8, p. e0221015. URL: https://www.rwhite.no/articles/2019-salih.pdf.\n\n\n[57] Steens, A. et al.  (2019). “Indirect effects of pneumococcal childhood vaccination in individuals treated with immunosuppressive drugs in ambulatory care: a case-cohort study”. In: Clinical Infectious Diseases 68.8, pp. 1367–1373. URL: https://www.rwhite.no/articles/2019-steens.pdf.\n\n\n[56] Winje, B. A. et al.  (2019). “Immigrant screening for latent tuberculosis infection: numbers needed to test and treat, a Norwegian population-based cohort study”. In: BMJ open 9.1, p. e023412. URL: https://www.rwhite.no/articles/2019-winje.pdf."
  },
  {
    "objectID": "publications.html#section-7",
    "href": "publications.html#section-7",
    "title": "White, Ph.D.",
    "section": "2018",
    "text": "2018\n\n[55] Henriksson, H. E. et al.  (2018). “Meteorological parameters and air pollen count in association with self-reported peripartum depressive symptoms”. In: European Psychiatry 54, pp. 10–18. URL: https://www.rwhite.no/articles/2018-henriksson.pdf.\n\n\n[54] Schein, Y. L. et al.  (2018). “Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study”. In: BMC infectious diseases 18.1, pp. 1–10. URL: https://www.rwhite.no/articles/2018-schein.pdf.\n\n\n[53] Weyde, K. V. et al.  (2018). “A longitudinal study of road traffic noise and body mass index trajectories from birth to 8 years”. In: Epidemiology (Cambridge, Mass.) 29.5, p. 729. URL: https://www.rwhite.no/articles/2018-weyde.pdf.\n\n\n[52] Winje, B. A. et al.  (2018). “Stratification by interferon-gamma release assay level predicts risk of incident TB”. In: Thorax 73.7, pp. 652–661. URL: https://www.rwhite.no/articles/2018-winje.pdf.\n\n\n[51] Wisløff, T. et al.  (2018). “Feasibility of reaching world health organization targets for hepatitis C and the cost-effectiveness of alternative strategies”. In: Journal of viral hepatitis 25.9, pp. 1066–1077. URL: https://www.rwhite.no/articles/2018-wisloff-feasibility.pdf.\n\n\n[50] Wisløff, T. et al.  (2018). “Economic evaluation of direct-acting antivirals for hepatitis C in Norway”. In: Pharmacoeconomics 36.5, pp. 591–601. URL: https://www.rwhite.no/articles/2018-wisloff-economic.pdf."
  },
  {
    "objectID": "publications.html#section-8",
    "href": "publications.html#section-8",
    "title": "White, Ph.D.",
    "section": "2017",
    "text": "2017\n\n[49] Andreassen, A. E. S. et al.  (2017). “The impact of methicillin-resistant S. aureus on length of stay, readmissions and costs: a register based case-control study of patients hospitalized in Norway”. In: Antimicrobial Resistance & Infection Control 6.1, pp. 1–8. URL: https://www.rwhite.no/articles/2017-andreassen.pdf.\n\n\n[48] Bränn, E. et al.  (2017). “Inflammatory markers in late pregnancy in association with postpartum depression—a nested case-control study”. In: Psychoneuroendocrinology 79, pp. 146–159. URL: https://www.rwhite.no/articles/2017-brann.pdf.\n\n\n[47] Decroo, T. et al.  (2017). “Effect of Community ART Groups on retention-in-care among patients on ART in Tete Province, Mozambique: a cohort study”. In: BMJ open 7.8, p. e016800. URL: https://www.rwhite.no/articles/2017-decroo.pdf.\n\n\n[46] Edvinsson, Å. et al.  (2017). “Lower inflammatory markers in women with antenatal depression brings the M1/M2 balance into focus from a new direction”. In: Psychoneuroendocrinology 80, pp. 15–25. URL: https://www.rwhite.no/articles/2017-edvinsson.pdf.\n\n\n[45] Makris, G. D. et al.  (2017). “Season of treatment initiation with antidepressants and suicidal behavior: A population-based cohort study in Sweden”. In: Journal of affective disorders 215, pp. 245–255. URL: https://www.rwhite.no/articles/2017-makris.pdf.\n\n\n[44] Meijerink, H. et al.  (2017). “Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973–2030”. In: BMC infectious diseases 17.1, pp. 1–12. URL: https://www.rwhite.no/articles/2017-meijerink.pdf.\n\n\n[43] Vestergaard, L. S. et al.  (2017). “Excess all-cause and influenza-attributable mortality in Europe, December 2016 to February 2017”. In: Eurosurveillance 22.14, p. 30506. URL: https://www.rwhite.no/articles/2017-vestergaard.pdf."
  },
  {
    "objectID": "publications.html#section-9",
    "href": "publications.html#section-9",
    "title": "White, Ph.D.",
    "section": "2016",
    "text": "2016\n\n[42] Agardh, E. E. et al.  (2016). “Alcohol-attributed disease burden in four Nordic countries: a comparison using the Global Burden of Disease, Injuries and Risk Factors 2013 study”. In: Addiction 111.10, pp. 1806–1813. URL: https://www.rwhite.no/articles/2016-agardh.pdf.\n\n\n[41] Bourne, R. R. A. et al.  (2016). “Number of people blind or visually impaired by glaucoma worldwide and in world regions 1990–2010: a meta-analysis”. In: PloS one 11.10, p. e0162229. URL: https://www.rwhite.no/articles/2016-bourne.pdf.\n\n\n[40] Leasher, J. L. et al.  (2016). “Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010”. In: Diabetes care 39.9, pp. 1643–1649. URL: https://www.rwhite.no/articles/2016-leasher.pdf.\n\n\n[39] MacDonald, E. et al.  (2016). “Are the current notification criteria for Lyme borreliosis in Norway suitable? Results of an evaluation of Lyme borreliosis surveillance in Norway, 1995–2013”. In: BMC Public Health 16.1, pp. 1–11. URL: https://www.rwhite.no/articles/2016-macdonald.pdf.\n\n\n[38] Mitnick, C. D. et al.  (2016). “Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method”. In: European Respiratory Journal 48.4, pp. 1160–1170. URL: https://www.rwhite.no/articles/2016-mitnick.pdf.\n\n\n[37] Naidoo, K. S. et al.  (2016). “Global vision impairment and blindness due to uncorrected refractive error, 1990–2010”. In: Optometry and Vision Science 93.3, pp. 227–234. URL: https://www.rwhite.no/articles/2016-naidoo.pdf.\n\n\n[36] Vestrheim, D. F. et al.  (2016). “Geographical differences in seroprevalence of Borrelia burgdorferi antibodies in Norway, 2011–2013”. In: Ticks and tick-borne diseases 7.5, pp. 698–702. URL: https://www.rwhite.no/articles/2016-vestrheim.pdf.\n\n\n[35] Vos, T. et al.  (2016). “Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015”. In: The lancet 388.10053, pp. 1545–1602. URL: https://www.rwhite.no/articles/2016-vos.pdf.\n\n\n[34] Wang, H. et al.  (2016). “Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015”. In: The lancet 388.10053, pp. 1459–1544. URL: https://www.rwhite.no/articles/2016-wang.pdf."
  },
  {
    "objectID": "publications.html#section-10",
    "href": "publications.html#section-10",
    "title": "White, Ph.D.",
    "section": "2015",
    "text": "2015\n\n[33] Forns, J. et al.  (2015). “Perfluoroalkyl substances measured in breast milk and child neuropsychological development in a Norwegian birth cohort study”. In: Environment international 83, pp. 176–182. URL: https://www.rwhite.no/articles/2015-forns.pdf.\n\n\n[32] Iszatt, N. et al.  (2015). “Prenatal and Postnatal Exposure to Persistent Organic Pollutants and Infant Growth: A Pooled Analysis of Seven European Birth Cohorts”. In: Environmental Health Perspectives 123.7, p. 731. URL: https://www.rwhite.no/articles/2015-iszatt.pdf.\n\n\n[31] Khairallah, M. et al.  (2015). “Number of people blind or visually impaired by cataract worldwide and in world regions, 1990 to 2010”. In: Investigative ophthalmology & visual science 56.11, pp. 6762–6769. URL: https://www.rwhite.no/articles/2015-khairallah.pdf.\n\n\n[30] MacDonald, E. et al.  (2015). “Risk factors for sporadic domestically acquired Campylobacter infections in Norway 2010–2011: A national prospective case-control study”. In: PLoS One 10.10, p. e0139636. URL: https://www.rwhite.no/articles/2015-macdonald.pdf.\n\n\n[29] Mandal, S. et al.  (2015). “Analysis of composition of microbiomes: a novel method for studying microbial composition”. In: Microbial ecology in health and disease 26.1, p. 27663. URL: https://www.rwhite.no/articles/2015-mandal.pdf.\n\n\n[28] Mathers, C. D. et al.  (2015). “Causes of international increases in older age life expectancy”. In: The Lancet 385.9967, pp. 540–548. URL: https://www.rwhite.no/articles/2015-mathers.pdf.\n\n\n[27] Ruiz, M. et al.  (2015). “Mother’s education and the risk of preterm and small for gestational age birth: a DRIVERS meta-analysis of 12 European cohorts”. In: J Epidemiol Community Health 69.9, pp. 826–833. URL: https://www.rwhite.no/articles/2015-ruiz.pdf.\n\n\n[26] Stevens, G. A. et al.  (2015). “Trends and mortality effects of vitamin A deficiency in children in 138 low-income and middle-income countries between 1991 and 2013: a pooled analysis of population-based surveys”. In: The Lancet Global Health 3.9, pp. e528–e536. URL: https://www.rwhite.no/articles/2015-stevens.pdf.\n\n\n[25] White, R. A. et al.  (2015). “Does suicide have a stronger association with seasonality than sunlight?” In: BMJ open 5.6, p. e007403. URL: https://www.rwhite.no/articles/2015-white-suicide.pdf.\n\n\n[24] White, R. A. et al.  (2015). “Projected treatment capacity needs in Sierra Leone”. In: PLoS currents 7. URL: https://www.rwhite.no/articles/2015-white-ebola.pdf."
  },
  {
    "objectID": "publications.html#section-11",
    "href": "publications.html#section-11",
    "title": "White, Ph.D.",
    "section": "2014",
    "text": "2014\n\n[23] Bourne, R. R. A. et al.  (2014). “Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990–2010”. In: British Journal of Ophthalmology 98.5, pp. 629–638. URL: https://www.rwhite.no/articles/2014-bourne.pdf.\n\n\n[22] Jonas, J. B. et al.  (2014). “Visual impairment and blindness due to macular diseases globally: a systematic review and meta-analysis”. In: American journal of ophthalmology 158.4, pp. 808–815. URL: https://www.rwhite.no/articles/2014-jonas-visual.pdf.\n\n\n[21] Jonas, J. B. et al.  (2014). “Prevalence and causes of vision loss in Central and South Asia: 1990–2010”. In: British Journal of Ophthalmology 98.5, pp. 592–598. URL: https://www.rwhite.no/articles/2014-jonas-prevalence.pdf.\n\n\n[20] Keeffe, J. et al.  (2014). “Prevalence and causes of vision loss in Southeast Asia and Oceania: 1990–2010”. In: British Journal of Ophthalmology 98.5, pp. 586–591. URL: https://www.rwhite.no/articles/2014-keeffe.pdf.\n\n\n[19] Khairallah, M. et al.  (2014). “Prevalence and causes of vision loss in North Africa and the Middle East: 1990–2010”. In: British Journal of Ophthalmology 98.5, pp. 605–611. URL: https://www.rwhite.no/articles/2014-khairallah.pdf.\n\n\n[18] Leasher, J. L. et al.  (2014). “Prevalence and causes of vision loss in Latin America and the Caribbean: 1990–2010”. In: British Journal of Ophthalmology 98.5, pp. 619–628. URL: https://www.rwhite.no/articles/2014-leasher.pdf.\n\n\n[17] Naidoo, K. et al.  (2014). “Prevalence and causes of vision loss in sub-Saharan Africa: 1990–2010”. In: British Journal of Ophthalmology 98.5, pp. 612–618. URL: https://www.rwhite.no/articles/2014-naidoo.pdf.\n\n\n[16] Wong, T. Y. et al.  (2014). “Prevalence and causes of vision loss in East Asia: 1990–2010”. In: British Journal of Ophthalmology 98.5, pp. 599–604. URL: https://www.rwhite.no/articles/2014-wong.pdf."
  },
  {
    "objectID": "publications.html#section-12",
    "href": "publications.html#section-12",
    "title": "White, Ph.D.",
    "section": "2013",
    "text": "2013\n\n[15] Bourne, R. R. et al.  (2013). “Causes of vision loss worldwide, 1990–2010: a systematic analysis”. In: The lancet global health 1.6, pp. e339–e349. URL: https://www.rwhite.no/articles/2013-bourne.pdf.\n\n\n[14] Miller, M. et al.  (2013). “Firearms and suicide in the United States: is risk independent of underlying suicidal behavior?” In: American journal of epidemiology 178.6, pp. 946–955. URL: https://www.rwhite.no/articles/2013-miller.pdf.\n\n\n[13] Stevens, G. A. et al.  (2013). “Global prevalence of vision impairment and blindness: magnitude and temporal trends, 1990–2010”. In: Ophthalmology 120.12, pp. 2377–2384. URL: https://www.rwhite.no/articles/2013-stevens.pdf.\n\n\n[12] Størdal, K. et al.  (2013). “Early feeding and risk of celiac disease in a prospective birth cohort”. In: Pediatrics 132.5, pp. e1202–e1209. URL: https://www.rwhite.no/articles/2013-stordal.pdf.\n\n\n[11] White, R. A. et al.  (2013). “Novel developmental analyses identify longitudinal patterns of early gut microbiota that affect infant growth”. In: PLoS computational biology 9.5, p. e1003042. URL: https://www.rwhite.no/articles/2013-white.pdf."
  },
  {
    "objectID": "publications.html#section-13",
    "href": "publications.html#section-13",
    "title": "White, Ph.D.",
    "section": "2012",
    "text": "2012\n\n[10] Bourne, R. R. et al.  (2012). “The Global Burden of Disease Study: the Impact of Vision Loss: prevalence and trends of blindness and visual impairment over the past 28 years”. In: Investigative Ophthalmology & Visual Science 53.14, pp. 3175–3175. URL: https://www.rwhite.no/articles/2012-bourne.pdf.\n\n\n[9] Fredrickson, M. J. et al.  (2012). “Randomized study of the effect of local anesthetic volume and concentration on the duration of peripheral nerve blockade”. In: Regional Anesthesia & Pain Medicine 37.5, pp. 495–501. URL: https://www.rwhite.no/articles/2012-fredrickson.pdf.\n\n\n[8] Lim, S. S. et al.  (2012). “A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010”. In: The lancet 380.9859, pp. 2224–2260. URL: https://www.rwhite.no/articles/2012-lim.pdf.\n\n\n[7] Murray, C. J. et al.  (2012). “Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010”. In: The lancet 380.9859, pp. 2197–2223. URL: https://www.rwhite.no/articles/2012-murray.pdf.\n\n\n[6] Stevens, G. A. et al.  (2012). “Trends in mild, moderate, and severe stunting and underweight, and progress towards MDG 1 in 141 developing countries: a systematic analysis of population representative data”. In: The lancet 380.9844, pp. 824–834. URL: https://www.rwhite.no/articles/2012-stevens.pdf.\n\n\n[5] Vos, T. et al.  (2012). “Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010”. In: The lancet 380.9859, pp. 2163–2196. URL: https://www.rwhite.no/articles/2012-vos.pdf.\n\n\n[4] White, R. A. (2012). “Novel Statistical Methods Applied in Clinical Trials and Gut Microbiota”. URL: https://www.rwhite.no/articles/2012-white.pdf."
  },
  {
    "objectID": "publications.html#section-14",
    "href": "publications.html#section-14",
    "title": "White, Ph.D.",
    "section": "2011",
    "text": "2011\n\n[3] Falzon, D. et al.  (2011). WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. URL: https://www.rwhite.no/articles/2011-falzon.pdf.\n\n\n[2] Fredrickson, M. J. et al.  (2011). “Low-volume ultrasound-guided nerve block provides inferior postoperative analgesia compared to a higher-volume landmark technique”. In: Regional Anesthesia and Pain Medicine 36.4, pp. 393–398. URL: https://www.rwhite.no/articles/2011-fredrickson.pdf.\n\n\n[1] White, R. et al.  (2011). “History of Military Service and the Risk of Suicidal Ideation: Findings From the 2008 National Survey on Drug Use and Health”. In: Suicide and Life-Threatening Behavior 41.5, pp. 554–561. URL: https://www.rwhite.no/articles/2011-white.pdf."
  },
  {
    "objectID": "post/2025-01-21-dramatiske-korona-funn-store-morketall/index.html",
    "href": "post/2025-01-21-dramatiske-korona-funn-store-morketall/index.html",
    "title": "Dramatiske korona-funn: – Store mørketall",
    "section": "",
    "text": "Publisert på Nettavisen den 21. januar 2025."
  },
  {
    "objectID": "post/2025-03-13-stadig-flere-barn-til-legen-med-utmattelse-etter-pandemien/index.html",
    "href": "post/2025-03-13-stadig-flere-barn-til-legen-med-utmattelse-etter-pandemien/index.html",
    "title": "Stadig flere barn til legen med utmattelse etter pandemien",
    "section": "",
    "text": "Publisert på Utdanningsnytt den 12. mars 2025."
  },
  {
    "objectID": "post/2024-06-28-flere-unge-dode-av-sykdom/index.html",
    "href": "post/2024-06-28-flere-unge-dode-av-sykdom/index.html",
    "title": "Flere unge døde av sykdom: Forskere slår alarm",
    "section": "",
    "text": "Publisert på nrk.no den 28. juni 2024.\nSaken oppsummert:\n\nI 2023 døde 378 nordmenn i alderen 1 til 39 år av sykdom, en overdødelighet på over 50% sammenlignet med utviklingen i perioden 2010 til 2019.\nFlere forskere mistenker at senfølger av covid-19 kan være årsaken til den økte dødeligheten.\nSykdommer som kreft og hjerte- og karsykdommer krevde flere liv enn ventet, men den største økningen kom i kategorien «alle andre sykdommer».\nForsker Richard White frykter at konsekvensene av covid-19 ikke blir tilstrekkelig vurdert av norske myndigheter.\nInfeksjonslege og koronaforsker Arne Søraas ber helseministeren om å gripe inn.\nFagdirektør Preben Aavitsland i FHI mener det er lite som tyder på at senfølger av covid-19 fører til økt dødelighet."
  },
  {
    "objectID": "post/2024-05-03-biased-statistics-about-long-term-consequences-of-covid-19/index.html",
    "href": "post/2024-05-03-biased-statistics-about-long-term-consequences-of-covid-19/index.html",
    "title": "Biased statistics about long-term consequences of COVID-19",
    "section": "",
    "text": "This is a translation of the original Norwegian op-ed, and discrepancies may exist.\n\n\n\nPublished in Dag og Tid on May 3, 2024.\n\n\nIn the article “More about long-term consequences” in Dag og Tid on April 26, Preben Aavitsland at the Norwegian Institute of Public Health claims that mortality among young people has been stable since 2015, and questions a number of studies on long-term consequences of COVID-19. While he is busy criticizing others’ handling of facts, Aavitsland’s use of statistics is also questionable.\nAavitsland, one of the co-authors of FHI’s excess mortality report (April 16, 2024), writes that the report shows that deaths among people under 40 have been stable since 2015, but the report states that there was an excess mortality of 105 people under 40 in 2023. Furthermore, the claim about a “stable trend” from 2015 to 2019 is incorrect.\nThe trend from 2000 to 2019 reveals that Aavitsland’s “stable trend” is normal variation within a 20-year constant decline, abruptly ended by an upturn in 2023. The report only shows data from 2010, which artificially emphasizes random variation in later years. These nuances are necessary to understand the overall picture, but Aavitsland’s desire is obviously not to show the whole picture.\nAavitsland claims that the FHI report shows that there is no increase in heart and cardiovascular deaths among younger people. That may be true, but one cannot use this report to establish this. The report shows data per quarter, which is affected by seasonal variations, and only shows figures from 2016 onwards, without a long-term trend analysis.\nAavitsland refers to a systematic review published in BMC Medicine, a journal with limited recognition, and claims that “apparently concerning findings are due to biases in the studies.” The conclusion in the same article says something completely different: “There is a broad spectrum of long-term cardiac complications of COVID-19.”\nAavitsland often claims that studies showing that long-term consequences are both common and serious are biased and without value for Norway. Statistical techniques can measure how resistant findings are to unmeasured biases. I have used them and found that many of the studies that Aavitsland has dismissed are actually robust. It is unclear why they are ignored by Aavitsland. Assessment of methodological validity should be left to experienced statisticians.\nAavitsland mentions that FHI conducts systematic literature reviews on long-term consequences, and refers to a self-published report from 2022 that is not peer-reviewed. What about 2023 and 2024?\nIn July 2023, FHI published another one that evaluated 6,918 studies but considered all as irrelevant. They were left with zero studies. This is not an exception. Aavitsland often dismisses peer-reviewed articles in the most recognized journals in the world that show that COVID-19 has serious long-term consequences for many, even after vaccination.\nA recent study of 188,137 Norwegians showed a connection between COVID-19 and long-term memory problems and was published in the world-renowned journal NEJM. Nevertheless, it has not influenced Norwegian health policy. Neither the government’s corona strategy nor FHI’s risk assessments mention long-term consequences. Is this because the existence of long-term consequences goes against the current strategy, where we oppose infection control measures?\nAavitsland presents it as if we only have two options: uncontrolled infection or lockdown. In Dag og Tid March 15, FHI’s Carol Holm-Hansen gave several alternatives that can protect us without being intrusive. But before we talk about the solution, authorities must first acknowledge that long-term consequences exist and constitute a societal problem.\nShould we blame the government, FHI, or both? Regardless, it is the Norwegian population that pays the price. With health at stake. For readers who don’t know anyone affected by long-term consequences, give it a few more COVID waves. WHO estimates that 1 in 10 infections results in long-term consequences, and studies estimate that vaccines are only about 50 percent effective in preventing them.\nNorway has had 5 million infections per year since 2022. This time I’ll let the reader do the statistics themselves.\nRichard Aubrey White has a PhD in biostatistics from Harvard University. He is a researcher at FHI, but does not speak on behalf of the institute."
  },
  {
    "objectID": "post/2025-04-22-we-must-protect-teachers-from-long-covid/index.html",
    "href": "post/2025-04-22-we-must-protect-teachers-from-long-covid/index.html",
    "title": "We must protect teachers from long COVID",
    "section": "",
    "text": "This is a translation of the original Norwegian op-ed, and discrepancies may exist.\n\n\n\nPublished on Utdanningsnytt on April 22, 2025.\n\n\nMarch 12, 2025, marked a historic moment for Norwegian public health. Erna Solberg acknowledged that long COVID may be an important cause of increased sick leave and made an election promise to improve treatment.\nBut treatment is only half the solution. We must also prevent.\nLong COVID is caused by coronavirus infections. The more often people get infected, the more will develop long COVID. If we reduce transmission, fewer will become chronically ill.\nEarly in the pandemic, it was mistakenly believed that the coronavirus spread via droplets. Now we know that the coronavirus is airborne – it spreads in the air like smoke. Fortunately, airborne viruses can be prevented by purifying indoor air.\nFlorence Nightingale wrote in 1859: “The very first rule of nursing: Keep the air he breathes as pure as outdoor air.” This principle should be something we strive for today as well. By purifying the air, we can prevent respiratory infections, allergic problems, and other discomfort.\nWe have three effective methods for purifying indoor air: ventilation, filtration, and UVC light.\n\nVentilation supplies fresh air, ideally through balanced ventilation.\nAir filtration removes airborne viruses using air purifiers. Finland has successfully used this in kindergartens to reduce sick leave. FHI and SINTEF are researching whether air filtration can prevent infections with the new coronavirus, but research takes time.\nUVC light has for decades been used in schools and hospitals to prevent the spread of measles, tuberculosis, and influenza. Newer “far UVC” technology is even safer and easier to install in high-traffic areas such as public transport and corridors. Danish ambulances and the U.S. military already use this technology.\n\nAn “indoor climate” revolution is happening around the world – but Norway is lagging behind\nThe Biden administration developed, as a consequence of the pandemic, new indoor climate standards to protect public health. Japanese restaurants display real-time measurements of air quality. Australia has recently passed a law stating that “students and staff in public schools deserve a safe learning environment, including good air quality … Poorly ventilated indoor spaces increase the spread of airborne diseases and pose a risk to young people, staff, and the entire community.”\nWhile other countries are taking action, Norway is lagging behind. The Norwegian Institute of Public Health’s indoor climate expert group was disbanded, during a period when the number of coronavirus infections increased significantly. In the time since, general practitioner consultations for exhaustion and sick leave related to long COVID have increased sharply. These problems affect not only adults but also children, who are constantly infected in schools with poor indoor climate and risk long-term health problems.\n\nTeachers are exposed – long COVID can be an occupational injury\nChildren don’t just infect each other – they can also infect their families and their teachers, even when children themselves have no symptoms. Some of them also get long COVID. 36% of injury reports related to COVID-19 have come from teachers, kindergarten employees, and other school staff. Long COVID can be an occupational injury. Trade unions must take action to ensure that schools become safe workplaces. This type of transmission can to some extent be prevented by improved air purification or ventilation in schools and kindergartens.\nGood indoor climate is crucial for Norway’s preparedness\nImproved indoor climate is not just about comfort, health, air quality, or preventing long COVID today. It is also important for Norway’s preparedness. We know that new pandemics will come. If we now make an effort to achieve safer indoor climate in Norwegian schools, kindergartens, and other public buildings, we will be better protected next time. It will function as a transmission-reducing measure, but it will also help limit the need for shutdowns. A better indoor climate protects us against the increasingly likely bird flu pandemic – and other future airborne pandemias.\nNorway has much to gain by acting now. Will Norwegian politicians help ensure Norway’s public health, workforce, and preparedness – or let Norway fall behind?\nRichard Aubrey White does not write on behalf of FHI."
  },
  {
    "objectID": "post/2025-05-10-promising-long-covid-treatment-without-evidence/index.html",
    "href": "post/2025-05-10-promising-long-covid-treatment-without-evidence/index.html",
    "title": "Promising long COVID treatment without evidence",
    "section": "",
    "text": "This is a translation of the original Norwegian op-ed, and discrepancies may exist.\n\n\n\nPublished on Forskersonen on May 10, 2025.\n\n\nApproximately 3–6 percent of coronavirus infections lead to long-lasting health problems, known as “long COVID.” With millions of coronavirus infections each year in Norway, we face a serious public health crisis manifested through increased sick leave, more deaths than expected among younger adults, and a significant increase in medical consultations due to exhaustion.\nHopeful study with serious weaknesses\nErna Solberg and the Conservative Party have acknowledged that long COVID may be an important cause of increased sick leave and made an election promise to improve treatment.\nDespite the severity of the situation and the Conservative Party’s election promise, there is no documented effective treatment for long COVID.\nSome researchers, some of whom have a background in controversial psychosocial theories about post-viral conditions, have proposed experimental psychosocial treatments as the solution.\nA recent study by Tom Farmen Nerli and colleagues proposes treatment “based on a cognitive and behavioral approach.” The study has created hope, but a closer examination reveals serious methodological weaknesses.\nMisleading results and questionable measurement methods\n“Clinically significant” is a crucial concept when assessing treatment effect. It means that the treatment provides real, noticeable improvement in the patient’s health—not just a difference that can be measured statistically. It is therefore not enough to demonstrate a change; it must be large enough to have practical significance for quality of life and function.\nThe study by Nerli uses a scale for physical function (SF-36-PF) where participants themselves assess the extent to which their health limits them in daily activities such as climbing stairs, carrying groceries, or vacuuming.\nIn the analysis plan, written before the results were known, the authors state that an improvement of at least 10 points on this scale is necessary for a treatment to be considered clinically significant.\nMisleading presentation of findings\nIn this study, the treatment group achieved on average only 9.2 points improvement—thus below the threshold value. They have indeed measured an effect, but according to the authors’ own criteria, it is not large enough to have practical significance.\nNevertheless, the authors present the treatment as clinically significant and effective in the article. This is clearly misleading.\nFurthermore, the authors use a problematic definition of “healthy.” They consider patients healthy if they score 85 or higher on the SF-36-PF scale, regardless of age and gender. A score of 85 is typical for a healthy 60-year-old woman, but the participants in the study had an average age of 42 years. Thus, using a score of 85 as the “healthy” threshold leads to an artificially high proportion of “healthy” individuals.\nLack of data sharing prevents verification\nStrong conclusions require openness and independent control. The authors promised in their data statement that anonymized data would be made available for scientific use. I requested an anonymized and limited dataset to be able to calculate real, age- and gender-adjusted recovery rates.\nThe dataset would contain only a few variables: Whether the participant received the intervention, whether they were healthy according to the authors’ definition, and whether they were healthy according to an age- and gender-adjusted definition at three time points.\nThe request was denied after six weeks. Akershus University Hospital HF believed the data were “sensitive personal information and subject to confidentiality,” despite no identifying information being requested.\nAnother justification was that “extraction of relevant variables and subsequent anonymization will also require some work effort from the researchers associated with the project.” This raises the question: Why was data sharing promised then?\nResearchers must not promise openness they cannot deliver. Such broken promises weaken research credibility and undermine the principle of independent reproducibility.\nHow many actually recovered?\nIt was only after I complained to the journal JAMA Network Open that the authors published the age- and gender-adjusted recovery rates. These showed that only 8 percent of participants in the control group recovered after twelve months—a strikingly low proportion that should cause serious concern among clinicians and health authorities.\nIn the intervention group, the proportion was 29 percentage points higher. But since the participants themselves assessed the outcomes (for example, “Is your health such that it limits you in moderate activities such as vacuuming?”), and knew whether they received the intervention or not, it is unclear how much of the intervention’s modest effect is due to placebo effect and response bias.\nThis means that participants may have overestimated improvement because they expected an effect, or wanted to confirm the researchers’ assumptions. Objective measures, such as number of steps per day, would likely have shown even weaker results.\nAn unblinded psychosocial treatment with a recovery rate of only 29 percent on a subjective measure under ideal trial conditions should not be presented as a solution for a complex, multisystemic condition like long COVID.\nOn the contrary, this underscores the need for biomedical treatment strategies targeting, among other things, viral persistence, post-acute inflammation, autoimmunity, thrombosis, reactivation of latent viruses, dysbiosis, gut translocation, and mitochondrial dysfunction.\nNeed for greater openness and better methodology\nMisleading presentation, weak methods, and secrecy of data are not just technical details, but serious errors with major consequences for those struggling with long COVID. Only honest and open science can form the basis for informed choices by patients, healthcare personnel, and politicians.\nUntil results can be confirmed through robust and independent research, we must be cautious about spreading hopes about experimental treatments.\nThe precautionary principle also suggests that we must prioritize prevention of long COVID, just as we do with all other diseases, while developing better treatment. Since long COVID is caused by an airborne virus, prevention must occur through better ventilation, air purification and use of FFP2 masks.\nWe owe both patients and society to demand openness and scientific integrity. Only in this way can we find the solutions that are needed.\nAbout the author: Richard Aubrey White has a PhD in biostatistics from Harvard University. He is a researcher at the Norwegian Institute of Public Health, but does not write on behalf of the institute."
  },
  {
    "objectID": "post/2024-11-11-covid-is-more-dangerous-than-you-think/index.html",
    "href": "post/2024-11-11-covid-is-more-dangerous-than-you-think/index.html",
    "title": "COVID is more dangerous than you think",
    "section": "",
    "text": "This is a translation of the original Norwegian op-ed, and discrepancies may exist.\n\n\n\nPublished on NRK on November 11, 2024.\n\n\nWhen the pandemic hit us in 2020, we knew little about COVID-19 and the virus that causes this entirely new disease. Now we know much more.\nIt has been shown that the coronavirus spreads almost exclusively through the air. If you don’t breathe in the virus, you won’t get infected. That’s why many people experience COVID as a cold and cough. But after the virus enters through the airways, it spreads throughout the entire body.\nWhat the coronavirus does to the body\nA virus consists of almost nothing but packaged genetic material. For the virus to reproduce, it must get inside the body’s cells. The virus “parasitizes” our cells to make many new copies of itself.\n\n“Damage can be seen in the brain, even after mild illness”\n\nThe coronavirus has a rather unique ability to get into many different cell types, including cells that form the lining of blood vessels and immune cells, and damage them. Therefore, COVID is not considered a respiratory infection, but a so-called systemic, multi-organ infectious disease.\nWhile vaccines and previous infections have made acute COVID less dangerous, concerns about the virus’s many long-term consequences have increased.\nResearch shows that the risk of long-term consequences increases the more severe the acute illness is, but there are still most cases of long-term consequences after mild illness, because this is so common.\nIn some patients with long COVID, it has been shown that the virus can remain inside the body’s cells and organs for a long time. They cannot completely get rid of it. It is therefore not surprising that new research finds that genes that control the body’s ability to fight viruses are linked to increased risk of long COVID.\n\n“The problems affect many and are often persistent”\n\nIt has also been seen that mice injected with antibodies from people with long COVID develop the symptoms that the patients have. It is therefore high time that we stop psychologizing these problems.\nIncreases the risk of many health problems\nDamage to ten different organ systems has been reported after COVID. Long-term consequences after COVID are therefore more than fatigue and shortness of breath. Cognitive problems such as “brain fog,” reduced memory, processing speed and concentration ability, and reduced ability for complex actions are the symptoms most commonly reported after COVID, and damage can be seen in the brain on MRI, even after mild illness.\nIt is concerning that large studies, including the Norwegian Corona Study, find that these problems affect many and are often persistent.\nThe risk of getting a new, completely different disease, such as type 1 and type 2 diabetes or an infectious disease, and the risk of dying from all causes, is also increased for several years after COVID. COVID has been found to be an independent risk factor for cardiovascular disease, even in previously healthy people. These diseases are also associated with increased need for health services.\n\n“There are most cases of long-term consequences after mild illness”\n\nIncreased pressure on the healthcare system and social security system\nEven though the risk of long-term consequences became somewhat lower after omicron arrived and people got vaccinated, studies with control groups still show that 3 percent or more develop health problems of varying degrees after having COVID. Each infection involves an increased risk.\nAs long as we don’t have more effective vaccines or medical treatments, we can therefore assume that the number of Norwegians who have problems with memory, concentration ability, and the ability to perform complex tasks will increase in the years ahead. With several million coronavirus infections each year in Norway, this constitutes a societal problem.\nWhen so few test themselves, people often don’t know they have had COVID. At the same time, long-term consequences can appear in the form of other diseases, long after we feel healthy.\nIn addition, general practitioners in Norway use a diagnostic coding system that lacks a specific code for long-term consequences after COVID. Therefore, much of the increased illness and mortality that follows after COVID will be registered under completely different diagnoses, such as A04 (exhaustion) or P29 (which includes fatigue). P29 is classified under “minor mental disorders.”\nLong COVID is likely the cause of a large number of sick leave cases with these diagnoses, which we know have increased significantly in the last two years.\n\n“Damage to ten different organ systems has been reported”\n\nWe must expect more sick leave, a more burdened healthcare system, and perhaps higher excess mortality also in the time ahead, as we have seen since the authorities stopped limiting the spread of infection in early 2022.\nEven though the number of people who become seriously ill and die from acute COVID is declining, the disease is thus a driver behind this development.\nHow to prevent?\nFirst, everyone who might have COVID should test themselves and avoid infecting others by staying home if the test is positive.\nIt has been shown that vaccines protect against long-term consequences, including damage to the cardiovascular system, and the increased risk of disease and death. Long-term consequences can affect all age groups.\nVaccines protect all age groups, have few side effects, and are approved for everyone over six months. Therefore, everyone should be offered basic vaccination and boosters each time new, updated COVID vaccines become available through adapted programs for different groups, as American health authorities recommend.\n\n“It is high time that we stop psychologizing these problems”\n\nBut protection from vaccination is not complete, and the effect drops rapidly after six months. The only sure way to prevent long-term consequences after COVID is currently to avoid getting infected.\nSince COVID spreads through the airways, we won’t get infected if there are no virus particles in the air we breathe. A face mask that effectively prevents particles from reaching the nose and mouth therefore provides good protection.\nIt is smart to use face masks at high infection risk, such as when there is a lot of infection in circulation and you are indoors with many others, or if someone has a cold.\nImproving indoor air quality can also reduce the number of sick people. Norway should invest in improving indoor ventilation and installing air purifiers in schools, public buildings, and workplaces, as other countries do. This has been shown to result in fewer infections among kindergarten and school children, reduced sick leave among parents and employees, and it can save money and increase quality of life.\nGetting COVID every other year is better for your health than getting COVID twice every year. For every infection case we prevent, there are also fewer who spread it further. Therefore, such preventive, simple infection control measures are more effective than many think, even though they are not perfect. They can probably save society large sums.\nRichard Aubrey White is a researcher at the Norwegian Institute of Public Health, but does not write on behalf of his employer."
  },
  {
    "objectID": "post/2025-04-22-vi-ma-beskytte-laererne-mot-long-covid/index.html",
    "href": "post/2025-04-22-vi-ma-beskytte-laererne-mot-long-covid/index.html",
    "title": "Vi må beskytte lærerne mot long covid",
    "section": "",
    "text": "Publisert på Utdanningsnytt den 22. april 2025.\n\n\nDen 12. mars 2025 markerte et historisk øyeblikk for norsk folkehelse. Erna Solberg anerkjente at long covid kan være en viktig årsak til økningen i sykefraværet og kom med et valgløfte om å forbedre behandlingen.\nMen behandling er bare halve løsningen. Vi må også forebygge.\nLong covid skyldes koronainfeksjoner. Jo oftere folk blir smittet, desto flere vil utvikle long covid. Hvis vi reduserer smitten, vil færre bli kronisk syke.\nTidlig i pandemien trodde man feilaktig at koronaviruset spredte seg via dråper. Nå vet vi at koronaviruset er luftbårent – det sprer seg i luften som røyk. Heldigvis kan luftbårne virus forebygges ved å rense inneluften.\nFlorence Nightingale skrev i 1859: «Den aller første regelen for sykepleie: Hold luften han puster så ren som uteluften.» Dette prinsippet bør vi strebe etter også i dag. Ved å rense luften kan vi forebygge luftveisinfeksjoner, allergiplager og annet ubehag.\nVi har tre effektive metoder for å rense inneluften: ventilasjon, filtrering og UVC-lys.\n\nVentilasjon tilfører frisk luft, ideelt gjennom balansert ventilasjon.\nLuftfiltrering fjerner luftbårne virus ved hjelp av luftrensere. Finland har med suksess brukt dette i barnehager for å redusere sykefravær. FHI og SINTEF forsker på om luftfiltrering kan forebygge infeksjoner med det nye koronaviruset, men forskningen tar tid.\nUVC-lys har i flere tiår vært brukt i skoler og sykehus for å hindre spredning av meslinger, tuberkulose og influensa. Nyere «far UVC»-teknologi er enda tryggere og lettere å installere i høyt trafikkerte områder som kollektivtransport og korridorer. Danske ambulanser og det amerikanske forsvaret bruker allerede denne teknologien.\n\nEn «inneklima»-revolusjon skjer nå over hele verden – men Norge henger etter\nBiden-administrasjonen utviklet, som en konsekvens av pandemien, nye inneklimastandarder for å beskytte folkehelsen. Japanske restauranter viser målinger av luftkvalitet i sanntid. Australia har nylig vedtatt en lov som slår fast at «elever og ansatte i offentlige skoler fortjener et trygt læringsmiljø, inkludert god luftkvalitet … Dårlig ventilerte innendørsrom øker spredningen av luftbårne sykdommer og utgjør en risiko for unge mennesker, ansatte og hele samfunnet.»\nMens andre land handler, henger Norge etter. Folkehelseinstituttets fagmiljø for inneklima ble lagt ned, i en periode hvor antallet koronainfeksjoner økte betydelig. I tiden etter, har fastlegekonsultasjoner for utmattelse og sykefravær knyttet til long covid økt kraftig. Disse plagene rammer ikke bare voksne, men også barn, som stadig smittes i skoler med dårlig inneklima og risikerer langvarige helseplager.\n Lærere er utsatt — long covid kan være en yrkesskade\nBarna smitter ikke bare hverandre — de kan også smitte familiene sine, og lærerne sine, selv når barna selv ikke har symptomer. Noen av dem får også long covid. 36 % av skademeldinger knyttet til covid-19 har kommet fra lærere, barnehageansatte og andre skoleansatte. Long covid kan være en yrkesskade. Fagforeningene må ta grep for å sikre at skolene blir trygge arbeidsplasser. Denne typen smitte kan i noen grad forebygges ved bedret luftrensing eller ventilasjon i skoler og barnehage.\nGodt inneklima er avgjørende for Norges beredskap\nForbedret inneklima handler ikke bare om trivsel, helse, luftkvalitet eller å forebygge long covid i dag. Det er også viktig for Norges beredskap. Vi vet at det vil komme nye pandemier. Dersom vi nå tar et løft for å få sikrere inneklima i norske skoler, barnehager og andre offentlige bygg, vil vi være bedre beskyttet neste gang. Det vil fungere som et smittereduserende tiltak, men det vil også bidra til å begrense behovet for nedstengninger. Et bedre inneklima beskytter oss mot den stadig mer sannsynlige fugleinfluensa-pandemien – og andre fremtidige luftbårne pandemier.\nNorge har mye å vinne på å handle nå. Vil norske politikere bidra til å sikre Norges folkehelse, arbeidskraft og beredskap – eller la Norge bli hengende etter?\nRichard Aubrey White skriver ikke på vegne av FHI."
  },
  {
    "objectID": "post/2025-03-25-all-cause-mortality-in-norway/index.html",
    "href": "post/2025-03-25-all-cause-mortality-in-norway/index.html",
    "title": "All-cause mortality in Norway",
    "section": "",
    "text": "Today the Norwegian Institute of Public Health published its report on all-cause mortality in Norway for 2024.\nThere are two points that are of interest:\nFirstly, the press release starts with:\n\nAfter periods with high mortality during the COVID-19 pandemic, mortality in Norway in 2024 was within expected levels.\n\n\nThis is interesting, because the press release then states “In 2024 mortality was within expected ranges based on the development in the period 2011-2019 and 2023.”\nSo it appears as though 2023 (a year with a large amount of excess mortality) is now included in the baseline. This is concerning because it means that the baseline is now higher than it was before.\nSecondly, the press release states that:\n\nNo excess mortality in any age groups.\n\n\nSo how much of this is due to the fact that the baseline has been shifted upwards? Lets find out.\nHere, I fit a Poisson regression with a baseline comprising of 2010, 2012-2019. I remove 2011 because of the terror attacks on the 22nd of July 2011. The regression includes an offset for population size. I then calculate the 5th, 50th and 95th percentiles of the posterior predictive distribution of the number of deaths in different age groups. I then plot the results as rates of death per 100 000 population.\nI have chosen a linear extrapolation out to 2023 and then set the 2024 baseline to be the same as 2023. I believe that this is reasonable because in last year’s report, the NIPH used a linear extrapolation out to 2023.\n\n\nShow the code\nlibrary(data.table)\nlibrary(magrittr)\nlibrary(ggplot2)\n\nif (interactive()) {\n  folder_location &lt;- \"post/2025-03-25-all-cause-mortality-in-norway/\"\n} else {\n  folder_location &lt;- \"\"\n}\n\n# Loading the cleaned data\nd_deaths &lt;- readxl::read_excel(glue::glue(\"{folder_location}10325_20250325-102517.xlsx\"))\nsetDT(d_deaths)\nd &lt;- melt.data.table(\n  d_deaths, \n  id.vars = \"age\",\n  variable.factor = FALSE,\n  value.name = \"deaths_n\"\n  )\nd[, year := as.numeric(variable)]\nd[, variable := NULL]\nd[, age_numeric := stringr::str_extract(age, \"\\\\d+\") %&gt;% as.numeric()]\nd[, age_cat := fcase(\n  age_numeric == 0, \"000_000\",\n  age_numeric %in% 1:19, \"001_019\",\n  age_numeric %in% 20:39, \"020_039\",\n  age_numeric %in% 40:64, \"040_064\",\n  age_numeric %in% 65:79, \"065_079\",\n  age_numeric %in% 80:200, \"080p\"\n)]\nd &lt;- d[, .(\n  deaths_n = sum(deaths_n)\n), keyby = .(year, age_cat)]\n\n\np &lt;- csdata::nor_population_by_age_cats(cats = list(\n  \"000_000\" = 0,\n  \"001_019\" = 1:19,\n  \"020_039\" = 20:39,\n  \"040_064\" = 40:64,\n  \"065_079\" = 65:79,\n  \"080p\" = 80:200\n))[location_code==\"nation_nor\"]\n\nd[p, on = c(\"year==calyear\", \"age_cat==age\"), pop_jan1_n := pop_jan1_n]\nd[,deaths_vs_pop_pr100000 := 100000*deaths_n/pop_jan1_n]\n\nd[, year_frozen_at_2023 := year]\nd[year &gt;= 2023, year_frozen_at_2023 := 2023]\n\np &lt;- plnr::Plan$new()\np$add_data(name=\"data\", direct = d)\n\np$add_argset(age = \"000_000\")\np$add_argset(age = \"001_019\")\np$add_argset(age = \"020_039\")\np$add_argset(age = \"040_064\")\np$add_argset(age = \"065_079\")\np$add_argset(age = \"080p\")\n\nanalysis_1 &lt;- function(argset, data){\n  if(plnr::is_run_directly()){\n    data &lt;- p$get_data()\n    argset &lt;- p$get_argset(1)\n  }\n  pd &lt;- data$data[age_cat==argset$age & year&gt;=2010]\n\n  fit &lt;- rstanarm::stan_glm(\n    deaths_n ~ year_frozen_at_2023, \n    data = pd[year!=2011 & year&lt;=2019], \n    offset=log(pop_jan1_n),\n    family = poisson,\n    refresh = 0\n  )\n\n  pred &lt;- rstanarm::posterior_predict(fit, pd, offset=log(pd$pop_jan1_n))\n  retval &lt;- apply(pred, 2, quantile, probs = c(0.05, 0.5, 0.95)) %&gt;%\n    t() %&gt;%\n    as.data.frame()\n  names(retval) &lt;- c(\"p5\", \"p50\", \"p95\")\n\n  return(cbind(pd, retval))\n}\n\np$apply_action_fn_to_all_argsets(fn = analysis_1)\n\nraw &lt;- p$run_all()\nr &lt;- rbindlist(raw)\n\nr[deaths_n &gt; p95]\n\nr[deaths_n &gt; p95 & year&gt;=2024]\n\nr[, age_pretty := fcase(\n  age_cat==\"000_000\", \"0 years old\",\n  age_cat==\"001_019\", \"1-19 years old\",\n  age_cat==\"020_039\", \"20-39 years old\",\n  age_cat==\"040_064\", \"40-64 years old\",\n  age_cat==\"065_079\", \"65-79 years old\",\n  age_cat==\"080p\", \"80+ years old\"\n)]\n\n\n\n\nCode\nq &lt;- ggplot(r[year&lt;=2024], aes(x = year))\nq &lt;- q + geom_ribbon(aes(ymin=100000*p5/pop_jan1_n, ymax=100000*p95/pop_jan1_n), fill = \"black\", alpha = 0.5)\nq &lt;- q + geom_line(aes(y = 100000*p50/pop_jan1_n))\nq &lt;- q + geom_point(aes(y = 100000*deaths_n/pop_jan1_n))\nq &lt;- q + geom_vline(xintercept = 2019.5, lty = 2, color = \"red\")\nq &lt;- q + facet_wrap(~age_pretty, scales = \"free\")\nq &lt;- q + scale_y_continuous(\"Deaths per 100 000 population\")\nq &lt;- q + scale_x_continuous(NULL, breaks = seq(2010, 2024, 2), minor_breaks = NULL)\nq &lt;- q + csstyle::set_x_axis_vertical()\nq &lt;- q + labs(\n  caption = \"Weekly baseline calculated from a poisson regression of 2010, 2012-2019.\\nData extracted from SSB table 10325\"\n)\nprint(q)\n\n\n\n\n\n\n\n\n\nUnfortunately, it appears as though there is still significant excess mortality in 2024, including in the younger age groups.\nThe Norwegian Institute of Public Health’s positive press release seems to be based primarily upon a shift in the baseline, rather than a true reduction in mortality. This is concerning, as it may lead to a false sense of security."
  },
  {
    "objectID": "post/2024-09-27-prevent-covid-19-prevent-sick-leave/index.html",
    "href": "post/2024-09-27-prevent-covid-19-prevent-sick-leave/index.html",
    "title": "Prevent COVID-19, prevent sick leave",
    "section": "",
    "text": "Published in Dag of Tid the 27th of September 2024.\n\n\nThis is a translation of the original Norwegian op-ed, and discrepancies may exist.\nIn the article “Not a Question of Morality, but of Good Treatment” in Dag og Tid on September 20, Marit Hermansen, Chief Medical Officer at NAV, claims that “the cause of mild mental health issues doesn’t play a large role. Whether the cause is COVID-19 or something else, many will benefit health-wise from being in adapted activity and work.”\nThis is incorrect.\nA bit of background: Sick leave has increased in several diagnostic codes compared to 2019. NAV’s sick leave registry has no code for Long COVID, meaning that people with Long COVID are spread across several codes based on symptoms. Long COVID can affect nearly all organ systems, including the brain. The largest increases are in the codes A04 (fatigue), P02 (acute stress reaction), and P29 (psychological symptom/complaint other). Fatigue is clearly linked to Long COVID, yet the narrative focuses only on “mild mental health issues” (P02 and P29). NAV researchers Moberg and Kabashi found that sick leave due to acute COVID-19 was associated with 25% and 18% higher sick leave for P02 and P29, respectively, in the following 12 weeks.\nAccording to the WHO, 1 in 10 COVID-19 infections lead to Long COVID, and studies estimate that vaccines are only about 50 % effective in preventing it. With the current “mass infection” strategy, Norway has had 5 million COVID-19 infections every year since 2022. Based on this, we can expect around 250,000 new cases of Long COVID each year — including in 2024 and 2025. The German Health Minister, Professor Lauterbach stated on September 17, 2024: “Long COVID is not gone, and it will not disappear. There is often no cure for those affected — and the number of those affected is growing.”\nThere is strong evidence that a large part of the increase in sick leave is due to Long COVID.\nNow, to Hermansen’s point: Good treatment must be adapted to the cause of the illness. If a person is burned out due to life or work circumstances, activity can help. But if someone is misdiagnosed as burned out, when they are actually suffering from Long COVID, then activity without adequate consideration of post-exertional malaise (PEM) can potentially be harmful.\nWe should prevent illness, not just treatment. If the increase in sick leave is due to Long COVID, then we must prevent COVID-19. This can be done by improving ventilation, using air purifiers, and recommending the use of FFP2 respirators in public spaces when there is high transmission. These protective measures are effective and do not significantly affect daily life. We can reduce the problem itself, and people can avoid getting sick — what we lack is the will to do so.\nIn the end, it’s about culpability. Since 2022, the country, under the Labour Party and Centre Party government, has pursed a “mass infection” strategy, without a risk assessment of Long COVID. Around 250,000 new Norwegians are affected by Long COVID every year. Health Minister Vestre has continued this policy, without evaluating the consequences regarding Long COVID, and has instead blamed the increased sick leave on “the pandemic [causing] us to behave a little differently” (Good Morning Norway, September 17).\nAt the same time, the government’s significant cuts to the Norwegian Insitute of Public Health’s budget in 2023, which led to the closure of the center for indoor air quality, have weakened Norway’s ability to legislate technical requirements for indoor air quality that can protect us against airborne viruses like SARS-CoV-2 (the virus that causes COVID-19). This is a betrayal of public health and a conflict of interest for the government — acknowledging Long COVID as a societal problem would draw attention to the “mass infection” strategy and the resources the government has removed.\nIf the increase in sick leave is due to Long COVID, then the government must be forced to take responsibility for its post-pandemic management and the subsequent health and economic consequences.\nSo yes, the cause does play a large role.\nRichard Aubrey White holds a PhD in biostatistics from Harvard University. He is a researcher at the Norwegian Institute of Public Health, but does not speak on behalf of the institute."
  },
  {
    "objectID": "post/2024-10-02-senfolger-av-covid-19-er-vanlige-og-ofte-vedvarende/index.html",
    "href": "post/2024-10-02-senfolger-av-covid-19-er-vanlige-og-ofte-vedvarende/index.html",
    "title": "Senfølger av covid-19 er vanlige og ofte vedvarende",
    "section": "",
    "text": "Publisert i Aftenposten den 2. oktober 2024.\n\n\nI en artikkel i Aftenposten 27. september hevder professor og direktør Preben Aavitsland ved Folkehelseinstituttet (FHI) at senfølger av covid-19 er «sjeldne og går ofte over etter hvert».\nDette er feil — senfølger av covid-19 er vanlige og ofte vedvarende.\nAavitslands påstand om varigheten kommer trolig fra FHIs studie, som kun analyserer antall fastlegebesøk etter koronasmitte. Hans tolkning av at færre besøk betyr at senfølgene har gått over, er feilaktig. Folk slutter å gå til legen når legen ikke kan hjelpe dem, selv om senfølgene vedvarer.\nØker den samlede risikoen\nKoronastudien, som ser på helse i stedet for fastlegebesøk, viste nylig at covid-19 førte til 6 prosent risiko for hukommelsesproblemer mer enn ett år senere hos nordmenn uten immunitet. Vaksiner og immunitet er cirka 50 prosent effektive mot senfølger, så risikoen kan reduseres til 3 prosent for de fleste. Dette gjelder pr. infeksjon.\nDen samlede risikoen etter to infeksjoner er da 5,9 prosent, etter fire infeksjoner 11,5 prosent, etter seks infeksjoner 16,7 prosent.\nDette er ett eksempel, men flere studier viser det samme resultatet — gjentatte infeksjoner øker den samlede risikoen til et uakseptabelt nivå. Dette må ses i konteksten av dagens «fri smitte»-strategi, der folk i gjennomsnitt blir smittet én gang i året.\nDet er ikke overraskende at økningen i sykefravær er drevet av tre diagnosekoder (A04, P02 og P29), som alle er forbundet med senfølger.\nBagatelliserer byrden\n«Fri smitte»-strategien var støttet av FHIs risikovurdering, som kun så på akutt covid-19. FHI har aldri publisert en risikovurdering av strategien som nevner senfølger.\nI lys av det høye sykefraværet, trolig på grunn av senfølger, har de som var ansvarlige for strategien og de manglende risikovurderingene, gode insentiver til å bagatellisere byrden senfølger utgjør for samfunnet.\nVi må forebygge covid-19-smitte og senfølger. Dette kan vi gjøre ved å forbedre ventilasjonen, bruke luftrensere og anbefale bruk av FFP2-åndedrettsvern når smitten er høy.\nRichard Aubrey White har en doktorgrad i biostatistikk fra Harvard University. White er forsker ved Folkehelseinstituttet, men uttaler seg ikke på vegne av FHI."
  },
  {
    "objectID": "post/2024-01-04-rekordmange-til-lege-med-utmattelse/index.html",
    "href": "post/2024-01-04-rekordmange-til-lege-med-utmattelse/index.html",
    "title": "Slår alarm: Rekordmange til lege med utmattelse",
    "section": "",
    "text": "Publisert på nrk.no den 4. jan 2024.\nSaken oppsummert:\n\nDet har vært en dramatisk økning i antall pasienter som oppsøker lege for utmattelse under pandemien.\nØkningen har skjedd i alle aldersgrupper, med unntak av barn i alderen 0–4 år.\nFHI-statistiker Richard Aubrey White og andre forskere er bekymret for utviklingen.\nØkningen i utmattelse kom samtidig med omikronvarianten, og det er en tidsmessig sammenheng mellom smittebølger og økning i utmattelse.\nFlere store studier viser at covid-19 kan gi alvorlige senfølger.\nForsker og infeksjonsmedisiner Arne Søraas oppfordrer norske folkehelsemyndigheter til å oppdatere seg på internasjonal forskning på området.\nFagdirektør Preben Aavitsland i FHI mener det ikke er nok god kunnskap til å slå fast at covid-19 fører til alvorlige senfølger."
  },
  {
    "objectID": "post/2024-05-03-tendensios-statistikk-om-senfolger/index.html",
    "href": "post/2024-05-03-tendensios-statistikk-om-senfolger/index.html",
    "title": "Tendensiøs statistikk om senfølger",
    "section": "",
    "text": "Publisert i Dag og Tid den 3. mai 2024.\n\n\nI innlegget «Meir om seinfølger» i Dag og Tid 26. april hevder Preben Aavitsland ved Folkehelseinstituttet at dødeligheten blant unge har vært stabil siden 2015, og trekker en rekke studier om senfølger av covid-19 i tvil. Mens han er opptatt med å kritisere andres omgang med fakta, er Aavitslands bruk av statistikk også tvilsom.\nAavitsland, en av medforfatterne til FHIs overdødelighetsrapport (16. april 2024), skriver at rapporten viser at dødsfall blant personer under 40 har vært stabile siden 2015, men i rapporten står det at det var en overdødelighet på 105 personer under 40 i 2023. Videre er påstanden om en «stabil trend» fra 2015 til 2019 feilaktig.\nTrenden fra 2000 til 2019 avslører at Aavitslands «stabile trend» er normal variasjon innenfor en 20-årig konstant nedgang, brått avsluttet av et oppsving i 2023. Rapporten viser kun data fra 2010, noe som legger kunstig vekt på tilfeldig variasjon i senere år. Disse nyansene er nødvendige for å forstå totalbildet, men Aavitslands ønske er tydeligvis ikke å vise helheten.\nAavitsland hevder at FHI-rapporten viser at det ikke er økning i hjerte- og kardødsfall hos yngre. Det kan stemme, men man kan ikke bruke denne rapporten til å fastslå dette. Rapporten viser data per kvartal, som påvirkes av sesongmessige variasjoner, og viser kun tall f.o.m. 2016, uten en langsiktig trendanalyse.\nAavitsland viser til en systematisk gjennomgang publisert i BMC Medicine, et tidsskrift med begrenset anerkjennelse, og hevder at «tilsynelatende urovekkende funn skyldes skjevheter i studiene». Konklusjonen i samme artikkel sier noe helt annet: «Det er et bredt spektrum av langvarige hjertekomplikasjoner av covid-19.»\nAavitsland påstår ofte at studier som viser at senfølger er både vanlige og alvorlige, er skjeve og uten verdi for Norge. Statistiske teknikker kan måle hvor motstandsdyktige funn er mot umålte skjevheter. Jeg har brukt dem og funnet at mange av studiene som Aavitsland har avskrevet, faktisk er robuste. Det er uklart hvorfor de ignoreres av Aavitsland. Vurdering av metodisk validitet bør overlates til erfarne statistikere.\nAavitsland nevner at FHI gjør systematiske litteraturgjennomganger om senfølger, og viser til en selvpublisert rapport fra 2022 som ikke er fagfellevurdert. Hva med 2023 og 2024?\nI juli 2023 publiserte FHI en til, som vurderte 6918 studier, men regnet alle som ikke relevante. De ble sittende igjen med null studier. Dette er ikke et unntak. Aavitsland avviser ofte fagfellevurderte artikler i de mest anerkjente tidsskriftene i verden som viser at covid-19 har alvorlige langtidskonsekvenser for mange, selv etter vaksinasjon.\nEn nylig studie av 188.137 nordmenn viste en sammenheng mellom covid-19 og langsiktige hukommelsesproblemer og ble publisert i det verdenskjente tidsskriftet NEJM. Allikevel har den ikke påvirket norsk helsepolitikk. Verken regjeringens koronastrategi eller FHIs risikovurderinger nevner senfølger. Er dette fordi eksistensen av senfølger går imot den nåværende strategien, hvor vi motsetter oss smitteverntiltak?\nAavitsland fremstiller det som om vi kun har to muligheter: ukontrollert smitte eller nedstengning. I Dag og Tid 15. mars ga FHIs Carol Holm-Hansen flere alternativ som kan beskytte oss uten å være inngripende. Men før vi snakker om løsningen, må myndighetene først anerkjenne at senfølger eksisterer og utgjør et samfunnsproblem.\nBør vi klandre regjeringen, FHI eller begge to? Uansett er det den norske befolkningen som betaler prisen. Med helsa som innsats. For lesere som ikke kjenner noen som er påvirket av senfølger, gi det noen covid-bølger til. WHO anslår at 1 av 10 infeksjoner gir senfølger, og studier anslår at vaksiner kun er ca. 50 prosent effektive i å forebygge dem.\nNorge har hatt 5 millioner infeksjoner i året siden 2022. Denne gangen vil jeg la leseren gjøre statistikken selv.\nRichard Aubrey White har ein doktorgrad i biostatistikk frå Harvard University. Han er forskar ved FHI, men uttalar seg ikkje på vegner av instituttet."
  },
  {
    "objectID": "post/2023-04-20-mice-with-interaction-terms/index.html",
    "href": "post/2023-04-20-mice-with-interaction-terms/index.html",
    "title": "Multivariate imputation by chained equations (MICE) with interaction terms",
    "section": "",
    "text": "We simulate a dataset where it is not harmful to be male nor a smoker (coefficient = 0), but the interaction of the two is very harmful (coefficient = 5).\nWe then set the outcome to missing for 70% of the males and 70% of the smokers, and run the following analyses:\n\nComplete case analysis\nBlindly imputed analysis (using MICE)\nImputed analysis (using MICE) where males and females were imputed separately.\n\nWe repeat this for multiple datasets with various sample sizes, to see how the imputation strategies are affected by the size of the dataset.\n\nlibrary(data.table)\nlibrary(magrittr)\nlibrary(ggplot2)\n\nsim_function &lt;- function(data, argset){\n  data &lt;- data.table(id = 1:argset$n)\n  \n  data[, is_male := rbinom(.N, 1, 0.5)]\n  data[, is_smoker := rbinom(.N, 1, 0.5)]\n  data[, lung_function := -1 + 0 * is_male + 0 * is_smoker + 5 * is_male * is_smoker + rnorm(.N, sd = 2)]\n  \n  data_missing &lt;- copy(data)\n  data_missing[is_male==1 & runif(.N)&lt;0.7, lung_function := NA]\n  data_missing[is_smoker==1 & runif(.N)&lt;0.7, lung_function := NA]\n  \n  # complete case analysis\n  coef_complete_case &lt;- coef(summary(lm(lung_function ~ is_male*is_smoker, data = data_missing)))[,1]\n  \n  # we impute the data blindly\n  data_imputed &lt;- mice::mice(data_missing, print=F, m = 20)\n  fit_imputed &lt;- with(data_imputed, lm(lung_function ~ is_male*is_smoker))\n  coef_imputed_blindly &lt;- mice::pool(fit_imputed)$pooled$estimate\n  \n  # we impute the data separately for males and females\n  data_imputed_male &lt;- mice::mice(data_missing[is_male==1], print=F, m = 20)\n  data_imputed_female &lt;- mice::mice(data_missing[is_male==0], print=F, m = 20)\n  data_imputed_sex_specific &lt;- mice:::rbind.mids(data_imputed_male, data_imputed_female)\n  fit_imputed &lt;- with(data_imputed_sex_specific, lm(lung_function ~ is_male*is_smoker))\n  coef_imputed_separately &lt;- mice::pool(fit_imputed)$pooled$estimate\n  \n  retval &lt;- data.table(\n    var = names(coef_complete_case),\n    coef_complete_case,\n    coef_imputed_blindly,\n    coef_imputed_separately,\n    n = argset$n\n  )\n  return(retval)\n}\n\np &lt;- plnr::Plan$new()\nfor(n in c(100, 500, 1000, 2000, 4000)) for(i in 1:100){\n  p$add_argset(\n    name = uuid::UUIDgenerate(),\n    n=n,\n    i=i\n  )\n}\np$apply_action_fn_to_all_argsets(sim_function)\nset.seed(1234)\nresults &lt;- p$run_all()\nresults &lt;- rbindlist(results)\n\nresults[var == \"is_male:is_smoker\", .(\n  coef_complete_case = round(mean(coef_complete_case), 2),\n  coef_imputed_blindly = round(mean(coef_imputed_blindly), 2),\n  coef_imputed_separately = round(mean(coef_imputed_separately), 2)\n), keyby=.(n)] %&gt;% \n  print()\n\nKey: &lt;n&gt;\n       n coef_complete_case coef_imputed_blindly coef_imputed_separately\n   &lt;num&gt;              &lt;num&gt;                &lt;num&gt;                   &lt;num&gt;\n1:   100               5.06                 1.33                    2.60\n2:   500               4.97                 3.56                    4.89\n3:  1000               5.10                 4.49                    5.12\n4:  2000               5.03                 4.97                    5.09\n5:  4000               5.05                 5.09                    5.09\n\n\nWe can see that (in this simple example) complete case analysis correctly captured the interaction’s coefficient of 5.\nMore interesting is that with lower sample sizes, imputing males/females separately performed better than imputing blindly, however, once the sample size became sufficient then there was little difference between the two methods.\nThe code used to impute the data separately for males and females:\ndata_imputed_male &lt;- mice::mice(data_missing[is_male==1], print=F, m = 20)\ndata_imputed_female &lt;- mice::mice(data_missing[is_male==0], print=F, m = 20)\ndata_imputed_sex_specific &lt;- mice:::rbind.mids(data_imputed_male, data_imputed_female)"
  },
  {
    "objectID": "post/2023-02-23-sampling-bias/index.html",
    "href": "post/2023-02-23-sampling-bias/index.html",
    "title": "Sampling bias",
    "section": "",
    "text": "library(data.table)\nlibrary(magrittr)\nlibrary(ggplot2)"
  },
  {
    "objectID": "post/2023-02-23-sampling-bias/index.html#what-is-sampling-bias",
    "href": "post/2023-02-23-sampling-bias/index.html#what-is-sampling-bias",
    "title": "Sampling bias",
    "section": "What is Sampling Bias?",
    "text": "What is Sampling Bias?\nSampling bias refers to the phenomenon of a biased sample being used in a study that does not accurately represent the population being studied. This can happen in a number of ways, such as through selection bias, survivorship bias, or measurement bias. When sampling bias is present, it can lead to inaccurate results, incorrect estimates of associations between variables, and incorrect conclusions. This, in turn, can have an impact on public policy decisions, research funding, and clinical practice."
  },
  {
    "objectID": "post/2023-02-23-sampling-bias/index.html#types-of-sampling-bias",
    "href": "post/2023-02-23-sampling-bias/index.html#types-of-sampling-bias",
    "title": "Sampling bias",
    "section": "Types of Sampling Bias",
    "text": "Types of Sampling Bias\nThere are several types of sampling bias, including:\n\n1. Selection Bias\nSelection bias occurs when the selection of study participants is not random or representative of the larger population. This can happen when certain groups are excluded or overrepresented, leading to inaccurate conclusions about the study population.\nFor example, if a study only recruits participants from a single geographic region, the results may not be generalizable to the larger population. Similarly, if a study only recruits individuals with a certain health condition, the results may not accurately reflect the general population.\n\n\n2. Survivorship Bias\nSurvivorship bias occurs when only the surviving members of a population are included in a study. This can lead to inaccurate conclusions about the population, as those who did not survive may have had different characteristics or experiences.\nFor example, if a study only includes individuals who survived a specific disease, the results may not be generalizable to the larger population of individuals who did not survive.\n\n\n3. Measurement Bias\nMeasurement bias occurs when the measurement instruments or techniques used in a study are inaccurate or unreliable. This can result in inaccurate data and misinterpretation of results.\nFor example, if a study relies on self-reported data, individuals may underreport or overreport certain behaviors, leading to inaccurate conclusions about the study population. Similarly, if a study uses different measurement techniques for different groups, the results may not be comparable and may lead to inaccurate conclusions."
  },
  {
    "objectID": "post/2023-02-23-sampling-bias/index.html#example-of-sampling-bias-in-a-study",
    "href": "post/2023-02-23-sampling-bias/index.html#example-of-sampling-bias-in-a-study",
    "title": "Sampling bias",
    "section": "Example of Sampling Bias in a Study",
    "text": "Example of Sampling Bias in a Study\nTo better understand the impact of sampling bias on study results, let’s take a look at an example.\nSuppose we want to study the relationship between smoking and lung function. We know that in our city there are 100,000 people, 20,000 of whom are smokers. To our study we recruit 5,000 smokers and 5,000 non-smokers (oversampling the smokers, a type of selection bias). We also collect data on how frequently they exercise, whether they have good genes for lung function, and whether they frequently wear hats.\nWe now want to overcome our selection bias when assessing the association between the outcome of lung function and the exposures of exercise, good genes, and the frequency of hat wearing.\n\nset.seed(4)\n\nd &lt;- data.table(id = 1:100000)\nd[, is_smoker := rbinom(.N, 1, 0.2)]\nd[, probability_of_exercises_frequently := ifelse(is_smoker==T, 0.05, 0.3)]\nd[, exercises_frequently := rbinom(.N, 1, probability_of_exercises_frequently)]\nd[, has_good_genes := rbinom(.N, 1, 0.2)]\nd[, wears_hats_frequently := rbinom(.N, 1, 0.2)]\n\nd[, lung_function := 30 - 10 * is_smoker + 5 * exercises_frequently + 8 * has_good_genes + rnorm(.N, mean = 0, sd = 3)]\n\nd[, probability_of_selection_uniform := 1/.N]\n\nd[, probability_of_selection_oversample_smoker := ifelse(is_smoker==T, 5, 1)]\nd[, probability_of_selection_oversample_smoker := probability_of_selection_oversample_smoker/sum(probability_of_selection_oversample_smoker)]\n\n# We have a dataset with oversampled smokers\nd_oversampled_smokers &lt;- d[sample(1:.N, size = 5000, prob = probability_of_selection_oversample_smoker)]\n(weight_smoker &lt;- mean(d$is_smoker)/mean(d_oversampled_smokers$is_smoker))\n\n[1] 0.3700516\n\n(weight_non_smoker &lt;- mean(!d$is_smoker)/mean(!d_oversampled_smokers$is_smoker))\n\n[1] 1.747289\n\nd_oversampled_smokers[, weights := ifelse(is_smoker==T, weight_smoker, weight_non_smoker)]\n\n# The real associations:\n# is_smoker: -10 (also associated with exercises_frequently!)\n# exercises_frequently: +5 (also associated with is_smoker!)\n# has_good_genes: +8 (only associated with outcome, not with other exposures)\n# wears_hats_frequently: 0 (not associated with outcome nor other exposures)\nsummary(lm(lung_function ~ is_smoker + exercises_frequently + has_good_genes + wears_hats_frequently, data=d))\n\n\nCall:\nlm(formula = lung_function ~ is_smoker + exercises_frequently + \n    has_good_genes + wears_hats_frequently, data = d)\n\nResiduals:\n     Min       1Q   Median       3Q      Max \n-12.6549  -2.0112   0.0055   2.0045  12.1835 \n\nCoefficients:\n                       Estimate Std. Error  t value Pr(&gt;|t|)    \n(Intercept)            30.02288    0.01421 2112.751   &lt;2e-16 ***\nis_smoker             -10.05071    0.02427 -414.150   &lt;2e-16 ***\nexercises_frequently    4.99532    0.02250  221.992   &lt;2e-16 ***\nhas_good_genes          7.98073    0.02355  338.831   &lt;2e-16 ***\nwears_hats_frequently  -0.01537    0.02360   -0.651    0.515    \n---\nSignif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1\n\nResidual standard error: 2.989 on 99995 degrees of freedom\nMultiple R-squared:  0.7975,    Adjusted R-squared:  0.7975 \nF-statistic: 9.847e+04 on 4 and 99995 DF,  p-value: &lt; 2.2e-16\n\n# When we run the model in the full data, excluding is_smoker, we get the following associations:\n# exercises_frequently: +7.2 (biased from association with is_smoker)\n# has_good_genes: +8 (not biased)\n# wears_hats_frequently: 0 (not biased)\nsummary(lm(lung_function ~ exercises_frequently + has_good_genes + wears_hats_frequently, data=d))\n\n\nCall:\nlm(formula = lung_function ~ exercises_frequently + has_good_genes + \n    wears_hats_frequently, data = d)\n\nResiduals:\n    Min      1Q  Median      3Q     Max \n-21.056  -2.670   0.928   3.445  14.532 \n\nCoefficients:\n                       Estimate Std. Error  t value Pr(&gt;|t|)    \n(Intercept)           2.747e+01  2.109e-02 1302.327   &lt;2e-16 ***\nexercises_frequently  7.172e+00  3.605e-02  198.941   &lt;2e-16 ***\nhas_good_genes        7.958e+00  3.881e-02  205.044   &lt;2e-16 ***\nwears_hats_frequently 4.393e-04  3.888e-02    0.011    0.991    \n---\nSignif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1\n\nResidual standard error: 4.926 on 99996 degrees of freedom\nMultiple R-squared:  0.4502,    Adjusted R-squared:  0.4502 \nF-statistic: 2.73e+04 on 3 and 99996 DF,  p-value: &lt; 2.2e-16\n\n# When we run the model in the biased data, with oversampling of smokers (that has also an association with the outcome):\n# exercises_frequently: +9.8 (biased from association with is_smoker and the biased sampling)\n# has_good_genes: +7.6 (not biased)\n# wears_hats_frequently: +0.3 (not biased)\nsummary(lm(lung_function ~ exercises_frequently + has_good_genes + wears_hats_frequently, data=d_oversampled_smokers))\n\n\nCall:\nlm(formula = lung_function ~ exercises_frequently + has_good_genes + \n    wears_hats_frequently, data = d_oversampled_smokers)\n\nResiduals:\n     Min       1Q   Median       3Q      Max \n-14.4131  -4.3613  -0.6571   4.4586  17.3734 \n\nCoefficients:\n                      Estimate Std. Error t value Pr(&gt;|t|)    \n(Intercept)            23.7436     0.1014 234.191   &lt;2e-16 ***\nexercises_frequently    9.8631     0.2140  46.095   &lt;2e-16 ***\nhas_good_genes          7.6164     0.1967  38.726   &lt;2e-16 ***\nwears_hats_frequently   0.3363     0.1905   1.765   0.0776 .  \n---\nSignif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1\n\nResidual standard error: 5.501 on 4996 degrees of freedom\nMultiple R-squared:  0.4221,    Adjusted R-squared:  0.4218 \nF-statistic:  1217 on 3 and 4996 DF,  p-value: &lt; 2.2e-16\n\n# Run the model in the biased data, with weights:\n# exercises_frequently: +7.4 (biased from association with is_smoker)\n# has_good_genes: +7.6 (not biased)\n# wears_hats_frequently: +0.3 (not biased)\nsummary(lm(lung_function ~ exercises_frequently + has_good_genes + wears_hats_frequently, data=d_oversampled_smokers, weights = weights))\n\n\nCall:\nlm(formula = lung_function ~ exercises_frequently + has_good_genes + \n    wears_hats_frequently, data = d_oversampled_smokers, weights = weights)\n\nWeighted Residuals:\n    Min      1Q  Median      3Q     Max \n-12.537  -4.885  -2.767   2.077  18.233 \n\nCoefficients:\n                      Estimate Std. Error t value Pr(&gt;|t|)    \n(Intercept)           27.33919    0.09322 293.291   &lt;2e-16 ***\nexercises_frequently   7.40799    0.16055  46.140   &lt;2e-16 ***\nhas_good_genes         7.60104    0.17490  43.459   &lt;2e-16 ***\nwears_hats_frequently  0.26672    0.16734   1.594    0.111    \n---\nSignif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1\n\nResidual standard error: 4.859 on 4996 degrees of freedom\nMultiple R-squared:   0.45, Adjusted R-squared:  0.4497 \nF-statistic:  1363 on 3 and 4996 DF,  p-value: &lt; 2.2e-16\n\n# Run the model in the biased data, with is_smoker:\n# is_smoker: -9.9 (not biased)\n# exercises_frequently: +5.3 (not biased)\n# has_good_genes: +7.8 (not biased)\n# wears_hats_frequently: +0.2 (not biased)\nsummary(lm(lung_function ~ is_smoker + exercises_frequently + has_good_genes + wears_hats_frequently, data=d_oversampled_smokers))\n\n\nCall:\nlm(formula = lung_function ~ is_smoker + exercises_frequently + \n    has_good_genes + wears_hats_frequently, data = d_oversampled_smokers)\n\nResiduals:\n     Min       1Q   Median       3Q      Max \n-10.6202  -1.9903  -0.0699   1.9855  11.1052 \n\nCoefficients:\n                      Estimate Std. Error  t value Pr(&gt;|t|)    \n(Intercept)           29.83110    0.07786  383.149   &lt;2e-16 ***\nis_smoker             -9.88043    0.08978 -110.051   &lt;2e-16 ***\nexercises_frequently   5.25052    0.12300   42.688   &lt;2e-16 ***\nhas_good_genes         7.79706    0.10630   73.350   &lt;2e-16 ***\nwears_hats_frequently  0.15569    0.10296    1.512    0.131    \n---\nSignif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1\n\nResidual standard error: 2.973 on 4995 degrees of freedom\nMultiple R-squared:  0.8313,    Adjusted R-squared:  0.8311 \nF-statistic:  6152 on 4 and 4995 DF,  p-value: &lt; 2.2e-16"
  },
  {
    "objectID": "post/2023-02-23-sampling-bias/index.html#conclusion",
    "href": "post/2023-02-23-sampling-bias/index.html#conclusion",
    "title": "Sampling bias",
    "section": "Conclusion",
    "text": "Conclusion\nConclusion: Biased datasets can be corrected for by either:\n\nSample weights\nIncluding the sampling variables as covariates in the regression model"
  },
  {
    "objectID": "post/2022-07-18-custom-airflow-docker-operator/index.html",
    "href": "post/2022-07-18-custom-airflow-docker-operator/index.html",
    "title": "Custom Airflow Docker operator (poor-man’s Kubernetes)",
    "section": "",
    "text": "This blog post has also been posted here."
  },
  {
    "objectID": "post/2022-07-18-custom-airflow-docker-operator/index.html#what-do-we-want",
    "href": "post/2022-07-18-custom-airflow-docker-operator/index.html#what-do-we-want",
    "title": "Custom Airflow Docker operator (poor-man’s Kubernetes)",
    "section": "What do we want?",
    "text": "What do we want?\nSykdomspulsen Analytics uses Airflow to schedule its tasks.\n\n\n\n\n\n\n\n\n\nAirflow and Sykdomspulsen Analytics’ tasks can be run on Kubernetes. This can be seen in the below graph, where one Airflow implementation dispatches tasks to both Server 1 and Server 2. However, with such a small team there is always the risk of something going wrong with a complicated Kubernetes setup. It is therefore preferable to have a failback solution that is independent of Kubernetes. We have achieved this by installing a duplicate Airflow system on each of the servers using Docker-compose. Each Docker-compose Airflow instance can dispatch tasks to its own server.\n\n\n\n\n\n\n\n\n\nHowever, this means that we have anywhere between 1 to 3 duplicate Airflow DAGs running at any time. All of these will be reading and writing to the same databases. This is obviously not desirable. We must have only one Airflow instance operative at any time."
  },
  {
    "objectID": "post/2022-07-18-custom-airflow-docker-operator/index.html#how-do-we-get-it",
    "href": "post/2022-07-18-custom-airflow-docker-operator/index.html#how-do-we-get-it",
    "title": "Custom Airflow Docker operator (poor-man’s Kubernetes)",
    "section": "How do we get it?",
    "text": "How do we get it?\nIt is not easy to seamlessly turn on and turn off multiple Airflow instances. We can, however, alter the operators inside each Airflow instance to be functional or non-functional.\nIt is for this reason that we developed a custom Airflow Docker operator. This custom Airflow Docker operator:\n\nChecks an external YAML config file (https://raw.githubusercontent.com/USERNAME/REPO/main/airflow-dag-on-server.yaml) to see which server each DAG should be run on.\nChecks to see if this server is the correct one.\nIf this is not the correct server, change the command to be excecuted to: echo NOT CORRECT SERVER.\nExecutes the command inside the Docker container."
  },
  {
    "objectID": "post/2022-07-18-custom-airflow-docker-operator/index.html#details",
    "href": "post/2022-07-18-custom-airflow-docker-operator/index.html#details",
    "title": "Custom Airflow Docker operator (poor-man’s Kubernetes)",
    "section": "Details",
    "text": "Details\nhttps://raw.githubusercontent.com/USERNAME/REPO/main/airflow-dag-on-server.yaml\n---\ndag_1: \"server-1.tld\"\ndocker-compose.yml (If using Podman)\n  volumes:\n    - /var/run/podman/podman.sock:/var/run/docker.sock\n  environment:\n    HOST_HOSTNAME: $HOSTNAME\n/opt/airflow/plugins/operators/sc_operators.py accesses the environmental variable HOST_HOSTNAME that is passed through from docker-compose.yml.\nimport os\nimport requests\nimport time\nimport yaml\n\nfrom airflow.operators.docker_operator import DockerOperator\n\nclass SCDockerOperator(DockerOperator):\n    def __init__(self, **kwargs) -&gt; None:\n        super().__init__(**kwargs)\n\n    def execute(self, context):\n        response = requests.get(\n            \"https://raw.githubusercontent.com/USERNAME/REPO/main/airflow-dag-on-server.yaml\",\n            headers = {\"Cache-Control\": \"no-cache\"}\n        )\n        unparsed_data = response.text\n    \n        data = yaml.safe_load(unparsed_data)\n        \n        print(data)\n        print(self.dag.dag_id)\n        \n        if self.dag.dag_id not in data:\n            self.command = '''bash -c \"echo NOT CORRECT SERVER\"'''\n        elif data[self.dag.dag_id] != os.getenv(\"HOST_HOSTNAME\"):\n            self.command = '''bash -c \"echo NOT CORRECT SERVER\"'''\n        else:\n            print(\"OK\")\n        \n        time.sleep(5)\n        retval = super().execute(context)\n        return retval\n/opt/airflow/dags/dag_1.py\nimport random\nfrom operators.sc_operators import SCDockerOperator\n\ntask = SCDockerOperator(\n    task_id='my_task',\n    image='localhost/splanalytics:latest',\n    container_name= 'my_task_' + str(random.randint(10,100000)),\n    api_version='auto',\n    auto_remove=True,\n    command=cmd,\n    docker_url='unix://var/run/docker.sock',\n    network_mode='bridge',\n    privileged = True,\n    dag=dag\n)"
  },
  {
    "objectID": "post/2022-07-18-custom-airflow-docker-operator/index.html#conclusion",
    "href": "post/2022-07-18-custom-airflow-docker-operator/index.html#conclusion",
    "title": "Custom Airflow Docker operator (poor-man’s Kubernetes)",
    "section": "Conclusion",
    "text": "Conclusion\nBy editing https://raw.githubusercontent.com/USERNAME/REPO/main/airflow-dag-on-server.yaml we can quickly choose which server will execute the desired task. This is an easy way to manually control identical installations of Airflow as a failback system."
  },
  {
    "objectID": "post/2021-11-18-poster-prize-for-sykdomspulsen/index.html",
    "href": "post/2021-11-18-poster-prize-for-sykdomspulsen/index.html",
    "title": "Sykdomspulsen receives prize for best poster",
    "section": "",
    "text": "Sykdomspulsen’s poster “Sykdomspulsen - An exciting and forward-looking infrastructure and website for the real-time surveillance of Covid-19, other infections, and deaths” received the prize for “Best Poster” at Helse- og Kvalitetsregisterkonferansen 2021."
  },
  {
    "objectID": "post/2022-12-13-all-cause-mortality-in-norway/index.html",
    "href": "post/2022-12-13-all-cause-mortality-in-norway/index.html",
    "title": "All-Cause Mortality in Norway",
    "section": "",
    "text": "library(data.table)\nlibrary(magrittr)\nlibrary(ggplot2)\n\nif (interactive()) {\n  folder_location &lt;- \"post/2022-12-13-all-cause-mortality-in-norway/\"\n} else {\n  folder_location &lt;- \"\"\n}\n\n\n# Downloading data\ndata &lt;- PxWebApiData::ApiData(\n  \"https://data.ssb.no/api/v0/en/table/07995\",\n  Kjonn = \"0\",\n  Alder = \"999A\",\n  Tid = as.character(2000:2022),\n  Uke = paste0(\"U\", formatC(1:52, width = 2, flag = \"0\"))\n)\n\n# Cleaning\nd_deaths &lt;- data$dataset[, c(\"Uke\", \"Tid\", \"value\")]\nsetDT(d_deaths)\nsetnames(d_deaths, c(\"week\", \"isoyear\", \"deaths_n\"))\nd_deaths[, isoweek := stringr::str_remove(week, \"U\")]\nd_deaths[, isoyearweek := paste0(isoyear, \"-\", isoweek)]\nd_deaths[, isoweek := as.numeric(isoweek)]\nd_deaths[, isoyear := as.numeric(isoyear)]\nd_deaths[, week := NULL]\nsetcolorder(d_deaths, c(\"isoyear\", \"isoweek\", \"isoyearweek\", \"deaths_n\"))\n\n# Removing the latest 3 weeks of data (due to registration delay)\nmax_isoweek &lt;- d_deaths[isoyear == 2022 & !is.na(deaths_n)]$isoweek %&gt;%\n  max() - 3\nd_deaths &lt;- d_deaths[isoweek &lt;= max_isoweek]\n\n\n# Aggregating\npd &lt;- d_deaths[, .(deaths_n = sum(deaths_n)), keyby = .(isoyear)]\n\n# Plotting\nq &lt;- ggplot(pd, aes(x = isoyear, y = deaths_n))\nq &lt;- q + geom_line()\nq &lt;- q + geom_point()\nq &lt;- q + scale_x_continuous(\n  \"Isoyear\",\n  breaks = seq(2000, 2022, 2)\n  )\nq &lt;- q + scale_y_continuous(\n  \"Number of deaths\",\n  labels = csstyle::format_num_as_nor_num_0,\n  breaks = seq(33000, 38000, 1000)\n)\nq &lt;- q + expand_limits(y = c(33000, 38000))\nq &lt;- q + labs(\n    title = glue::glue(\n      \"Deaths in Norway, occurring between isoweeks 1 and {max_isoweek} (inclusive)\"\n    )\n  )\nq &lt;- q + labs(caption = \"Data extracted 2022-12-13 from SSB table 07995.\")\nq\n\n\n\n\n\n\n\n\n\n# Estimating the baseline\nsetorder(d_deaths, isoyearweek)\nfor(isoyear_pred in 2011:2022) for(isoweek_model in unique(d_deaths$isoweek)){\n\n  # Determining the training data\n  if(isoyear_pred &lt;= 2019){\n    isoyear_train &lt;- (isoyear_pred-10):(isoyear_pred-1)\n  } else {\n    isoyear_train &lt;- 2010:2019\n  }\n  \n  # Fitting the model\n  fit &lt;- glm(\n    deaths_n ~ isoyear, \n    data = d_deaths[isoweek %in% isoweek_model & isoyear %in% isoyear_train],\n    family = \"poisson\"\n  )\n  \n  # Predicting the baseline\n  pred &lt;- predict(\n      fit, \n      d_deaths[isoweek %in% isoweek_model & isoyear %in% isoyear_pred]\n    ) %&gt;% \n    exp()\n  d_deaths[\n    isoweek %in% isoweek_model & isoyear %in% isoyear_pred, \n    deaths_baseline_n := pred\n  ]\n}\n\n\n# Calculating the excess mortality\nd_deaths[, deaths_excess_n := deaths_n - deaths_baseline_n]\n\n\n# Aggregating\npd &lt;- d_deaths[\n  !is.na(deaths_excess_n),\n  .(deaths_excess_n = sum(deaths_excess_n)), \n  keyby = .(isoyear)\n]\n\n# Plotting\nq &lt;- ggplot(pd, aes(x = isoyear, y = deaths_excess_n))\nq &lt;- q + geom_col()\nq &lt;- q + geom_hline(yintercept = 0, color = \"black\")\nq &lt;- q + scale_x_continuous(\n  \"Isoyear\",\n  breaks = seq(2011, 2022, 1)\n  )\nq &lt;- q + scale_y_continuous(\n  \"Number of excess deaths\",\n  labels = csstyle::format_num_as_nor_num_0,\n  breaks = seq(-1000, 4000, 500)\n)\nq &lt;- q + labs(\n    title = glue::glue(\n      \"Excess deaths in Norway, occurring between isoweeks 1 and {max_isoweek} (inclusive)\"\n    )\n  )\nq &lt;- q + labs(\n  caption = \"Weekly baseline calculated from a poisson regression of the previous 10 years of data.\\nBaselines for 2020, 2021, and 2022 calculated using data for 2010-2019.\\nData extracted 2022-12-13 from SSB table 07995.\"\n)\nq"
  },
  {
    "objectID": "post/2023-04-14-sparse-inference/index.html",
    "href": "post/2023-04-14-sparse-inference/index.html",
    "title": "Sparse inference",
    "section": "",
    "text": "Machine learning and statistical modeling are two important tools in data science that are used to make predictions and infer relationships between variables, respectively. Models for prediction aim to estimate the relationship between inputs and outputs in order to make accurate predictions about new, unseen data. In contrast, models for inference aim to understand the underlying relationships between variables in the data, often in the form of identifying causal relationships.\nIn this blog post, we will explore using models for inference using a simulated dataset, and we will apply penalized regression to perform feature selection on a binary outcome. Penalized regression is particularly useful in situations where the number of predictors (i.e. independent variables) is much larger than the sample size.\nWe will investigate the frequentist solution of using a two-stage solution with LASSO regression via glmnet and then using the selectiveInference package to perform post inference and adjust for the bias introduced by the selection process. We will also investigate a Bayesian solution that approximates a LASSO regression via a Laplace prior.\noptions(mc.cores = parallel::detectCores())\n\nfit &lt;- rstanarm::stan_glm(\n  formula = y ~ .,\n  data = data,\n  family = binomial(),\n  prior = rstanarm::laplace(),\n  chains = 4,\n  iter = 5000,\n  refresh=0\n)\n\nretval &lt;- data.frame(\n  var = names(coef(fit)),\n  Odds_Ratio = round(exp(coef(fit)),3),\n  round(exp(rstanarm::posterior_interval(fit, prob = 0.9)),3),\n  pvalue_equivalent = round(bayestestR::pd_to_p(bayestestR::p_direction(fit)$pd),2)\n)\nrow.names(retval) &lt;- NULL\nretval$var[retval$pvalue_equivalent &lt; 0.05] &lt;- paste0(\"*\", retval$var[retval$pvalue_equivalent &lt; 0.05])\nnames(retval) &lt;- c(\n  \"Variable\",\n  \"Odds ratio\",\n  \"Cred int 5%\",\n  \"Cred int 95%\",\n  \"Pvalue equivalent\"\n)\nretval\n\n      Variable Odds ratio Cred int 5% Cred int 95% Pvalue equivalent\n1  (Intercept)      1.009       0.951        1.072              0.81\n2          *x1      4.046       3.742        4.382              0.00\n3          *x2      2.965       2.761        3.193              0.00\n4          *x3      1.931       1.810        2.061              0.00\n5           x4      0.953       0.898        1.010              0.17\n6           x5      1.018       0.961        1.078              0.59\n7           x6      0.999       0.942        1.059              0.98\n8           x7      0.985       0.928        1.043              0.65\n9           x8      0.973       0.918        1.032              0.45\n10          x9      0.961       0.906        1.021              0.26\n11         x10      0.998       0.941        1.058              0.95\n12         x11      1.041       0.980        1.108              0.26\n13         x12      0.962       0.908        1.021              0.29\n14         x13      1.039       0.978        1.104              0.29\n15         x14      1.002       0.942        1.066              0.95\n16         x15      0.999       0.942        1.058              0.97\n17         x16      0.960       0.905        1.017              0.24\n18         x17      1.031       0.972        1.096              0.39\n19         x18      0.958       0.902        1.016              0.23\n20         x19      0.993       0.937        1.053              0.84\n21         x20      1.008       0.949        1.069              0.83\n22         x21      0.985       0.928        1.043              0.66\n23         x22      1.043       0.985        1.106              0.23\n24         x23      0.958       0.902        1.016              0.22\n25         x24      0.997       0.939        1.058              0.94\n26         x25      1.039       0.977        1.106              0.29\n27         x26      0.980       0.925        1.036              0.58\n28         x27      1.039       0.980        1.101              0.29\n29         x28      1.013       0.955        1.075              0.71\n30         x29      1.023       0.963        1.087              0.54\n31         x30      1.006       0.948        1.067              0.86\n32        *x31      0.904       0.851        0.960              0.01\n33         x32      1.026       0.967        1.089              0.47\n34         x33      1.032       0.973        1.096              0.39\n35         x34      1.001       0.943        1.063              0.97\n36         x35      1.006       0.950        1.068              0.85\n37         x36      1.049       0.990        1.114              0.17\n38         x37      1.024       0.965        1.086              0.52\n39         x38      1.060       1.001        1.125              0.10\n40         x39      1.021       0.962        1.084              0.57\n41         x40      1.030       0.971        1.092              0.41\n42         x41      0.986       0.928        1.046              0.69\n43         x42      1.006       0.949        1.068              0.87\n44         x43      1.026       0.967        1.090              0.49\n45         x44      0.948       0.893        1.005              0.13\n46         x45      1.043       0.982        1.109              0.23\n47         x46      1.012       0.954        1.072              0.73\n48         x47      1.005       0.948        1.065              0.88\n49         x48      0.953       0.899        1.010              0.17\n50         x49      0.960       0.905        1.018              0.25\n51         x50      0.969       0.913        1.025              0.35"
  },
  {
    "objectID": "post/2023-04-14-sparse-inference/index.html#introduction",
    "href": "post/2023-04-14-sparse-inference/index.html#introduction",
    "title": "Sparse inference",
    "section": "",
    "text": "Machine learning and statistical modeling are two important tools in data science that are used to make predictions and infer relationships between variables, respectively. Models for prediction aim to estimate the relationship between inputs and outputs in order to make accurate predictions about new, unseen data. In contrast, models for inference aim to understand the underlying relationships between variables in the data, often in the form of identifying causal relationships.\nIn this blog post, we will explore using models for inference using a simulated dataset, and we will apply penalized regression to perform feature selection on a binary outcome. Penalized regression is particularly useful in situations where the number of predictors (i.e. independent variables) is much larger than the sample size.\nWe will investigate the frequentist solution of using a two-stage solution with LASSO regression via glmnet and then using the selectiveInference package to perform post inference and adjust for the bias introduced by the selection process. We will also investigate a Bayesian solution that approximates a LASSO regression via a Laplace prior."
  },
  {
    "objectID": "post/2023-04-14-sparse-inference/index.html#simulating-a-dataset",
    "href": "post/2023-04-14-sparse-inference/index.html#simulating-a-dataset",
    "title": "Sparse inference",
    "section": "Simulating a Dataset",
    "text": "Simulating a Dataset\nWe will simulate a dataset with n = 5000 people and p = 50 variables, where only three of the 50 variables will have an association with the binary outcome, and they will have odds ratios of 4, 3, and 2. The remaining variables will have no association with the outcome.\n\nlibrary(data.table)\nlibrary(magrittr)\nlibrary(ggplot2)\n\nset.seed(123)\nn &lt;- 5000\np &lt;- 50\nx &lt;- matrix(rnorm(n * p), nrow = n)\nbeta &lt;- c(log(4), log(3), log(2), rep(0, 47))\nprob &lt;- plogis(x %*% beta)\ny &lt;- rbinom(n, 1, prob)\n\ndata &lt;- data.frame(cbind(y,x))\ncolnames(data) &lt;- c(\"y\", paste0(\"x\",1:ncol(x)))\n\nx &lt;- model.matrix(y ~ ., data = data)[,-1]\ny &lt;- data$y"
  },
  {
    "objectID": "post/2023-04-14-sparse-inference/index.html#lasso-regression",
    "href": "post/2023-04-14-sparse-inference/index.html#lasso-regression",
    "title": "Sparse inference",
    "section": "LASSO Regression",
    "text": "LASSO Regression\nWe will now fit a LASSO regression model using the glmnet package in R. LASSO is a popular method for feature selection in high-dimensional data, where the number of predictors p is much larger than the number of observations n.\n\n# get standard deviation of X, because we will need to standardize/scale it outside of glmnet\nsds &lt;- apply(x, 2, sd)\n\n# standardize x\nx_scaled &lt;- scale(x,TRUE,TRUE)\n\n# run glmnet\ncfit &lt;- glmnet::cv.glmnet(x_scaled,y,standardize=FALSE, family=\"binomial\")\ncoef(cfit)\n\n51 x 1 sparse Matrix of class \"dgCMatrix\"\n                     s1\n(Intercept) 0.008303975\nx1          1.081745656\nx2          0.821477348\nx3          0.452041341\nx4          .          \nx5          .          \nx6          .          \nx7          .          \nx8          .          \nx9          .          \nx10         .          \nx11         .          \nx12         .          \nx13         .          \nx14         .          \nx15         .          \nx16         .          \nx17         .          \nx18         .          \nx19         .          \nx20         .          \nx21         .          \nx22         .          \nx23         .          \nx24         .          \nx25         .          \nx26         .          \nx27         .          \nx28         .          \nx29         .          \nx30         .          \nx31         .          \nx32         .          \nx33         .          \nx34         .          \nx35         .          \nx36         .          \nx37         .          \nx38         .          \nx39         .          \nx40         .          \nx41         .          \nx42         .          \nx43         .          \nx44         .          \nx45         .          \nx46         .          \nx47         .          \nx48         .          \nx49         .          \nx50         ."
  },
  {
    "objectID": "post/2023-04-14-sparse-inference/index.html#no-confidence-intervals",
    "href": "post/2023-04-14-sparse-inference/index.html#no-confidence-intervals",
    "title": "Sparse inference",
    "section": "No confidence intervals",
    "text": "No confidence intervals\nNote that LASSO regression does not provide any confidence intervals or p-values, only coeficient estimates."
  },
  {
    "objectID": "post/2023-04-14-sparse-inference/index.html#bayesian-logistic-regression-using-rstanarm",
    "href": "post/2023-04-14-sparse-inference/index.html#bayesian-logistic-regression-using-rstanarm",
    "title": "Sparse inference",
    "section": "Bayesian Logistic Regression using rstanarm",
    "text": "Bayesian Logistic Regression using rstanarm\nAnother way to perform inference on a logistic regression model with feature selection is through Bayesian methods. In particular, we can use the rstanarm R package to fit a Bayesian logistic regression model with a Laplace prior."
  },
  {
    "objectID": "post/2023-04-14-sparse-inference/index.html#laplace-prior",
    "href": "post/2023-04-14-sparse-inference/index.html#laplace-prior",
    "title": "Sparse inference",
    "section": "Laplace prior",
    "text": "Laplace prior\nThe Laplace prior is used to promote sparsity by assigning a probability distribution to the coefficients that puts more probability mass around zero. It is equivalent to LASSO regression (Tibshirani 1996)."
  },
  {
    "objectID": "post/2023-04-14-sparse-inference/index.html#p-value-equivalent",
    "href": "post/2023-04-14-sparse-inference/index.html#p-value-equivalent",
    "title": "Sparse inference",
    "section": "P-value equivalent",
    "text": "P-value equivalent\nProbability of Direction (PoD) and p-values are both statistical measures used in hypothesis testing Makowski et al. (2019). They are similar in that they both provide evidence for or against a null hypothesis. PoD measures the proportion of posterior draws from a Bayesian model that are in the direction of the alternative hypothesis. It provides a measure of the strength of evidence for the alternative hypothesis relative to the null hypothesis. A high PoD value indicates strong evidence in favor of the alternative hypothesis, while a low PoD value indicates weak evidence in favor of the alternative hypothesis.\nSimilarly, a p-value measures the probability of obtaining a test statistic as extreme as or more extreme than the observed value, assuming that the null hypothesis is true. A low p-value indicates that the observed result is unlikely to have occurred by chance alone, providing evidence against the null hypothesis.\nTo convert PoD to a p-value equivalent, one approach is to use the following formula:\np-value = 2 * min(PoD, 1-PoD)\nThis formula assumes a two-tailed test and converts the PoD to a p-value for a test of the null hypothesis that the effect size is equal to zero. The resulting p-value can be interpreted as the probability of obtaining the observed result or a more extreme result under the null hypothesis."
  },
  {
    "objectID": "post/2023-04-14-sparse-inference/index.html#conclusion",
    "href": "post/2023-04-14-sparse-inference/index.html#conclusion",
    "title": "Sparse inference",
    "section": "Conclusion",
    "text": "Conclusion\nThe blog article discusses the limitations of using LASSO (Least Absolute Shrinkage and Selection Operator) models for statistical inference, particularly in situations where the number of predictors (i.e. independent variables) is much larger than the sample size. In these cases, LASSO models can suffer from high variability in the estimated coefficients, which can lead to incorrect or unreliable conclusions.\nOne proposed solution to this problem is to use a two-stage inference approach, where LASSO is first used to select a subset of predictors, and then a separate statistical method (such as ordinary least squares) is used to estimate the coefficients for the selected predictors. However, this two-stage approach can also have limitations, such as a loss of power in the second stage and increased computational complexity.\nIn contrast, Bayesian statistics offer a one-stage inference approach that can provide more reliable and interpretable results in complex modeling situations. Bayesian statistics allow for the incorporation of prior knowledge and uncertainty in the model, which can help to reduce variability and improve accuracy. Bayesian methods also provide a framework for model comparison and selection, which can help to identify the most appropriate model for a given dataset.\nOverall, while LASSO models can be useful in certain situations, their limitations in high-dimensional data settings highlight the advantages of Bayesian statistics for reliable and interpretable statistical inference."
  },
  {
    "objectID": "post/2023-08-26-all-cause-mortality-in-norway/index.html",
    "href": "post/2023-08-26-all-cause-mortality-in-norway/index.html",
    "title": "All-cause mortality in Norway",
    "section": "",
    "text": "library(data.table)\nlibrary(magrittr)\nlibrary(ggplot2)\n\nif (interactive()) {\n  folder_location &lt;- \"post/2023-08-26-all-cause-mortality-in-norway/\"\n} else {\n  folder_location &lt;- \"\"\n}\n\n\n# Downloading data\nd_deaths &lt;- fread(\"https://data.ssb.no/api/v0/dataset/932937.csv?lang=en\")\nsetnames(d_deaths, c(\"sex\", \"age\", \"week\", \"content\", \"deaths_n\"))\nd_deaths[, isoweek := stringr::str_extract(week, \"[0-9][0-9]$\")]\nd_deaths[, isoyear := stringr::str_extract(week, \"^[0-9][0-9][0-9][0-9]\")]\nd_deaths[, isoyearweek := paste0(isoyear, \"-\", isoweek)]\nd_deaths[, isoweek := as.numeric(isoweek)]\nd_deaths[, isoyear := as.numeric(isoyear)]\nd_deaths[, week := NULL]\nd_deaths &lt;- d_deaths[isoyear &gt;= 2004]\nd_deaths &lt;- d_deaths[sex==\"0 Both sexes\"]\nd_deaths[, sex := NULL]\nd_deaths[, content := NULL]\nsetcolorder(d_deaths, c(\"age\", \"isoyear\", \"isoweek\", \"isoyearweek\", \"deaths_n\"))\nsetorder(d_deaths, age, isoyearweek)\n# Removing the latest 3 weeks of data (due to registration delay)\nmax_isoweek &lt;- d_deaths[isoyear == 2023 & !is.na(deaths_n)]$isoweek %&gt;%\n  max() - 3\nd_deaths &lt;- d_deaths[isoweek &lt;= max_isoweek]\n\n# recategorizing age\nunique(d_deaths$age)\nd_deaths[, age := fcase(\n  age == \"F00-04 0-4 years\", \"0-19\",\n  age == \"F05-09 5-9 years\", \"0-19\",\n  age == \"F10-14 10-14 years\", \"0-19\",\n age == \"F15-19 15-19 years\", \"0-19\",\n age == \"F20-24 20-24 years\", \"20-39\",\n age == \"F25-29 25-29 years\", \"20-39\",\n age == \"F30-34 30-34 years\", \"20-39\",\n age == \"F35-39 35-39 years\", \"20-39\",\n age == \"F40-44 40-44 years\", \"40-59\",\n age == \"F45-49 45-49 years\", \"40-59\",\n age == \"F50-54 50-54 years\", \"40-59\",\n age == \"F55-59 55-59 years\", \"40-59\",\n age == \"F60-64 60-64 years\", \"60-69\",\n age == \"F65-69 65-69 years\", \"60-69\",\n age == \"F70-74 70-74 years\", \"70-79\",\n age == \"F75-79 75-79 years\", \"70-79\",\n age == \"F80-84 80-84 years\", \"80-89\",\n age == \"F85-89 85-89 years\", \"80-89\",\n age == \"F90-94 90-94 years\", \"90+\",\n age == \"F95-99 95-99 years\", \"90+\",\n age == \"F100G5+ 100 years or older\", \"90+\"\n)]\nd_deaths &lt;- d_deaths[,.(\n  deaths_n = sum(deaths_n)\n), keyby=.(\n  age, isoyear, isoweek, isoyearweek\n)]\n\n\n# Aggregating\npd &lt;- d_deaths[, .(deaths_n = sum(deaths_n)), keyby = .(isoyear, age)]\npd[\n  csdata::nor_population_by_age_cats(list(\"0-19\"=0:19, \"20-39\"=20:39, \"40-59\"=40:59, \"60-69\"=60:69, \"70-79\"=70:79, \"80-89\"=80:89, \"90+\"=90:110))[granularity_geo==\"nation\"],\n  on = c(\"isoyear==calyear\", \"age\"),\n  pop_jan1_n := pop_jan1_n\n  ]\npd[, deaths_pr1000000 := 1000000*deaths_n/pop_jan1_n]\n\n# Estimating the baseline\nfor(x_age in unique(pd$age))for(isoyear_pred in 2011:2023){\n\n  # Determining the training data\n  if(isoyear_pred &lt;= 2019){\n    isoyear_train &lt;- (isoyear_pred-5):(isoyear_pred-1)\n  } else {\n    isoyear_train &lt;- 2010:2019\n  }\n  \n  # Fitting the model\n  fit &lt;- glm(\n    deaths_n ~ isoyear + offset(log(pop_jan1_n)), \n    #deaths_n ~ isoyear, \n    data = pd[age %in% x_age & isoyear %in% isoyear_train],\n    family = \"poisson\"\n  )\n  \n  # Predicting the baseline\n  pred &lt;- predict(\n      fit, \n      pd[age %in% x_age & isoyear %in% isoyear_pred]\n    ) %&gt;% \n    exp()\n  pd[\n    age %in% x_age & isoyear %in% isoyear_pred, \n    deaths_baseline_n := pred\n  ]\n}\n\n# Calculating the excess mortality\npd[, deaths_baseline_pr1000000 := 1000000*deaths_baseline_n/pop_jan1_n]\npd[, deaths_excess_n := deaths_n - deaths_baseline_n]\npd[, deaths_excess_pr100 := 100*deaths_excess_n/deaths_baseline_n]\n\n\n# Plotting\nq &lt;- ggplot(pd, aes(x = isoyear, y = deaths_pr1000000))\nq &lt;- q + annotate(\"rect\", xmin=2019.5, xmax=Inf, ymin=-Inf,ymax=Inf, fill=\"red\", alpha = 0.2)\nq &lt;- q + geom_line(mapping = aes(y=deaths_baseline_pr1000000, color = \"Baseline\"), lwd = 2, alpha = 0.8)\nq &lt;- q + geom_line(mapping=aes(color=\"Observed\"))\nq &lt;- q + geom_point(mapping=aes(color=\"Observed\"))\nq &lt;- q + scale_x_continuous(\n  \"Isoyear\",\n  breaks = seq(2000, 2023, 2)\n  )\nq &lt;- q + scale_color_manual(NULL, values=c(\"green\", \"black\"))\nq &lt;- q + scale_y_continuous(\"Deaths per 1 000 000 population\")\nq &lt;- q + facet_wrap(~age, scales = \"free_y\")\nq &lt;- q + labs(\n    title = glue::glue(\n      \"Deaths in Norway, occurring between isoweeks 1 and {max_isoweek} (inclusive)\"\n    )\n  )\nq &lt;- q + labs(caption = \"Data extracted 2023-08-29 from SSB table 932937.\")\nq &lt;- q + csstyle::set_x_axis_vertical()\nq\n\nWarning: Removed 7 rows containing missing values or values outside the scale range\n(`geom_line()`).\n\n\n\n\n\n\n\n\n# Plotting\nq &lt;- ggplot(pd, aes(x = isoyear, y = deaths_excess_pr100))\nq &lt;- q + annotate(\"rect\", xmin=2019.5, xmax=Inf, ymin=-Inf,ymax=Inf, fill=\"red\", alpha = 0.2)\nq &lt;- q + geom_col()\nq &lt;- q + geom_hline(yintercept = 0, color = \"black\")\nq &lt;- q + scale_x_continuous(\n  \"Isoyear\",\n  breaks = seq(2011, 2023, 1)\n  )\nq &lt;- q + facet_wrap(~age)\nq &lt;- q + scale_y_continuous(\"Percentage excess (%)\")\n# q &lt;- q + scale_y_continuous(\n#   \"Number of excess deaths\",\n#   labels = csstyle::format_num_as_nor_num_0,\n#   breaks = seq(-1000, 4000, 500)\n# )\nq &lt;- q + labs(\n    title = glue::glue(\n      \"Excess deaths in Norway, occurring between isoweeks 1 and {max_isoweek} (inclusive)\"\n    )\n  )\nq &lt;- q + labs(\n  caption = \"Baseline calculated from a poisson regression of the previous 10 years of data.\\nBaselines for 2020, 2021, and 2022 calculated using data for 2010-2019.\\nData extracted 2023-08-29 from SSB table 932937.\"\n)\nq &lt;- q + csstyle::set_x_axis_vertical()\nq\n\nWarning: Removed 49 rows containing missing values or values outside the scale range\n(`geom_col()`)."
  },
  {
    "objectID": "post/2024-08-13-angrepet-mot-folkehelsa-fortsetter/index.html",
    "href": "post/2024-08-13-angrepet-mot-folkehelsa-fortsetter/index.html",
    "title": "Angrepet mot folkehelsa fortsetter",
    "section": "",
    "text": "Publisert i Fædrelandsvennen den 13. august 2024.\n\n\nRichard Aubrey White har doktorgrad i biostatistikk fra Harvard University og er forsker ved FHI, men uttaler seg ikke på vegne av arbeidsgiveren.\nPreben Aavitsland begynte sine angrep på bruk av munnbind den 30. januar 2020, hvor han kalte bruken «en kulturell greie.» Den 2. august i år fortsatte han i Fædrelandsvennen, ved å hevde at munnbind er en «lykkeamulett mot korona.» Selv om FHIs nye studie viser at munnbind reduserer luftveisinfeksjoner med 29 pst., er det ikke nok til å tilfredsstille Aavitsland om at de virker.\nFHI-studien har tre feil som undergraver Aavitslands argumenter.\nFor det første ble deltakerne bedt om å bruke munnbind i det offentlige rom i to uker, og så rapportere symptomene sine. Anta at perioden varte fra 14. til 27. februar: For en som har blitt smittet med covid-19 tar det mellom to og seks dager før man viser symptomer, som betyr at en person som ble smittet 13. februar trolig ikke vil vise symptomer før 18. februar (godt inne i studieperioden). Denne feilen påvirker den første halvdelen av studieperioden, noe som gjør at munnbind fremstår som mindre effektive enn de faktisk er. De fleste studiene ignorerer den første perioden for å unngå slike skjeve data, men ikke FHI-studien.\nDet blir som å utføre en graviditetstest den 28. februar for et par som har ubeskyttet sex hver dag fra 8. til 13. februar, og deretter blir bedt om å bruke kondom fra 14. til 27. februar. Da vil kondomer heller ikke virke særlig effektive.\nFor det andre ble ikke deltakerne bedt om å bruke munnbind på jobb. Munnbind, som kondomer og sikkerhetsbelter, er bare effektive mens de brukes.\nFor det tredje spres korona som røyk gjennom luften. Kirurgiske munnbind er ikke egnet for å beskytte mot luftbåren smitte, som er grunnen til at mange helsemyndigheter anbefaler FFP2-åndedrettsvern eller bedre.\nMed disse feilene er det overraskende at FHI fant at kirurgiske munnbind allikevel reduserte risikoen med 29 pst. Fjern den første uken med skjev data og be deltakerne bruke FFP2-åndedrettsvern (også på jobb), så vil man stå igjen med enda sterkere resultater. Noe en nylig gjennomgang konkluderte med.\nAavitsland nevner hudirritasjon og hodepine som ulempene ved munnbind, men ikke ulempene ved senfølger av covid-19, som kardiovaskulære komplikasjoner, kognitive problemer, hjernetåke og utmattelse. Senfølger er vanlige (men ignorert av norske helsemyndigheter); blant 20-64 åringene er legebesøk for utmattelse 75 pst. høyere i 2024 enn i 2019.\nDet er ironisk at Aavitsland frykter at munnbind vil oppmuntre syke mennesker til å gå på jobb og smitte andre. En av de beste metodene for å holde folk hjemme mens de er smittsomme, er å bruke hurtigtester for å identifisere riktig isolasjonsperiode (noen er smittsomme etter at symptomene har sluttet), noe han i VG har hevdet er unødvendig.\nHvorfor jobber Aavitsland så hardt for å undergrave folkehelsestrategier som er vanlige utenfor Norge? Er det fordi Norge har vært på villspor så lenge at det er vanskelig å snu uten å miste ansikt?"
  },
  {
    "objectID": "post/2024-09-27-forebygg-covid-19-forebygg-sykefravaer/index.html",
    "href": "post/2024-09-27-forebygg-covid-19-forebygg-sykefravaer/index.html",
    "title": "Forebygg covid-19, forebygg sykefravær",
    "section": "",
    "text": "Publisert i Dag of Tid den 27. september 2024.\n\n\nI innlegget «Ikke et spørsmål om moral, men om god behandling» i Dag og Tid 20. september hevder Marit Hermansen, sjeflege i Nav, at «det spiller ikke så stor rolle hva som er årsaken til at man opplever lettere psykiske lidelser. Enten årsaken er korona eller noe annet, vil svært mange tjene helsemessig på å være i tilpasset aktivitet og arbeid.»\nDette er feil.\nLitt bakgrunn: Sykefraværet har økt i flere diagnosekoder sammenlignet med 2019. Navs sykefraværsregister har ingen kode for senfølger av covid-19, dermed er personer med senfølger spredt over flere koder basert på symptomer. Senfølger av covid-19 kan påvirke nesten alle organsystemer, inkludert hjernen. De største økningene tilhører kodene A04 (utmattelse), P02 (psykisk ubalanse situasjonsbetinget) og P29 (psykiske symptomer/plager). Utmattelse har en tydelig tilknytning til senfølger av covid-19, likevel fokuserer narrativet kun på «lettere psykiske lidelser» (P02 og P29). Nav-forskerne Moberg og Kabashi har funnet at sykefravær på grunn av akutt covid-19 var assosiert med 25 % og 18 % høyere sykefravær for henholdsvis P02 og P29 i løpet av de påfølgende 12 ukene.\nIfølge WHO gir 1 av 10 koronainfeksjoner senfølger, og studier anslår at vaksiner kun er ca. 50 % effektive i å forebygge disse. Med dagens «fri smitte»-strategi har Norge hatt 5 millioner infeksjoner hvert år siden 2022. Ut fra dette kan vi forvente ca. 250 000 nye tilfeller med senfølger hvert år – også i 2024 og 2025. Den tyske helseministeren prof. Lauterbach uttalte den 17. september 2024: «Senfølger av covid-19 er ikke borte, og de vil ikke forsvinne. Det finnes ofte ingen kur for de som er rammet – og antallet rammede vokser.»\nDet er gode bevis for at en stor del av økningen i sykefraværet skyldes senfølger av covid-19.\nNå til Hermansens sak: God behandling må tilpasses sykdommens årsak. Dersom en person er utbrent på grunn av livs- eller arbeidsforhold, kan aktivitet hjelpe. Men hvis noen feildiagnostiseres som utbrent, mens de faktisk lider av senfølger av covid-19, kan aktivitet uten tilstrekkelig hensyn til anstrengelsesutløst sykdomsfølelse/symptomforverring (PEM) potensielt være skadelig.\nVi bør forebygge sykdom, ikke bare behandle den. Dersom økningen i sykefravær skyldes senfølger av covid-19, må vi forebygge covid-19. Dette kan gjøres ved å forbedre ventilasjon, øke luftrensing og anbefale bruk av FFP2-åndedrettsvern i offentlige rom når det er mye smitte. Disse tiltakene er effektive og påvirker ikke dagliglivet nevneverdig. Vi kan redusere selve problemet, og folk kan slippe å bli syke – det vi mangler, er vilje.\nTil slutt handler det om ansvar. Siden 2022 har landet, under Arbeiderpartiet og Senterpartiets regjering, ført en «fri smitte»-politikk uten en risikovurdering av senfølger av covid-19. Rundt 250 000 nye nordmenn er rammet av senfølger hvert år. Helseminister Vestre har videreført denne linjen, uten å ha evaluert konsekvensene med hensyn til senfølger, og har i stedet lagt skylden for det økte sykefraværet på at «pandemien har ført til at vi har litt annen atferd» (God morgen Norge, 17. september).\nSamtidig har regjeringens store kutt i FHIs budsjett i 2023, som førte til nedleggelsen av FHIs fagmiljø for inneklima, svekket Norges evne til å lage lover om tekniske krav til inneklima/byggverk som kan beskytte oss mot luftbårne virus som korona. Dette er et svik mot folkehelsa og en interessekonflikt for regjeringen – å anerkjenne senfølger som et samfunnsproblem ville rette oppmerksomheten mot «fri smitte»-politikken og de ressursene som regjeringen har fjernet.\nDersom økningen i sykefravær skyldes senfølger av covid-19, må dette tvinge regjeringen til å stå til ansvar for sin post-pandemiske håndtering og de påfølgende helsemessige og økonomiske konsekvensene.\nSå ja, årsaken spiller en stor rolle.\nRichard Aubrey White har ein doktorgrad i biostatistikk frå Harvard University. Han er forskar ved FHI, men uttalar seg ikkje på vegner av instituttet."
  },
  {
    "objectID": "post/2024-11-11-covid-er-farligere-enn-du-tror/index.html",
    "href": "post/2024-11-11-covid-er-farligere-enn-du-tror/index.html",
    "title": "Covid er farligere enn du tror",
    "section": "",
    "text": "Publisert på NRK den 11. november 2024.\n\n\nDa pandemien traff oss i 2020 visste vi lite om covid-19 og viruset som forårsaker denne helt nye sykdommen. Nå vet vi mye mer.\nDet har vist seg at koronaviruset nesten utelukkende smitter gjennom luften. Hvis du ikke puster inn viruset, blir du ikke smittet. Derfor merker mange covid som forkjølelse og hoste. Men etter at viruset er kommet inn gjennom luftveiene, sprer det seg videre til hele kroppen.\nHva koronaviruset gjør med kroppen\nEt virus består nesten bare av innpakket arvemateriale. For at viruset skal kunne formere seg, må det komme seg inn i kroppens celler. Viruset «snylter» på cellene våre for å lage mange nye kopier av seg selv.\n\n«Skader kan ses på hjernen, også etter mild sykdom»\n\nKoronaviruset har en ganske unik evne til å komme seg inn i mange ulike celletyper, inkludert cellene som danner innsiden av blodårene og immunceller, og skade dem. Derfor anses ikke covid å være en luftveisinfeksjon, men en såkalt systemisk, multiorgan infeksjonssykdom\nSamtidig som vaksiner og tidligere smitte har gjort akutt covid mindre farlig, har bekymringene for virusets mange senskader økt.\nForskning viser at risikoen for senskader øker jo mer alvorlig den akutte sykdommen er, men det er likevel flest tilfeller av senskader etter mild sykdom, fordi dette er så vanlig.\nHos noen pasienter med long covid er det vist at viruset kan forbli inne i kroppens celler og organer i lang tid. De klarer ikke helt å bli kvitt det. Da er det ikke overraskende at ny forskning finner at gener som styrer kroppens evne til å bekjempe virus er knyttet til økt risiko for long covid.\n\n«Plagene rammer mange, og er ofte vedvarende»\n\nDet er også sett at mus som får injisert antistoffer fra folk med long covid, får de symptomene som pasientene har. Det er derfor på høy tid at vi slutter å psykologisere disse plagene.\nØker risikoen for mange helseplager\nDet er rapportert skade på ti ulike organsystemer etter covid. Senskader etter covid er altså mer enn slitenhet og tung pust. Kognitive plager som «hjernetåke», nedsatt hukommelse, tempo og konsentrasjonsevne, og redusert evne til sammensatte handlinger er de symptomene som oftest rapporteres etter covid, og skader kan ses på hjernen ved MR, også etter mild sykdom.\nDet er bekymringsfullt at store studier, inkludert den norske Koronastudien, finner at disse plagene rammer mange, og er ofte vedvarende.\nRisikoen for å få en ny, helt annen sykdom, som diabetes type 1 og type 2 eller en infeksjonssykdom, og risikoen for å dø av alle årsaker, er også økt i flere år etter covid. Covid er funnet å være en egen risikofaktor for hjerte- og karsykdom, også hos tidligere friske. Disse sykdommene er også forbundet med økt behov for helsetjenester.\n\n«Det er flest tilfeller av senskader etter mild sykdom»\n\nØkt press på helsevesenet og trygdevesenet\nSelv om risikoen for senskader ble noe lavere etter at omikron kom og folk ble vaksinert, ser man fortsatt i studier med kontrollgrupper at 3 prosent eller mer får helseplager av varierende grad etter gjennomgått covid. Hver infeksjon innebærer en økt risiko.\nSå lenge vi ikke har mer effektive vaksiner eller medisinske behandlinger, kan vi derfor anta at antall nordmenn som har problemer med hukommelse, konsentrasjonsevne og evnen til å utføre komplekse oppgaver, vil øke i årene fremover. Med noen millioner koronainfeksjoner hvert år i Norge, utgjør dette et samfunnsproblem.\nNår så få tester seg, vet folk ofte ikke at de har hatt covid. Samtidig kan altså senskader dukke opp i form av annen sykdom, lenge etter at vi føler oss friske.\nI tillegg bruker allmennlegene i Norge et kodesystem for diagnoser som mangler en egen kode for senskader etter covid. Derfor vil mye av den økte syke- og dødeligheten som følger etter covid, bli registrert under helt andre diagnoser, som A04 (utmattelse) eller P29 (som inkluderer slitenhet). P29 sorterer under «lettere psykiske lidelser».\nLong covid er trolig årsak til et stort antall sykmeldinger med disse diagnosene, som vi vet er økt mye de siste to år.\n\n«Det er rapportert skade på ti ulike organsystemer»\n\nVi må forvente flere sykmeldte, et mer belastet helsevesen og kanskje høyere overdødelighet også i tiden fremover, slik vi har sett siden myndighetene sluttet å begrense smittespredningen i begynnelsen av 2022.\nSelv om antallet som blir alvorlig syke og dør av akutt covid synker, er altså sykdommen en driver bak denne utviklingen.\nHvordan forebygge?\nFor det første bør alle som kan ha covid, teste seg og unngå å smitte andre ved å holde seg hjemme hvis testen er positiv.\nDet er vist at vaksinene beskytter mot senskader, inkludert skader på hjerte-karsystemet, og den økte risikoen for sykdom og død. Senskader kan ramme alle aldersgrupper.\nVaksinene beskytter alle aldersgrupper, har få bivirkninger, og er godkjent for alle over seks måneder. Derfor bør alle tilbys grunnvaksinasjon og boostere hver gang det kommer nye, oppdaterte covid-vaksiner etter tilpassede opplegg for ulike grupper, slik amerikanske helsemyndigheter anbefaler.\n\n«Det er på høy tid at vi slutter å psykologisere disse plagene»\n\nMen beskyttelsen fra vaksinasjon er ikke fullgod, og effekten faller raskt etter et halvt års tid. Den eneste sikre måten å forebygge senskader etter covid er per i dag å unngå å bli smittet.\nSiden covid smitter gjennom luftveiene, blir vi ikke smittet hvis det ikke er viruspartikler i luften vi puster inn. Et munnbind som effektivt hindrer partiklene å nå frem til nese og munn, gir derfor god beskyttelse.\nDet er lurt å bruke munnbind ved høy smitterisiko, som når det er mye smitte i omløp og man er innendørs med mange andre, eller om noen er forkjølet.\nBedring av inneklima kan også redusere antall syke. Norge bør satse på å bedre ventilasjonen innendørs og installere luftrensere i skoler, offentlige bygg og arbeidsplasser, slik andre land gjør. Dette er vist å gi færre infeksjoner hos barnehage- og skolebarn, redusert sykefravær hos foreldre og ansatte, og det kan spare penger og øke livskvaliteten.\nÅ få covid annethvert år er bedre for helsen din enn å få covid to ganger hvert år. For hvert smittetilfelle vi forebygger, er det også færre som smitter videre. Derfor er slike forebyggende, enkle smitteverntiltak mer effektive enn mange tror, selv om de ikke er perfekte. De kan trolig spare samfunnet for store summer.\nRichard Aubrey White er forsker ved Folkehelseinstituttet, men skriver ikke på vegne av arbeidsgiveren."
  },
  {
    "objectID": "post/2024-10-02-long-covid-is-common-and-often-permanent/index.html",
    "href": "post/2024-10-02-long-covid-is-common-and-often-permanent/index.html",
    "title": "Long Covid is common and often permanent",
    "section": "",
    "text": "Published in Aftenposten the 2nd of October 2024.\n\n\nThis is a translation of the original Norwegian op-ed, and discrepancies may exist.\nIn an article in Aftenposten on September 27, Professor and Director Preben Aavitsland at the Norwegian Institute of Public Health (NIPH) claims that long covid is “rare and often resolves over time.”\nThis is incorrect — long covid is common and often permanent.\nAavitsland’s claim about duration likely stems from NIPH’s study, which only analyzes the number of general practitioner visits after COVID-19 infection. His interpretation — that fewer visits means the long covid is cured — is incorrect. People stop going to the doctor when the doctor can’t help them, even if the symptoms persist.\nCumulative Risk Increases\nA health-based COVID-19 study — which looked at health status rather than doctor visits — recently showed that COVID-19 led to a 6 percent risk of memory problems more than a year later in Norwegians without prior immunity. Vaccination and prior immunity are about 50 percent effective at preventing long covid, so the risk can be reduced to around 3 percent per infection for most people.\nThe cumulative risk after two infections is then 5.9 percent; after four infections, 11.5 percent; after six infections, 16.7 percent.\nThis is one example, but several studies show the same result — repeated infections increase cumulative risk to an unacceptable level. This must be seen in the context of today’s mass-infection strategy, where people are infected on average once a year.\nIt is no surprise that the rise in sick leave is driven by three diagnostic codes (A04, P02, and P29), all of which are associated with long covid.\nDownplaying the Burden\nThe mass-infection strategy was supported by NIPH’s risk assessments, which only considered acute COVID-19. The NIPH has never published a risk assessment of the strategy that includes long covid.\nIn light of the high rates of sick leave, likely due to long-term effects, those responsible for the strategy — and for the missing risk assessments — have strong incentives to downplay the burden long covid places on society.\nWe must prevent COVID-19 infections and long covid. This can be done by improving ventilation, using air purifiers, and recommending the use of FFP2 respirators when transmission is high.\nRichard Aubrey White holds a Ph.D. in biostatistics from Harvard University. White is a researcher at the Norwegian Institute of Public Health, but does not speak on behalf of the NIPH."
  },
  {
    "objectID": "post/2025-01-18-debatten-om-sykefravaer-er-fort-pa-feil-premisser/index.html",
    "href": "post/2025-01-18-debatten-om-sykefravaer-er-fort-pa-feil-premisser/index.html",
    "title": "Debatten om sykefravær er ført på feil premisser",
    "section": "",
    "text": "Publisert på Fri Fagbevegelse den 18. januar 2025.\nPå Debatten 7. januar spurte Erna Solberg «Det er ikke bare i Norge [sykefraværet] økte, … men i de fleste andre land har sykefraværet gått ned igjen nå, men ikke her. Hvorfor?»\nDette spørsmålet har preget Norge i flere måneder, men dessverre, er debatten ført på feil premisser.\nDet er tre tidsperioder som er relevante i diskusjonen om sykefravær: 2019 («før pandemien»), 2020–2022 («pandemiårene») og 2023 («etter pandemien»).\nUnder årene med pandemi hadde hvert land ulike tiltak, men i etterkant har alle europeiske land valgt samme strategi: Ignorere covid og dens senfølger.\nDette betyr at Solbergs sammenligning i praksis er en skjult sammenligning av pandemitiltak, siden disse varierte betydelig mellom landene. I 2023 er det ingen forskjeller mellom landenes strategier for tiden etter pandemien.\nDette gir inntrykk av at Norge gjør det «dårlig» sammenlignet med andre land, men dette er en feilaktig konklusjon. Grunnen er enkel: Norge gjorde en eksepsjonelt god jobb under pandemien.\nDermed fremstår andre land som om de har «forbedret» seg etter pandemien, når sannheten er at deres pandemi-strategier var svake.\nI tillegg, når vi sammenligner sykefraværet i 2023 med 2022, ser vi at Norge faktisk ligger midt på treet i Europa.\nDette viser at hysteriet rundt norsk sykefravær er sterkt overdrevet.\nFor å få en nøytral vurdering av dagens sykefravær, bør vi sammenligne 2023 med 2019, da 2019 representerer et referanseår som ikke er påvirket av pandemien.\nDenne analysen avdekker to viktige funn:\nDe fleste europeiske land har høyere sykefravær i 2023 enn i 2019, og Norge er helt gjennomsnittlig i denne sammenligningen.\nMed dette perspektivet blir det klart at oppstyret rundt norsk sykefravær er ubegrunnet. Norge står seg godt i et europeisk perspektiv etter pandemien."
  },
  {
    "objectID": "post/2025-01-18-debatten-om-sykefravaer-er-fort-pa-feil-premisser/index.html#hvorfor-er-sykefraværet-høyere-nå-enn-i-2019",
    "href": "post/2025-01-18-debatten-om-sykefravaer-er-fort-pa-feil-premisser/index.html#hvorfor-er-sykefraværet-høyere-nå-enn-i-2019",
    "title": "Debatten om sykefravær er ført på feil premisser",
    "section": "Hvorfor er sykefraværet høyere nå enn i 2019?",
    "text": "Hvorfor er sykefraværet høyere nå enn i 2019?\nFra 2023 har de fleste europeiske land hatt en la det skure-strategi med fri smitte, der mange blir smittet av covid-19 minst én gang i året.\nDen 10. januar 2025 publiserte forskere fra FHI en studie som viser at blant nordmenn med tre vaksinedoser hadde omikronsmitte en risiko på 6 prosent for langvarige symptomer, kjent som «long covid» eller «senfølger av covid-19».\nDette innebærer at opptil 250.000 nordmenn kan få long covid hvert år. Det er tydelig at dette vil øke sykefraværet – noe vi allerede ser i tallene.\nTo vitenskapelige artikler fra to norske forskergrupper kom uavhengig av hverandre til samme konklusjon: En betydelig del av økningen i det norske sykefraværet skyldes sykdommer knyttet til akutt covid-19 og senfølger av covid-19. En studie fant til og med en tidsmessig sammenheng med koronabølger."
  },
  {
    "objectID": "post/2025-01-18-debatten-om-sykefravaer-er-fort-pa-feil-premisser/index.html#men-hva-med-resten-av-verden-de-har-også-covid",
    "href": "post/2025-01-18-debatten-om-sykefravaer-er-fort-pa-feil-premisser/index.html#men-hva-med-resten-av-verden-de-har-også-covid",
    "title": "Debatten om sykefravær er ført på feil premisser",
    "section": "«Men hva med resten av verden? De har også covid!»",
    "text": "«Men hva med resten av verden? De har også covid!»\nJa, og vi ser lignende trender der.\nFra 2012 til 2019 var andelen voksne i Spania som rapporterte om en kronisk helsetilstand stabil på rundt 30 prosent. Da undersøkelsen startet opp igjen tidlig i 2022, hadde denne andelen hoppet til 42,3 prosent. I den siste rapporten fra oktober 2024 var andelen oppe i 49,5.\nI USA var det fra 2015 til 2019 omtrent 30 millioner voksne med en funksjonsnedsettelse. Tidlig i 2022 var tallet cirka 32 millioner, og nå, i november 2024, er det 34,8 millioner.\nI Storbritannia var antallet voksne som var ute av arbeid på grunn av langvarig sykdom stabilt på rundt to millioner fra 2013 til 2019. Sent i 2021 nådde det 2,4 millioner, og nå ligger det på 2,8 millioner.\nDette er selvfølgelig kun indisier, men det er også akkurat hva vi forventer å se fra millioner av gjentatte koronainfeksjoner hvert år."
  },
  {
    "objectID": "post/2025-01-18-debatten-om-sykefravaer-er-fort-pa-feil-premisser/index.html#som-å-spille-russisk-rulett-med-kronisk-sykdom",
    "href": "post/2025-01-18-debatten-om-sykefravaer-er-fort-pa-feil-premisser/index.html#som-å-spille-russisk-rulett-med-kronisk-sykdom",
    "title": "Debatten om sykefravær er ført på feil premisser",
    "section": "Som å spille russisk rulett med kronisk sykdom",
    "text": "Som å spille russisk rulett med kronisk sykdom\nCovid er farligere enn du tror. Hver reinfeksjon er som å spille russisk rulett med kronisk sykdom. Sykefravær er bare toppen av isfjellet.\nMange med long covid er fortsatt i full jobb, bare med betydelig redusert livskvalitet. I tillegg finnes det ulike grader av long covid – for de med mild long covid kan reinfeksjon forverre tilstanden. Forebygging er derfor avgjørende.\nMed målrettede tiltak mot det luftbårne koronaviruset kan vi redusere covid-19 betydelig med lavterskeltiltak:\n\nInformasjonskampanjer om risikoen for long covid (som i Australia) for å informere befolkningen om hvorfor det er så viktig å fortsette å bekjempe covid-19.\nForbedre ventilasjon og luftfiltrering, spesielt i skoler og på sykehus. Dette gjøres i mange land, som Australia og USA, men ikke i Norge.\nUV-C-desinfisering av luft, som brukes for å beskytte mot tuberkulose.\nAnbefalinger om å bruke FFP2-munnbind innendørs og på kollektivtransport når det er mye smitte.\nBevare dagens sykefraværsordning, slik at folk har råd til å bli hjemme mens de er syke og/eller smittsomme. En studie fra FHI viser at rask sykemelding ved nye oppståtte luftveissymptomer er kostnadseffektivt fordi det hindrer videre smitte til kollegaer.\n\nRichard Aubrey White er forsker ved Folkehelseinstituttet, men skriver ikke på vegne av arbeidsgiveren."
  },
  {
    "objectID": "post/2025-05-10-lofterik-behandling-av-long-covid-uten-bevis/index.html",
    "href": "post/2025-05-10-lofterik-behandling-av-long-covid-uten-bevis/index.html",
    "title": "Løfterik behandling av long covid uten bevis",
    "section": "",
    "text": "Publisert på Forskersonen den 10. mai 2025.\n\n\nOmtrent 3–6 prosent av koronainfeksjoner fører til langvarige helseplager, kjent som «long covid». Med millioner av koronainfeksjoner hvert år i Norge, står vi overfor en alvorlig folkehelsekrise synliggjort gjennom økt sykefravær, flere dødsfall enn forventet blant yngre voksne og en betydelig økning i legekonsultasjoner på grunn av utmattelse.\nHåpefull studie med alvorlige svakheter\nErna Solberg og Høyre har anerkjent at long covid kan være en viktig årsak til økningen i sykefraværet og kommet med et valgløfte om å forbedre behandlingen.\nTil tross for situasjonens alvor og Høyres valgløfte, finnes det ingen dokumentert effektiv behandling mot long covid.\nEnkelte forskere, hvorav noen har bakgrunn i kontroversielle psykososiale teorier om postvirale lidelser, har foreslått eksperimentelle psykososiale behandlinger som løsningen.\nEn nylig studie av Tom Farmen Nerli med flere, foreslår behandling «basert på en kognitiv og atferdsmessig tilnærming.» Studien har skapt håp, men en nærmere undersøkelse avslører alvorlige metodiske svakheter.\nMisvisende resultater og tvilsomme målemetoder\n«Klinisk signifikant» er et avgjørende begrep når man vurderer behandlingseffekt. Det betyr at behandlingen gir en reell, merkbar forbedring i pasientens helse—ikke bare en forskjell som lar seg måle statistisk. Det holder altså ikke å påvise en endring; den må være stor nok til å ha praktisk betydning for livskvalitet og funksjon.\nStudien fra Nerli bruker en skala for fysisk funksjon (SF-36-PF) der deltakerne selv vurderer i hvilken grad helsen begrenser dem i hverdagsaktiviteter som å gå trapper, bære varer eller støvsuge.\nI analyseplanen, skrevet før resultatene var kjent, oppgir forfatterne at en forbedring på minst 10 poeng på denne skalaen er nødvendig for at en behandling skal anses som klinisk signifikant.\nMisvisende fremstilling av funn\nI denne studien oppnådde behandlingsgruppen i gjennomsnitt bare 9,2 poengs forbedring - altså under terskelverdien. De har riktignok målt en effekt, men ifølge forfatternes egne kriterier er den ikke stor nok til å ha praktisk betydning.\nLikevel fremstiller forfatterne behandlingen som klinisk signifikant og effektiv i artikkelen. Dette er klart misvisende.\nVidere bruker forfatterne en problematisk definisjon av «frisk». De anser pasienter som friske dersom de scorer 85 eller høyere på SF-36-PF-skalaen, uten hensyn til alder og kjønn. En score på 85 er typisk for en frisk 60-årig kvinne, men deltakerne i studien hadde en gjennomsnittsalder på 42 år. Dermed fører bruken av en score på 85 som «frisk»-terskel til en kunstig høy andel «friske».\nManglende datadeling hindrer etterprøving\nSterke konklusjoner krever åpenhet og uavhengig kontroll. Forfatterne lovet i sin dataerklæring at anonymiserte data skulle gjøres tilgjengelig for vitenskapelig bruk. Jeg ba om et anonymisert og begrenset datasett for å kunne beregne reelle, alders- og kjønnsjusterte tilfriskningsrater.\nDatasettet ville inneholde kun få variabler: Hvorvidt deltakeren fikk intervensjonen, om vedkommende var frisk etter forfatternes definisjon og om vedkommende var frisk etter en alders- og kjønnsjustert definisjon ved tre tidspunkt. Forespørselen ble avslått etter halvannen måned. Akershus universitetssykehus HF mente dataene var «personsensitive og underlagt taushetsplikt», til tross for at ingen identifiserende informasjon ble etterspurt. En annen begrunnelse var at «uttrekk av relevante variabler og etterfølgende anonymisering vil dessuten kreve en viss arbeidsinnsats fra forskerne tilknyttet prosjektet.» Dette reiser spørsmålet: Hvorfor ble det da lovet datadeling?\nForskere må ikke love åpenhet de ikke kan innfri. Slike løftebrudd svekker forskningens troverdighet og undergraver prinsippet om uavhengig etterprøvbarhet.\nHvor mange ble egentlig friske?\nDet var først etter at jeg klaget til tidsskriftet JAMA Network Open at forfatterne offentliggjorde de alders- og kjønnsjusterte tilfriskningsratene. Disse viste at bare 8 prosent av deltakerne i kontrollgruppen ble friske etter tolv måneder—en oppsiktsvekkende lav andel som burde vekke alvorlig bekymring hos klinikere og helsemyndigheter.\nI intervensjonsgruppen var andelen 29 prosentpoeng høyere. Men siden deltakerne selv vurderte utfallene (for eksempel «Er helsen din slik at den begrenser deg i moderate aktiviteter som å støvsuge?»), og visste om de fikk intervensjonen eller ikke, er det uklart hvor mye av intervensjonens beskjedne effekt som skyldes placeboeffekten og svarskjevhet.\nDet vil si at deltakerne kan ha overvurdert bedring fordi de forventet effekt, eller ønsket å bekrefte forskernes antakelser. Objektive mål, som antall skritt per dag, ville trolig ha vist enda svakere resultater.\nEn ublindet psykososial behandling med tilfriskningsrate på kun 29 prosent på et subjektivt mål under ideelle forsøksforhold, bør ikke presenteres som en løsning for en kompleks, multisystemisk tilstand som long covid.\nTvert imot understreker dette behovet for biomedisinske behandlingsstrategier rettet mot blant annet viral persistens, postakutt inflammasjon, autoimmunitet, trombose, reaktivering av latente virus, dysbiose, tarmtranslokasjon og mitokondriell dysfunksjon.\nBehov for større åpenhet og bedre metodebruk\nMisvisende fremstilling, svake metoder og hemmelighold av data er ikke bare tekniske detaljer, men alvorlige feil med store konsekvenser for de som sliter med long covid. Bare ærlig og åpen vitenskap kan danne grunnlaget for informerte valg hos pasienter, helsepersonell og politikere.\nInntil resultater kan bekreftes gjennom robust og uavhengig forskning, må vi være varsomme med å spre forhåpninger om eksperimentelle behandlinger.\nFøre-var-prinsippet tilsier også at vi må prioritere forebygging av long covid, akkurat som vi gjør med alle andre sykdommer, samtidig som vi utvikler bedre behandling. Siden long covid skyldes et luftbårent virus, må forebygging skje gjennom bedre ventilasjon, luftrensing og bruk av FFP2-munnbind.\nVi skylder både pasientene og samfunnet å kreve åpenhet og vitenskapelig redelighet. Bare slik kan vi finne løsningene som trengs.\nOm forfatteren: Richard Aubrey White har doktorgrad i biostatistikk fra Harvard University. Han er forsker ved Folkehelseinstituttet, men skriver ikke på vegne av instituttet."
  },
  {
    "objectID": "post/2025-01-18-the-sick-leave-debate-is-based-on-wrong-premises/index.html",
    "href": "post/2025-01-18-the-sick-leave-debate-is-based-on-wrong-premises/index.html",
    "title": "The sick leave debate is based on wrong premises",
    "section": "",
    "text": "This is a translation of the original Norwegian op-ed, and discrepancies may exist.\nOn “The Debate” on January 7, Erna Solberg asked: “It’s not just in Norway that [sick leave] increased, … but in most other countries, sick leave has gone down again now, but not here. Why?”\nThis question has dominated Norway for several months, but unfortunately, the debate is based on wrong premises.\nThere are three time periods relevant to the discussion about sick leave: 2019 (“before the pandemic”), 2020–2022 (“the pandemic years”), and 2023 (“after the pandemic”).\nDuring the pandemic years, each country had different measures, but afterwards, all European countries chose the same strategy: Ignore COVID and its long-term consequences.\nThis means that Solberg’s comparison is in practice a hidden comparison of pandemic measures, since these varied significantly between countries. In 2023, there are no differences between countries’ strategies for the post-pandemic period.\nThis gives the impression that Norway is doing “poorly” compared to other countries, but this is a false conclusion. The reason is simple: Norway did an exceptionally good job during the pandemic.\nThus, other countries appear to have “improved” after the pandemic, when the truth is that their pandemic strategies were weak.\nIn addition, when we compare sick leave in 2023 with 2022, we see that Norway is actually in the middle of the pack in Europe.\nThis shows that the hysteria around Norwegian sick leave is greatly exaggerated.\nTo get a neutral assessment of today’s sick leave, we should compare 2023 with 2019, as 2019 represents a reference year that is not affected by the pandemic.\nThis analysis reveals two important findings:\nMost European countries have higher sick leave in 2023 than in 2019, and Norway is completely average in this comparison.\nWith this perspective, it becomes clear that the uproar around Norwegian sick leave is unfounded. Norway is doing well in a European perspective after the pandemic."
  },
  {
    "objectID": "post/2025-01-18-the-sick-leave-debate-is-based-on-wrong-premises/index.html#why-is-sick-leave-higher-now-than-in-2019",
    "href": "post/2025-01-18-the-sick-leave-debate-is-based-on-wrong-premises/index.html#why-is-sick-leave-higher-now-than-in-2019",
    "title": "The sick leave debate is based on wrong premises",
    "section": "Why is sick leave higher now than in 2019?",
    "text": "Why is sick leave higher now than in 2019?\nFrom 2023, most European countries have had a “let it rip” strategy with free transmission, where many get infected with COVID-19 at least once a year.\nOn January 10, 2025, researchers from the Norwegian Institute of Public Health (FHI) published a study showing that among Norwegians with three vaccine doses, omicron infection had a 6 percent risk of long-lasting symptoms, known as “long COVID” or “long-term consequences of COVID-19.”\nThis means that up to 250,000 Norwegians can get long COVID each year. It is clear that this will increase sick leave – something we already see in the numbers.\nTwo scientific articles from two Norwegian research groups independently reached the same conclusion: A significant portion of the increase in Norwegian sick leave is due to diseases related to acute COVID-19 and long-term consequences of COVID-19. One study even found a temporal connection with coronavirus waves."
  },
  {
    "objectID": "post/2025-01-18-the-sick-leave-debate-is-based-on-wrong-premises/index.html#but-what-about-the-rest-of-the-world-they-also-have-covid",
    "href": "post/2025-01-18-the-sick-leave-debate-is-based-on-wrong-premises/index.html#but-what-about-the-rest-of-the-world-they-also-have-covid",
    "title": "The sick leave debate is based on wrong premises",
    "section": "“But what about the rest of the world? They also have COVID!”",
    "text": "“But what about the rest of the world? They also have COVID!”\nYes, and we see similar trends there.\nFrom 2012 to 2019, the proportion of adults in Spain who reported having a chronic health condition was stable at around 30 percent. When the survey resumed in early 2022, this proportion had jumped to 42.3 percent. In the latest report from October 2024, the proportion was up to 49.5 percent.\nIn the USA, from 2015 to 2019, there were approximately 30 million adults with a disability. Early in 2022, the number was about 32 million, and now, in November 2024, it is 34.8 million.\nIn the UK, the number of adults who were out of work due to long-term illness was stable at around two million from 2013 to 2019. Late in 2021, it reached 2.4 million, and now it stands at 2.8 million.\nThis is of course only circumstantial evidence, but it is also exactly what we expect to see from millions of repeated coronavirus infections each year."
  },
  {
    "objectID": "post/2025-01-18-the-sick-leave-debate-is-based-on-wrong-premises/index.html#like-playing-russian-roulette-with-chronic-disease",
    "href": "post/2025-01-18-the-sick-leave-debate-is-based-on-wrong-premises/index.html#like-playing-russian-roulette-with-chronic-disease",
    "title": "The sick leave debate is based on wrong premises",
    "section": "Like playing Russian roulette with chronic disease",
    "text": "Like playing Russian roulette with chronic disease\nCOVID is more dangerous than you think. Each reinfection is like playing Russian roulette with chronic disease. Sick leave is just the tip of the iceberg.\nMany with long COVID are still in full-time work, just with significantly reduced quality of life. In addition, there are different degrees of long COVID – for those with mild long COVID, reinfection can worsen the condition. Prevention is therefore crucial.\nWith targeted measures against the airborne coronavirus, we can significantly reduce COVID-19 with low-threshold measures:\n\nInformation campaigns about the risk of long COVID (as in Australia) to inform the population about why it is so important to continue fighting COVID-19.\nImprove ventilation and air filtration, especially in schools and hospitals. This is done in many countries, such as Australia and the USA, but not in Norway.\nUV-C air disinfection, which is used to protect against tuberculosis.\nRecommendations to use FFP2 masks indoors and on public transport when there is high transmission.\nPreserve today’s sick leave system, so people can afford to stay home while they are sick and/or infectious. A study from FHI shows that rapid sick leave for newly emerging respiratory symptoms is cost-effective because it prevents further transmission to colleagues.\n\nRichard Aubrey White is a researcher at the Norwegian Institute of Public Health, but does not write on behalf of his employer."
  },
  {
    "objectID": "post/2024-08-13-the-attack-on-public-health-continues/index.html",
    "href": "post/2024-08-13-the-attack-on-public-health-continues/index.html",
    "title": "The attack on public health continues",
    "section": "",
    "text": "This is a translation of the original Norwegian op-ed, and discrepancies may exist.\n\n\n\nPublished in Fædrelandsvennen on August 13, 2024.\n\n\nRichard Aubrey White has a PhD in biostatistics from Harvard University and is a researcher at FHI, but does not speak on behalf of his employer.\nPreben Aavitsland began his attacks on the use of face masks on January 30, 2020, where he called the use “a cultural thing.” On August 2 this year, he continued in Fædrelandsvennen, by claiming that face masks are a “lucky charm against corona.” Even though FHI’s new study shows that face masks reduce respiratory infections by 29 percent, it is not enough to satisfy Aavitsland that they work.\nThe FHI study has three flaws that undermine Aavitsland’s arguments.\nFirst, participants were asked to use face masks in public spaces for two weeks, and then report their symptoms. Assume that the period lasted from February 14 to 27: For someone who has been infected with COVID-19, it takes between two and six days before they show symptoms, which means that a person who was infected on February 13 probably won’t show symptoms until February 18 (well into the study period). This error affects the first half of the study period, making face masks appear less effective than they actually are. Most studies ignore the first period to avoid such biased data, but not the FHI study.\nIt’s like performing a pregnancy test on February 28 for a couple who has unprotected sex every day from February 8 to 13, and then is asked to use condoms from February 14 to 27. Then condoms won’t appear particularly effective either.\nSecond, participants were not asked to use face masks at work. Face masks, like condoms and seat belts, are only effective while being used.\nThird, corona spreads like smoke through the air. Surgical masks are not suitable for protecting against airborne transmission, which is why many health authorities recommend FFP2 respirators or better.\nWith these flaws, it is surprising that FHI found that surgical masks still reduced risk by 29 percent. Remove the first week with biased data and ask participants to use FFP2 respirators (also at work), and you will be left with even stronger results. Something a recent review concluded.\nAavitsland mentions skin irritation and headache as the disadvantages of face masks, but not the disadvantages of long-term consequences of COVID-19, such as cardiovascular complications, cognitive problems, brain fog, and fatigue. Long-term consequences are common (but ignored by Norwegian health authorities); among 20-64 year-olds, doctor visits for exhaustion are 75 percent higher in 2024 than in 2019.\nIt is ironic that Aavitsland fears that face masks will encourage sick people to go to work and infect others. One of the best methods for keeping people home while they are infectious is to use rapid tests to identify the correct isolation period (some are infectious after symptoms have ended), which he in VG has claimed is unnecessary.\nWhy does Aavitsland work so hard to undermine public health strategies that are common outside Norway? Is it because Norway has been on the wrong track for so long that it is difficult to turn around without losing face?"
  },
  {
    "objectID": "post/2024-01-04-record-numbers-to-doctor-with-exhaustion/index.html",
    "href": "post/2024-01-04-record-numbers-to-doctor-with-exhaustion/index.html",
    "title": "Sounding alarm: Record numbers to doctor with exhaustion",
    "section": "",
    "text": "This is a translation of the original Norwegian news article, and discrepancies may exist.\n\nPublished on nrk.no on January 4, 2024.\nThe case summarized:\n\nThere has been a dramatic increase in the number of patients seeking medical attention for exhaustion during the pandemic.\nThe increase has occurred in all age groups, with the exception of children aged 0–4 years.\nFHI statistician Richard Aubrey White and other researchers are concerned about the development.\nThe increase in exhaustion came simultaneously with the omicron variant, and there is a temporal connection between infection waves and increases in exhaustion.\nSeveral large studies show that COVID-19 can cause serious long-term consequences.\nResearcher and infectious disease physician Arne Søraas urges Norwegian public health authorities to update themselves on international research in the field.\nProfessional director Preben Aavitsland at FHI believes there is not enough good knowledge to establish that COVID-19 leads to serious long-term consequences."
  },
  {
    "objectID": "post/2025-07-14-random-intercepts-do-not-fix-confounding/index.html",
    "href": "post/2025-07-14-random-intercepts-do-not-fix-confounding/index.html",
    "title": "Random intercepts do not fix confounding",
    "section": "",
    "text": "Mixed effects models are a crucial tool in the modern epidemiologist’s toolbox. They allow for the estimation of both fixed and random effects, which can help to account for the correlation structure in the data. However, it is a common misconception that random intercepts can fix epidemiological confounding.\nThis post will use lme4 and rstanarm to demonstrate that this is not the case, and then provide some guidance on how to properly adjust for confounding and when random intercepts should be used.\nA common aim in the field of epidemiology is to precisely measure the association between two variables, typically referred to as the outcome and exposure. The estimation of this association is typically biased due to confounders. A confounder is defined as an independent variable that is associated with both the outcome and the exposure. The presence of a confounder can lead to biased estimates of the exposure-outcome association, unless it is appropriately taken into account.\n\n\nConsider the following simple linear regression model:\n\\[\n\\text{Formula 1: } Y_i = \\beta_0 + \\beta_1 X_i + \\epsilon_i,\\ i=1 \\dots n\n\\]\nwhere \\(Y_i\\) is the outcome, \\(X_i\\) is the exposure, and \\(\\epsilon_i\\) is the error term. The parameter of interest is \\(\\beta_1\\), which represents the association between the exposure and the outcome.\nNow, if there is a confounder \\(C_i\\) that is associated with both \\(X\\) and \\(Y\\), then the estimate of \\(\\beta_1\\) in Formula 1 will be biased. An unbiased estimate of \\(\\beta_1\\) can be obtained by adjusting for the confounder:\n\\[\n\\text{Formula 2: } Y_i = \\beta_0 + \\beta_1 X_i + \\beta_2 C_i + \\epsilon_i,\\ i=1 \\dots n\n\\]\nWhen there are no unmeasured confounders, \\(\\beta_1\\) can be considered to be the conditional causal effect of \\(X\\) on \\(Y\\) given \\(C\\).\n\\[\n\\text{Formula 3: } \\beta_1 = E[Y|X, C=1] - E[Y|X, C=0]\n\\]\nA more complex situation occurs when there are multiple clusters in the data, such as patients within hospitals, or students within schools. In this case, a random intercept can be added to the model to account for the correlation within clusters:\n\\[\n\\text{Formula 4: } Y_{ij} = \\beta_0 + u_{0j} + \\beta_1 X_{ij} + \\epsilon_{ij}\n\\]\nwhere \\(u_{0j} \\sim N(0, \\sigma_u^2)\\) represents the random intercept for cluster \\(j\\), and \\(\\epsilon_{ij} \\sim N(0, \\sigma_e^2)\\) represents the individual-level error term.\nThe key question is: Does the random intercept \\(u_{0j}\\) adequately control for cluster-level confounding?"
  },
  {
    "objectID": "post/2025-07-14-random-intercepts-do-not-fix-confounding/index.html#mathematical-framework",
    "href": "post/2025-07-14-random-intercepts-do-not-fix-confounding/index.html#mathematical-framework",
    "title": "Random intercepts do not fix confounding",
    "section": "",
    "text": "Consider the following simple linear regression model:\n\\[\n\\text{Formula 1: } Y_i = \\beta_0 + \\beta_1 X_i + \\epsilon_i,\\ i=1 \\dots n\n\\]\nwhere \\(Y_i\\) is the outcome, \\(X_i\\) is the exposure, and \\(\\epsilon_i\\) is the error term. The parameter of interest is \\(\\beta_1\\), which represents the association between the exposure and the outcome.\nNow, if there is a confounder \\(C_i\\) that is associated with both \\(X\\) and \\(Y\\), then the estimate of \\(\\beta_1\\) in Formula 1 will be biased. An unbiased estimate of \\(\\beta_1\\) can be obtained by adjusting for the confounder:\n\\[\n\\text{Formula 2: } Y_i = \\beta_0 + \\beta_1 X_i + \\beta_2 C_i + \\epsilon_i,\\ i=1 \\dots n\n\\]\nWhen there are no unmeasured confounders, \\(\\beta_1\\) can be considered to be the conditional causal effect of \\(X\\) on \\(Y\\) given \\(C\\).\n\\[\n\\text{Formula 3: } \\beta_1 = E[Y|X, C=1] - E[Y|X, C=0]\n\\]\nA more complex situation occurs when there are multiple clusters in the data, such as patients within hospitals, or students within schools. In this case, a random intercept can be added to the model to account for the correlation within clusters:\n\\[\n\\text{Formula 4: } Y_{ij} = \\beta_0 + u_{0j} + \\beta_1 X_{ij} + \\epsilon_{ij}\n\\]\nwhere \\(u_{0j} \\sim N(0, \\sigma_u^2)\\) represents the random intercept for cluster \\(j\\), and \\(\\epsilon_{ij} \\sim N(0, \\sigma_e^2)\\) represents the individual-level error term.\nThe key question is: Does the random intercept \\(u_{0j}\\) adequately control for cluster-level confounding?"
  },
  {
    "objectID": "post/2025-07-14-random-intercepts-do-not-fix-confounding/index.html#results-interpretation",
    "href": "post/2025-07-14-random-intercepts-do-not-fix-confounding/index.html#results-interpretation",
    "title": "Random intercepts do not fix confounding",
    "section": "Results interpretation",
    "text": "Results interpretation\nThe simulation results show:\n\n\n\n\n\n\n\n\n\nThe key findings are:\n\nFixed effects models (both lm with cluster dummies and fixest) correctly estimate the causal effect with minimal bias\nRandom intercepts models show substantial bias, failing to adequately control for the cluster-level confounder\n\nThis demonstrates that when confounding occurs at the cluster level, random intercepts do not provide adequate control for confounding, while fixed effects do."
  },
  {
    "objectID": "post/2025-07-14-random-intercepts-do-not-fix-confounding/index.html#use-random-intercepts-when",
    "href": "post/2025-07-14-random-intercepts-do-not-fix-confounding/index.html#use-random-intercepts-when",
    "title": "Random intercepts do not fix confounding",
    "section": "Use random intercepts when:",
    "text": "Use random intercepts when:\n\nYou want to make inferences about the population of clusters (not just the observed clusters).\nThe clusters are a random sample from a larger population.\nYou’re primarily interested in individual-level effects.\nThe cluster-level variables are not confounders."
  },
  {
    "objectID": "post/2025-07-14-random-intercepts-do-not-fix-confounding/index.html#use-fixed-effects-when",
    "href": "post/2025-07-14-random-intercepts-do-not-fix-confounding/index.html#use-fixed-effects-when",
    "title": "Random intercepts do not fix confounding",
    "section": "Use fixed effects when:",
    "text": "Use fixed effects when:\n\nYou want to control for all time-invariant cluster-level confounders.\nYou’re making inferences about the specific clusters in your data.\nThe cluster-level variables are potential confounders.\nYou want the most robust estimate of the exposure effect."
  },
  {
    "objectID": "post/2024-03-03-reagerer-pa-hoye-dodstall-blant-unge/index.html",
    "href": "post/2024-03-03-reagerer-pa-hoye-dodstall-blant-unge/index.html",
    "title": "Reagerer på høye dødstall blant unge",
    "section": "",
    "text": "Publisert på nrk.no den 3. mars 2024.\nSaken oppsummert:\n\nFor første gang på minst 20 år, er det registrert overdødelighet blant unge i Norge, ifølge beregninger forskere har utført.\nI 2022 ble det registrert en overdødelighet for alle aldersgrupper på hele 11,5 prosent, som tilsvarer 4 682 flere dødsfall enn forventet.\nOverdødeligheten fortsatte også i 2023, og det er ikke bare de eldste som faller bort i større grad enn ventet.\nForsker Richard Aubrey White mener at covid-19 peker seg ut som en sannsynlig forklaring på overdødeligheten.\nWhite frykter at gjentatte smittebølger vil skade folkehelsa.\nFHI bekrefter tidvis høyere dødelighet blant unge, men vil ikke spekulere på årsakene før grundigere analyser er gjort.\nDødsårsaksregisteret er ikke klart før til sommeren, og først da vil det være mulig å få svar på hva som har forårsaket overdødeligheten."
  },
  {
    "objectID": "post/2025-03-23-de-fleste-tenker-ikke-pa-covid-lenger/index.html",
    "href": "post/2025-03-23-de-fleste-tenker-ikke-pa-covid-lenger/index.html",
    "title": "De fleste tenker ikke på covid lenger - men for Gro-Rita har viruset endret alt",
    "section": "",
    "text": "Publisert på Bladet Vesterålen den 23. mars 2025."
  },
  {
    "objectID": "post/2025-06-13-eksplosiv-okning-barn-sliter-med-hukommelsen/index.html",
    "href": "post/2025-06-13-eksplosiv-okning-barn-sliter-med-hukommelsen/index.html",
    "title": "Eksplosiv økning: Barn sliter med hukommelsen",
    "section": "",
    "text": "Publisert på nrk.no den 13. juni 2025.\nSaken oppsummert:\n\nAntall legebesøk for hukommelsesforstyrrelser har økt kraftig, også blant barn i alderen 5–14 år.\nForsker Richard Aubrey White mener senfølger av covid-19 kan være en vesentlig årsak til økningen, basert på data som viser økning i hukommelsesproblemer etter pandemibølger.\nHjerneforsker Marte Roa Syvertsen peker på skjermbruk og sosiale medier som mulige årsaker, og understreker viktigheten av søvn, fysisk aktivitet og sosial kontakt.\nFHI er forsiktige i sine tolkninger og peker på at økt bruk av diagnosekoder og flere fastleger kan bidra til økningen, men etterlyser mer forskning.\nToppforskeren David Putrino advarer om at gjentatte koronainfeksjoner kan føre til kognitive problemer hos barn."
  },
  {
    "objectID": "presentations.html",
    "href": "presentations.html",
    "title": "White, Ph.D.",
    "section": "",
    "text": "The Consequences of COVID-19 and Long Covid. [Webinar in English]\n\nIntroduction and Welcome\n\nTime: 00:00 - 00:06\nLisa Norén, GP and spokesperson\n\nThe Norwegian Corona Study and Long Covid (in Norwegian)\n\nTime: 00:06 - 00:38\nArne Søraas, M.D., PhD.\n\nPASC — more than fatigue. Increased risk of disease and death after COVID-19 and the effect of COVID vaccines\n\nTime: 00:38 - 01:10\nGunhild A. Nyborg, M.D., PhD, Exam. Oecon\n\nHealthcare usage and sick leave in 2023\n\nTime: 01:10 - 01:39\nRichard Aubrey White, PhD\n\nQ&A Session with Lisa Norén\n\nTime: 01:39 - 02:02"
  },
  {
    "objectID": "presentations.html#section",
    "href": "presentations.html#section",
    "title": "White, Ph.D.",
    "section": "",
    "text": "The Consequences of COVID-19 and Long Covid. [Webinar in English]\n\nIntroduction and Welcome\n\nTime: 00:00 - 00:06\nLisa Norén, GP and spokesperson\n\nThe Norwegian Corona Study and Long Covid (in Norwegian)\n\nTime: 00:06 - 00:38\nArne Søraas, M.D., PhD.\n\nPASC — more than fatigue. Increased risk of disease and death after COVID-19 and the effect of COVID vaccines\n\nTime: 00:38 - 01:10\nGunhild A. Nyborg, M.D., PhD, Exam. Oecon\n\nHealthcare usage and sick leave in 2023\n\nTime: 01:10 - 01:39\nRichard Aubrey White, PhD\n\nQ&A Session with Lisa Norén\n\nTime: 01:39 - 02:02"
  },
  {
    "objectID": "presentations.html#section-1",
    "href": "presentations.html#section-1",
    "title": "White, Ph.D.",
    "section": "2024",
    "text": "2024\n\nLeve med ME podcast\nCovid er ikke over — long covid er den usynlige helsekrisen som få snakker om. I denne episoden møter vi Richard Aubrey White, statistiker og smittevernforsker, som deler sine erfaringer og innsikt i hva long covid betyr for enkeltmennesker og samfunnet. Hvorfor er helsefagarbeidere, lærere og familier spesielt utsatt? Hva kan vi gjøre for å redusere risikoen? Og hvordan vil helsevesenet se ut om 10 år dersom vi ikke handler nå? Bli med på en viktig samtale om en sykdom som påvirker langt flere enn du tror. [Podcast]\n\n\nNorges Myalgisk Encefalopati Forening\nHelsetjenestebruk og sykefravær i 2023 sammenlignet med trender før pandemien i Norge\n\n\n\nNasjonal kompetansetjeneste for CFS/ME\nTraces of COVID-19 on primary healthcare consultations and medically certified sick leave in 2023. [pdf]\n\n\nUppsala University\nPractical data management for modern open science. [pdf]\n\n\nR/Medicine\norg + plnr: Packages for Organized Project Material and Effective Analysis. [pdf]"
  },
  {
    "objectID": "presentations.html#section-2",
    "href": "presentations.html#section-2",
    "title": "White, Ph.D.",
    "section": "2023",
    "text": "2023\n\nNorthern European Symposium on Automated Surveillance\nCore Surveillance 9 as a framework for real-time analysis and disease surveillance, using NorSySS as an example. [pdf]\n\n\nUkrainian Symposium on Syndromic Surveillance\nThe Role of Statistics in Syndromic Surveillance. [pdf]"
  },
  {
    "objectID": "CLAUDE.html",
    "href": "CLAUDE.html",
    "title": "CLAUDE.md",
    "section": "",
    "text": "This file provides guidance to Claude Code (claude.ai/code) when working with code in this repository.\n\n\nThis is a personal academic website built with Quarto, rendered as a static site and hosted on GitHub Pages. The site contains blog posts, academic publications, presentations, CV, and recipes.\n\n\n\n\n\n\nquarto render . - Renders the entire site to the docs/ directory\n./deploy.sh - Full deployment script that renders the site, commits docs, and pushes to main\nRscript -e \"quarto::quarto_render('.')\" - Alternative R-based render command\n\n\n\n\n\nquarto preview - Start local development server with live reload\nquarto render post/path/to/post.qmd - Render a specific post\nquarto render recipe/path/to/recipe.qmd - Render a specific recipe\n\n\n\n\n\n\n\n\npost/ - Blog posts (academic, health-related topics)\nrecipe/ - Recipe collection\narticles/ - PDF copies of academic publications\npresentations/ - PDF copies of presentations\ndocs/ - Generated site output (published to GitHub Pages)\n\n\n\n\n\n_quarto.yml - Main Quarto configuration\npost/_metadata.yml - Post-specific metadata (freeze: true, title-block-banner: true)\nrecipe/_metadata.yml - Recipe-specific metadata\npublications.bib - Bibliography file for academic publications\nproject.Rproj - R project settings\n\n\n\n\n\nComputational freeze enabled for posts (freeze: true) to avoid re-executing R code\nUses Flatly theme with custom title block styling\nIntegrated with GoatCounter analytics\nGitHub and Twitter/X social links in navbar\n\n\n\n\n\n\n\nThe blog follows a specific bilingual pattern: - English-only posts: If the core post is written in English, it remains English-only - Norwegian posts with translations: If the core post is written in Norwegian, it should have: - Original Norwegian version with categories: [\"Norsk\", ...] - English translation version with categories: [\"English\", ...] - Translation pairs use same date but different slug language (e.g., 2024-09-27-forebygg-covid-19-forebygg-sykefravaer/ vs 2024-09-27-prevent-covid-19-prevent-sick-leave/) - English translations include disclaimer: “This is a translation of the original Norwegian op-ed, and discrepancies may exist.” - Both versions typically share the same images\n\n\n\n\nCreate new directory in post/ with date-slug format: YYYY-MM-DD-slug-title/\nCreate .qmd file with same name as directory\nInclude required frontmatter (title, date, categories with language)\nPosts are frozen by default - R code execution is cached\nFor Norwegian posts, create English translation with parallel directory structure and translation disclaimer\n\n\n\n\n\nCreate new directory in recipe/ with recipe name\nCreate .qmd file with same name as directory\nInclude any accompanying images in the same directory\n\n\n\n\n\nSite renders to docs/ directory\nGitHub Pages serves from docs/ folder on main branch\nThe deploy.sh script handles the full build and deployment pipeline\n\n\n\n\n\n\n\n\nUses R with Quarto for rendering\nRStudio project configured with spaces (2), UTF-8 encoding\nPackage build type configured\n\n\n\n\n\nMain branch serves as both development and production\ndocs/ folder is committed and serves as GitHub Pages source\nDeploy script automatically commits docs changes\n\n\n\n\n\nComputational freeze prevents expensive re-computation of R code\nStatic site generation for fast loading\nPDF assets stored directly in repository for reliable access\n\n\n\n\n\n\n\nStatus: In progress - converting R Journal article to blog post\nLocation: post/2025-07-14-random-intercepts-do-not-fix-confounding/\nSource Files: - Random intercepts do not fix confounding.Rmd - Incomplete R Journal article with theoretical content - Run.R - Complete simulation code demonstrating the concept\nTarget: Create random-intercepts-do-not-fix-confounding.qmd blog post\nProgress: - [x] Project setup and planning - [x] CLAUDE.md updated with project status - [x] Create .qmd file structure with proper frontmatter - [x] Integrate theoretical content from .rmd to .qmd - [x] Integrate simulation code from Run.R into .qmd - [x] Complete the incomplete Formula 4 section and add results interpretation - [x] Add conclusion with practical guidance and test code execution\nStatus: COMPLETED - Blog post created at random-intercepts-do-not-fix-confounding.qmd\nFinal Output: Complete blog post combining theoretical content from .rmd file and simulation code from Run.R, with proper conclusions and practical guidance."
  },
  {
    "objectID": "CLAUDE.html#project-overview",
    "href": "CLAUDE.html#project-overview",
    "title": "CLAUDE.md",
    "section": "",
    "text": "This is a personal academic website built with Quarto, rendered as a static site and hosted on GitHub Pages. The site contains blog posts, academic publications, presentations, CV, and recipes."
  },
  {
    "objectID": "CLAUDE.html#key-commands",
    "href": "CLAUDE.html#key-commands",
    "title": "CLAUDE.md",
    "section": "",
    "text": "quarto render . - Renders the entire site to the docs/ directory\n./deploy.sh - Full deployment script that renders the site, commits docs, and pushes to main\nRscript -e \"quarto::quarto_render('.')\" - Alternative R-based render command\n\n\n\n\n\nquarto preview - Start local development server with live reload\nquarto render post/path/to/post.qmd - Render a specific post\nquarto render recipe/path/to/recipe.qmd - Render a specific recipe"
  },
  {
    "objectID": "CLAUDE.html#project-structure",
    "href": "CLAUDE.html#project-structure",
    "title": "CLAUDE.md",
    "section": "",
    "text": "post/ - Blog posts (academic, health-related topics)\nrecipe/ - Recipe collection\narticles/ - PDF copies of academic publications\npresentations/ - PDF copies of presentations\ndocs/ - Generated site output (published to GitHub Pages)\n\n\n\n\n\n_quarto.yml - Main Quarto configuration\npost/_metadata.yml - Post-specific metadata (freeze: true, title-block-banner: true)\nrecipe/_metadata.yml - Recipe-specific metadata\npublications.bib - Bibliography file for academic publications\nproject.Rproj - R project settings\n\n\n\n\n\nComputational freeze enabled for posts (freeze: true) to avoid re-executing R code\nUses Flatly theme with custom title block styling\nIntegrated with GoatCounter analytics\nGitHub and Twitter/X social links in navbar"
  },
  {
    "objectID": "CLAUDE.html#content-creation-workflow",
    "href": "CLAUDE.html#content-creation-workflow",
    "title": "CLAUDE.md",
    "section": "",
    "text": "The blog follows a specific bilingual pattern: - English-only posts: If the core post is written in English, it remains English-only - Norwegian posts with translations: If the core post is written in Norwegian, it should have: - Original Norwegian version with categories: [\"Norsk\", ...] - English translation version with categories: [\"English\", ...] - Translation pairs use same date but different slug language (e.g., 2024-09-27-forebygg-covid-19-forebygg-sykefravaer/ vs 2024-09-27-prevent-covid-19-prevent-sick-leave/) - English translations include disclaimer: “This is a translation of the original Norwegian op-ed, and discrepancies may exist.” - Both versions typically share the same images\n\n\n\n\nCreate new directory in post/ with date-slug format: YYYY-MM-DD-slug-title/\nCreate .qmd file with same name as directory\nInclude required frontmatter (title, date, categories with language)\nPosts are frozen by default - R code execution is cached\nFor Norwegian posts, create English translation with parallel directory structure and translation disclaimer\n\n\n\n\n\nCreate new directory in recipe/ with recipe name\nCreate .qmd file with same name as directory\nInclude any accompanying images in the same directory\n\n\n\n\n\nSite renders to docs/ directory\nGitHub Pages serves from docs/ folder on main branch\nThe deploy.sh script handles the full build and deployment pipeline"
  },
  {
    "objectID": "CLAUDE.html#technical-notes",
    "href": "CLAUDE.html#technical-notes",
    "title": "CLAUDE.md",
    "section": "",
    "text": "Uses R with Quarto for rendering\nRStudio project configured with spaces (2), UTF-8 encoding\nPackage build type configured\n\n\n\n\n\nMain branch serves as both development and production\ndocs/ folder is committed and serves as GitHub Pages source\nDeploy script automatically commits docs changes\n\n\n\n\n\nComputational freeze prevents expensive re-computation of R code\nStatic site generation for fast loading\nPDF assets stored directly in repository for reliable access"
  },
  {
    "objectID": "CLAUDE.html#current-project-status",
    "href": "CLAUDE.html#current-project-status",
    "title": "CLAUDE.md",
    "section": "",
    "text": "Status: In progress - converting R Journal article to blog post\nLocation: post/2025-07-14-random-intercepts-do-not-fix-confounding/\nSource Files: - Random intercepts do not fix confounding.Rmd - Incomplete R Journal article with theoretical content - Run.R - Complete simulation code demonstrating the concept\nTarget: Create random-intercepts-do-not-fix-confounding.qmd blog post\nProgress: - [x] Project setup and planning - [x] CLAUDE.md updated with project status - [x] Create .qmd file structure with proper frontmatter - [x] Integrate theoretical content from .rmd to .qmd - [x] Integrate simulation code from Run.R into .qmd - [x] Complete the incomplete Formula 4 section and add results interpretation - [x] Add conclusion with practical guidance and test code execution\nStatus: COMPLETED - Blog post created at random-intercepts-do-not-fix-confounding.qmd\nFinal Output: Complete blog post combining theoretical content from .rmd file and simulation code from Run.R, with proper conclusions and practical guidance."
  }
]